Strong leasing and value-creating projects

Biljana Pehrsson, CEO, comments: Kungsleden completed 2016 strongly. Favourable progress in leasing continued during the fourth quarter and led to a satisfactory full year outcome for both new leasing and net leasing. This is due to favourable rental market conditions in our prioritised markets and the strong drive within the organisation. Thanks to the newly signed leases in 2016 and a full pipeline of refurbishment and development projects, Kungsleden will now double the investment pace for the coming years. Gradually we want to raise the quality of our portfolio whilst increasing the earning capability. On 2 February 2017 Kungsleden’s Board resolved to conduct a new share issue that allows us to achieve our ambitious investment program, whilst strengthening the balance sheet. This will enable further profitable growth with financial discipline. Much progress has been made within Kungsleden during 2016. The organisation has become more established and strengthened, and I see a positive energy and engagement resonating throughout the company. The streamlining of the property portfolio has continued at a good pace. Almost 80 per cent of the portfolio is now allocated in our prioritised markets, whilst the proportion of offices has increased. Properties located in clusters achieve overall better results than other areas in the property portfolio. We have also benefited from strong economic growth and a robust property market. From the current starting point, I expect that these favourable conditions will apply throughout 2017. STRONG NEW LEASINGS AND PROFITABLE INVESTMENTS Rental activities accelerated towards the end of the year and new leasing for 2016 reached a historic high of SEK 216 (133) million with net leasing of SEK 99 (7) million. In the fourth quarter new leasing totalled SEK 67 (40) million and net leasing amounted to SEK 50 (10) million. Particularly strong were net leasing in our clusters: SEK 72 million for the full year. Robust new leasing enable profitable investments in tenant improvements and the modernisation of our properties. This will have an effect on rental revenues and net operating revenue from 2018 onwards. Kungsleden’s four large refurbishment and extension projects are entering intensive construction stages and one of these projects will be completed towards the end of 2017. In addition, we have a strong pipeline of new projects including new constructions which we are planning to secure during 2017 and deliver from 2018 onwards. All in all, we are doubling the pace of our projects and investments within our existing portfolio. Previously these have equated to an annual total of SEK 300 to 500 million and are set to increase up to an average of SEK 1,000 million per year from 2017 to 2019. VALUE INCREASES AND IMPROVED FINANCIAL KEY FIGURES In 2016, the realised and unrealised changes in value of the property portfolio amounted to SEK1,690 million. Reduced yield requirements, improved net operating revenue and investments had a positive effect on the value of the property. The increase in value, combined with reduced borrowing, led to the borrowing rate dropping to 56.4 per cent (61.9). The equity ratio has risen to 36.8 per cent (33.1). Also, the long-term net asset value (EPRA NAV) has risen during the year and amounted to SEK 69.32 (56.76) per share. Return on equity increased to 18.5 per cent against the 5.5 per cent last year when the outcome of Kungsleden’s previous tax process negatively impacted on earnings. STRATEGIC TRANSACTIONS The streamlining of our property portfolio continued during 2016. The total divestment of non-strategic property equates to approximately SEK 700 million. Thus, we are on our way toward the objective to divest for SEK 2 billion over the two years 2016–2017. In 2016 we began realising values in properties with potential for residential development. During the year, we completed five transactions with potential residential building rights at a price of SEK 321 million. Earnings amounted to SEK 42 million of which SEK 13 million will be reported in 2017. In addition, we will obtain earn-outs for created building rights of approximately SEK 240 million when the zoning plans have been legally approved. The divestment means that the future residential building rights are priced from SEK 5,000 to 10,000 per square metre. The prospects are favourable for continued development of zoning plans and the divestment of properties with potential for residential building rights from Kungsleden’s portfolio. An important element in the portfolio’s optimisation is the reinvestment of those resources released through the divestments. I am very pleased with the strategic acquisitions we completed in December, especially the agreement with Steen & Ström AB to buy the Emporia Office building – just over 0,000 sq.m. of modern office space in Emporia shopping centre in Hyllie in Malmö. Hyllie is Malmö’s most expansive area with great potential. This diverse city with its strategic communication hub location has just the right conditions to develop and become one of our primary clusters. GOOD STARTING POSITION On 16 November, Kungsleden was selected as the best equal opportunities company of the Exchange by the Foundation AllBright. The appointment was, to a great extent, based on the survey responses from the employees which had a 94 per cent respondent rate. The fact that so many participated makes me proud because it shows great commitment, which is fully in line with our values of professionalism, consideration and positivity. Kungsleden’s professional leasing team has also attracted attention externally at the beginning of 2017 when we won several titles in the “Leasing People of the Year 2016” award. With effect from 1 January 2017, we have merged two asset and property management regions and created the three more equally large asset and property management units – Stockholm, Gothenburg/Malmö and Mälardalen. The local organisation within the property management areas has also been strengthened through more market areas established with locally anchored employees. We will now proceed towards the aim to be one of the most successful and profitable listed property companies by 2020. The recently announced new share issue will give us the resources for continued profitable growth with financial balance. 

Pandox AB (publ) year-end report January – December 2016

Quarter October– December 2016 · Revenue from Property Management amounted to MSEK 458 (365). Adjusted for currency effects and comparable units, the increase was 6 percent. · Net operating income from Property Management amounted to MSEK 368 (306). Adjusted for currency effects and comparable units, the increase was 2 percent. · Net operating income from Operator Activities amounted to MSEK 130 (104). Adjusted for currency effects and comparable units, the increase was 10 percent. · EBITDA amounted to MSEK 464 (381). · Profit for the period amounted to MSEK 772 (681). · Cash earnings amounted to MSEK 314 (263 adjusted for extra tax cost). · Earnings per share before and after dilution amounted to SEK 5.08 (4.54). · A directed share issue raised MSEK 1,012 before transaction costs. Period January – December 2016 · Revenue from Property Management amounted to MSEK 1,787 (1,543). Adjusted for currency effects and comparable units, the increase was 6 percent. · Net operating income from Property Management amounted to MSEK 1,495 (1,280). Adjusted for currency effects and comparable units, the increase was 7 percent. · Net operating income from Operator Activities amounted to MSEK 439 (416). Adjusted for currency effects and comparable units, the decrease was 1 percent. · EBITDA amounted to MSEK 1,817 (1,603). · Profit for the period amounted to MSEK 2,214 (2,131). · Cash earnings amounted to MSEK 1,289 (1,080 adjusted for non-recurring items net). · Earnings per share before and after dilution amounted to SEK 14.65 (14.21). · The Board of Directors is proposing a dividend of SEK 4.10 (3.80) per share, total MSEK 646 (570). Significant events after the period · Pandox signed twenty-year lease agreements for seven operations hotels in the Nordics with Scandic Hotels Group and ended its operator agreement for Grand Hotel Oslo. Attachment: Year-end report January – December 2016 FOR FURTHER INFORMATION, PLEASE CONTACT:Anders Nissen, CEO, +46 (0) 708 46 02 02Liia Nõu, CFO, +46 (0) 702 37 44 04Anders Berg, Director of Communications and IR, +46 (0) 760 95 19 40 This information is information that Pandox AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on 16 February 2017. About PandoxPandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio currently comprises 120 hotels with more than 26,000 hotel rooms in ten countries. Pandox’s business is organised into Property Management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator Activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are, as of 18 June 2015, listed on Nasdaq Stockholm. www.pandox.se.

Full year report 2016

Business highlights fourth quarter 2016  · Positive pivotal phase 3 trial results received for long-acting buprenorphine, CAM2038, for treatment of opioid addiction. · Start of Phase 1-trial of CAM2047, CAM2038 and CAM2058 for treatment of nausea and pain. · Stage 1 of the establishment of Camurus´ European commercial organization and operational structure completed. · Expansion of collaboration and license agreement with Braeburn Pharmaceuticals. · Preclinical development program for CAM2043 for treatment of pulmonary arterial hypertension completed. · Three presentations of long-acting buprenorphine, CAM2038, at ISAM annual meeting 2016 in Montreal. · Capital Markets and R&D Day held at the Royal Swedish Engineering Academy in Stockholm.  Financial summary fourth quarter 2016  · Revenues MSEK 37.1 (36.3). · Operating result before and after items affecting comparability MSEK -35.1 (-4.9) and MSEK -35.1 (‑40.4), respectively. · Result after tax MSEK -27.8 (-31.9). · Earnings per share SEK -0.75 (-1.05), before and after dilution. · Cash position MSEK 508.6 (716.1). Financial summary full year 2016  · Revenues MSEK 113.7 (154.8). · Operating result before and after items affecting comparability MSEK -102.5 (-30.5) and MSEK -102.5 (-204.1) respectively. · Result after tax MSEK -81.0 (-159.5) · Earnings per share SEK -2.17 (-6.02), before and after dilution. · Cash position MSEK 508.6 (716.1). CEO comments The final quarter of 2016 saw us achieve a major milestone for Camurus. Results from our completed Phase 3 study of CAM2038 in opioid dependence demonstrated significantly better treatment effect with our long-acting depots versus standard of care with daily sublingual tablets. With this achievement, we now initiated the work on the market approval applications for both the EMA and FDA. Our long-acting buprenorphine depots, CAM2038, for treatment of opioid dependence, clearly fulfilled efficacy primary endpoints agreed with the European Medicines Agency (EMA) as well as US Food and Drug Administration (FDA). Additionally, secondary analyses demonstrated superior efficacy versus daily sublingual buprenorphine/naloxone tablets. These clear-cut, positive Phase 3 results are particularly impressive in the light of the randomized, controlled double blind, double dummy design, and with regard to the complex patient population that was included directly from the active opioid misuse. Approximately 70% of the 428 study participants were using heroin and more than half of them were injection opioid users. Most of them also used other illicit drugs, including cocaine, amphetamine and marijuana. This group is representative of patients starting their treatment of opioid dependency both in EU and the US. Present daily treatment with buprenorphine or methadone has been clearly demonstrated to be effective in decreasing opioid misuse, reducing mortality and the spreading of infectious diseases. Unfortunately, these treatments have some significant limitations. These include poor treatment adherence, costs and stigma in connection to need of frequent clinic visits and supervised dosing, overdosing, as well as diversion and misuse. Using long-acting medications, these limitations can be significantly reduced, or even eliminated, as pointed out by Prof. Edward Nunes MD, PhD, Columbia University Medical School during his presentation at Camurus’ first Capital Markets and R&D Day in Stockholm, December 14, 2016. Combined with the documented treatment efficacy and favorable safety profile, our long-acting depot products have the potential to transform the treatment of opioid dependence and provide improvement to patients, healthcare providers and society. Process of filing market authorization and new drug applications for CAM2038 to the EMA and FDA mid 2017 are on track. During the period, important advances were also made regarding commercial manufacturing as well as establishment of our commercial organization and operational structure in front of the planned launching of CAM2038 in Europe during 2018. We have been working closely with experts and stakeholders within the various national health systems, as well as performing health economic analyses and modelling. Initial results will be presented at the AMCP Managed Care Specialty Pharmacy Annual Meeting i Denver, Colorado in March 2017. In our collaboration with Novartis, following the announcement of positive Phase 2 results for our subcutaneous long-acting octreotide depot, CAM2029, for treatment of acromegaly and neuroendocrine tumours (NET), a clinical study report has been completed during the quarter. Results will be presented at several conferences during the spring, including ENETS, Barcelona in March and at ENDO, Orlando in April. After completed preparations for GMP-manufacturing of the product during the quarter, GMP manufacturing is now initiated ahead of planned Phase 3 start later in the year. In the collaboration with Rhythm regarding weekly setmelanotide FluidCrystal® investigational product for treatment of genetic obesity disease, GMP-manufacturing was successfully completed and preparations of a clinical trial are ongoing ahead of the start during 2017. In our early development pipeline, we initiated a clinical pharmacokinetic study of new product candidates for treatment of pain as well as nausea and vomiting. Two of the programs are conducted with our US partner Braeburn Pharmaceuticals, after having expanded our license agreement during the period. A new exciting program in our pipeline is a subcutaneous depot of treprostinil, CAM2043, for treatment of pulmonary arterial hypertension. PAH is a rare progressive lung and heart disease with a poor life expectancy of less than 3 years, if left untreated. Based on our preclinical results, we believe that CAM2043 has potential to significantly improve treatment versus available treatments. Presently treprostinil is administrated using continuous infusion, a complex procedure associated with significant and treatment limiting side-effects such as pain and serious infections. The PAH market exceeded USD 4 billion 2015, with treprostinil representing about 25%. Our strong results delivered during the past year have resulted in an increased interest in Camurus and contributed to a positive development of the company value. Behind the success is our team of fantastic coworkers, dedicated partners and clinical investigators, as well as their study teams. Warm thanks to you all! Fredrik TibergPresident and CEO For more information: Fredrik Tiberg, CEO and Head of ResearchTel. +46 (0)46 286 46 92fredrik.tiberg@camurus.com    Rein Piir, VP Investor RelationsTel. +46 (0)70 853 72 92ir@camurus.com  This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, 07.00 AM CET on 16 February 2017.

QT GROUP PLC FINANCIAL REPORTING 2017

Segment reporting Qt Group comprises of one reportable segment that offers software development tools to its customers. The chief operating decision maker of Qt Group is the CEO together with the Group’s management team. Due to the business model of Qt Group and the nature of its operations and governance structure, Qt Group forms one reportable operating segment, Qt Group. The figures of the reportable segment form the figures of Qt Group. Revenue from products and services Qt Group has previously reported its revenue as one consolidated revenue figure for the Group.   In 2017, Qt Group reports revenue from products and services as follows: license sales and consulting, as well as support and maintenance. License sales and consulting comprises of developer licenses, distribution licenses (runtimes) and consulting. Support and maintenance comprises of maintenance fees. Comparison figures 2016 Revenue by 1-3/2 4-6/2 7-9/2016 10-12/2016 1-12/2016products 016 016andservices ThousandEURLicense 4 435 6 215 4 567 5 855 21 073sales andconsultingSupport and 2 713 2 720 2 900 2 989 11 322maintenance Revenue 7 148 8 935 7 467 8 845 32 395total Revenue from geographical locations In financial statements, Qt Group reports revenue from geographical locations by the location of assets as follows: North America and rest of the world. Qt Group PLC Board of Directors FURTHER INFORMATION CFO Mika Harjuaho, +358 9 8861 8040 Qt Group Plc Qt Group Plc is responsible for Qt development, productization and licensing under commercial and open source licenses. The Qt offering includes a development environment that enables the reuse of software code across numerous different operating systems, platforms and screen types, ranging from desktops and embedded systems to wearables and mobile devices. Qt is used by approximately 1 million developers worldwide and is the leading independent technology behind millions of devices and applications. Qt is the platform of choice for in-vehicle systems, industrial automation devices and other business critical applications manufacturers, and is used by leading global players in 70+ industries. The Qt Company operates in China, Finland, Germany, Japan, Korea, Norway, Russia and USA with about 200 employees worldwide. The Qt Group is headquartered in Espoo, Finland and is listed on Nasdaq Helsinki Stock Exchange. The company’s net sales in year 2015 was 27 MEUR. To learn more visit http://qt.io

Qt Group Plc updates its strategy and long-term goals and is planning to seek additional funding via rights issue

We are surrounded by touch screens and smart devices as digitalization is everywhere—not only in the consumer market but also in industrial equipment. The market penetration of touch screens, and the importance of a great user experience has grown so that the consumers are often making purchase decisions, such as on a car or a smart TV, based on its software content and user experience, and not on the form factor. On the other hand, the same user experience and content should work seamlessly across all the end user devices. Qt technology allows manufacturers to easily create graphical user interfaces for touch screens and software that works across all consumer devices such as desktop computers, smart phones, TVs and cars, as well as in industry, for example, on the factory floor. Today, Qt technology is already in use in more than 70 industries. For example, the automotive industry has in recent years taken Qt as a fundamental technology for the development of digital entertainment and control systems. Qt has business and development activities with most of the major global automobile manufacturers. The Board of Directors of Qt Group Plc wishes to accelerate this growth as witnessed in recent years by investing more in strategic growth areas, such as: · Growing the global sales network and · Product offering in selected industries Many of the key industries in which the company is pursuing growth in market share are undergoing technological transformations that involve making choices of technology platforms for the coming years. As these markets are being divided between the market players right now, it is essential for the company to aggressively capture market share and, most importantly, conclude significant commercial contracts with major OEMs. Contracts with large manufacturers enable scalable growth and continuous revenue streams in Qt’s distribution licensing based revenue model in embedded systems. The more devices are produced with Qt technology, the larger the number of distribution licenses sold. As the product development lifecycles in many industries—such as the automotive industry—are 2–3 years long, the investments being made now are geared towards boosting distribution license revenue particularly from 2019 onwards. Long-term financial goals In accordance with the updated strategy, the Board of Directors has set the following financial targets to be reached by the end of 2021: +--------------------------------+----------------+|Value |Target |+--------------------------------+----------------+|Annual turnover |100 million euro|+--------------------------------+----------------+|Operating profit margin (EBIT-%)|Over 15 % |+--------------------------------+----------------+ Due to investments made into the company’s growth, operating profit is estimated to be negative between 2017 and 2018 because of the upfront investments. In 2019, a positive commercial result is expected, at which time the operating profit margin is estimated to increase and operating profit of more than 15 percent of sales to be realized in 2021. Growth in net sales is primarily based on organic growth by increasing investments into embedded systems and industrial sectors, focusing on product development and expanding the sales network. Selected acquisitions, regarding the technology or services, are a possibility for accelerating the growth. The company's aim is to refrain from the distribution of dividends until further notice. Growing the global sales network Qt Group aims to expand its sales network by increasing the number of its own operating locations as well as the number of retailers. The plan for the company’s own operating locations is to cover the company’s largest geographical markets, which are currently the United States, Germany, China, South Korea and Japan. In the sales of embedded systems in particular, sales cycles are long and they require a local presence. Growth will also be pursued by developing the sales model and organisation with more focus on named strategic customer accounts. The company will seek to grow its network of retailers, particularly in countries with smaller business potential or where the local operating methods or markets deviate significantly from the company’s current operating methods or markets. The aim is also to expand the network of retailers to technology partners that operate globally or have their own distribution networks. The sales network will also be enhanced by increasing online distribution via the Internet. The current view of Qt Group’s Board of Directors is that the self-service based sales channel has limited significance to Qt’s business, but it enables the company to allocate its own sales resources better. Product offering for selected industries Qt provides technology solutions for two main market segments: 1. Platform independent application development for desktop and mobile applications 2. Development of embedded systems Desktop and mobile application development markets are stable for Qt, where the development tool has a good reputation, market share and a large customer base. The company’s Board of Directors believe this market will continue to grow steadily and will continue to bring a steady cash flow. However, these market growth opportunities are restricted by the limited number of software developers. In the embedded systems market the company’s revenue model is, to a large extent, based on the number of products manufactured by means of the distribution license. For this reason, the embedded systems market provides a more scalable target market in comparison to desktop and mobile applications. The Internet of Things (IoT) will revolutionize many industries and change the way in which future devices and systems are developed. As a result of these changes, more and more devices are intelligent, connected to other devices, and connected to the network. The value provided by embedded devices to the user is often based on the user experience, this is also the case in an industrial environment. Although the device will only be used by a trained specialist, for example, in a factory or a hospital environment, it is important that the usability of the device is comparable to the usability of a consumer device, such as a smartphone. Thus with the proliferation of the Internet of Things, above all, the need to create good user interfaces will increase. On the other hand, when the same user experience needs to be available on every device easily and effectively, the need for a platform-agnostic solution like Qt grows. By using Qt, embedded equipment manufacturers can develop software for their devices, and, above all, create user interfaces efficiently. In practice, this means delivering products to the market faster using Qt. In addition, Qt offers device manufacturers with the ability to create their own platforms with external software, such as intelligent-TV or in-car entertainment systems, which offer external services. Qt technology is ideally suited for making embedded systems and platform-independent applications and user interfaces. This competitive advantage will be further developed with a focus on development tools, and thus enhancing customers' development cycles, support for new software and hardware technologies and additional features for creating user interfaces, among other things. Industry-focused approach enables long-term growth—Automotive industry the primary one A specific strategic focus area for the company regarding the embedded systems market is the additional investment in selected industries such as Automotive, Automation and Digital Television sectors. By introducing additional industry-specific solutions and integrations the company can offer better value and grow the market share and revenue in these industries. Especially for the Automotive industry the company will continue its additional investments to grow the market share by developing specific technology solutions and expanding the automotive-specific sales network. Dual-licensed technology A growing trend in the software industry is the utilization of open source code and solutions. Qt technology has been dual-licensed under open source and commercial licenses over the whole 20 years of its history. Because of this, Qt has a wide and vibrant ecosystem of over one million developers. The development of Qt technology itself takes widely place in the open source community together with other companies, organizations and individual code contributors which enhances the product quality, creditability and the ability to introduce new features to the technology. As an open source solution Qt offers device vendors a truly independent solution for creating their own software platforms and ecosystems for their own application developers. For instance automotive OEMs and smart TV vendors can create entertainment systems that enable external 3rdparty content so that the vendors maintain their ownership and control of the end user data. This is a highly important competitive advantage of Qt compared to other application ecosystems. The open source licensing scheme of Qt was updated during 2016 with Qt 5.7 release so that it is clearer when a commercial license is required over an open source license especially when creating commercial end user devices. The Board of Directors believes that this will have a positive impact on the development of the company’s revenue as it improves the commercial conversion during years 2017-2019. Rights Issue to Fund Investments into Growth Qt's Board of Directors has decided to propose 14/03/2017 convening the Company's Annual General Meeting on authorizing the Board to decide on seeking additional funding of approximately EUR 15 million via share issue based on shareholders' pre-emptive subscription-based rights offering (the "Share Issue"). The Board of Directors proposes to the AGM that the AGM authorize the Board to decide on issuing a total maximum of 4,500,000 new shares or treasury shares in one or more Share Issues against payment. The company's four largest shareholders, Ingman Development Oy Ab, Keskinäinen Eläkevakuutusyhtiö Ilmarinen, Jyrki Hallikainen and Kari Karvinen, have preliminarily announced their intention to participate in the Share Issue in proportion to their respective share of ownership. In accordance with the authorization as proposed by the Board of Directors, the Board of Directors will decide on detailed terms and conditions of the Share Issue. Qt Group Plc Qt Group Plc is responsible for Qt development, productization and licensing under commercial and open source licenses. The Qt offering includes a development environment that enables the reuse of software code across numerous different operating systems, platforms and screen types, ranging from desktops and embedded systems to wearables and mobile devices. Qt is used by approximately 1 million developers worldwide and is the leading independent technology behind millions of devices and applications. Qt is the platform of choice for in-vehicle systems, industrial automation devices and other business critical applications manufacturers, and is used by leading global players in 70+ industries. The Qt Company operates in China, Finland, Germany, Japan, Korea, Norway, Russia and USA with about 200 employees worldwide. The Qt Group is headquartered in Espoo, Finland and is listed on Nasdaq Helsinki Stock Exchange. The company’s net sales in year 2015 was 27 MEUR. To learn more visit http://qt.io

Year-end report 1 January – 31 December 2016

3 months ended 31 December 2016 · Local currency sales increased by 8% and Euro sales increased by 5% to €355.1m (€339.5m). · Number of registered actives* decreased by 7% to 3.0m. · EBITDA amounted to €49.0m (€39.7m). · Operating margin was 11.8% (9.6%, adjusted** 11.5%), impacted by -110 bps from currencies, and operating profit was €42.0m (€32.6m, adjusted** €38.9m). The operating margin was favourably impacted by a VAT income related to the Russian tax case, fully offset by Ukrainian and other one-off restructuring costs as well as costs linked to the outsourcing of financial and IT operations to IBM. · Net profit was €25.2m (€8.9m, adjusted** €15.2m) and diluted EPS €0.44 (€0.16, adjusted** €0.27). · Cash flow from operating activities was €61.7m (€68.8m). · The first quarter to date sales development is approximately 11% in local currency. *Replaces the former definition “active consultants” and represents Consultants having placed at least one order during the last 3 months.**Adjusted for non-recurring items of €6.3m in the fourth quarter 2015. 12 months ended 31 December 2016 · Local currency sales increased by 12% and Euro sales increased by 3% to €1,249.4m (€1,211.6m) · EBITDA amounted to €148.2m (€117.4m). · Operating margin was 9.5% (7.5%, adjusted* 8.3%), impacted by -250 bps from currencies, and operating profit was €119.2m (€90.6m, adjusted* €100.2m). · Net profit was €66.7m (€34.2m, adjusted** €43.2m) and diluted EPS €1.18 (€0.62, adjusted** €0.79). · Cash flow from operating activities amounted to €113.1m (€122.2m). · The Board of Directors will propose to the 2017 AGM a total dividend of €1.50 per share for 2016, of which €1.00 (€0.40) per share is to be considered as ordinary and €0.50 to be considered as extra dividend. The ordinary dividend is to be paid in equal quarterly instalments of €0.25 respectively starting in the second quarter 2017, and the extra dividend is to be paid during the second quarter 2017. *Adjusted for non-recurring items of €9.6m during the period 2015.**Adjusted for additional non-recurring items of (€0.5m) during the period 2015. CEO Magnus Brännström comments“2016 was a year when we made significant steps to improve the overall position of Oriflame and when the success from our online leaders and the sales of Skin Care and Wellness sets and routines reached new levels. It was a year when we returned to Euro growth, delivered double-digit local currency growth and increased the profitability each consecutive quarter – despite challenging market conditions and deteriorating macro. 2017 marks the 50th anniversary of Oriflame and we are reaching this milestone stronger than ever before, equipped with a good underlying momentum, solid strategy and strong financial position. At the same time, many of our markets continue to be volatile and face highly uncertain geopolitical and macroeconomic conditions. The first quarter has started in a promising way and we will continue to deliver on our strategy – ready to meet an ever-changing world during the next 50 years.” OtherA Swedish translation is available on www.oriflame.com. Conference call for the financial communityThe company will host a conference call on Thursday, 16 February 2017 at 9.30 CET. Participant access numbers:SE: +46856642698DK: +4535445575FI: +358981710491NO: +4723500252UK: +442030089801US: +18557532235The conference call will also be audio web cast in “listen-only” mode through Oriflame’s website: www.oriflame.com or through http://oriflame-ir.creo.se/170216 16 February 2017 Magnus BrännströmChief Executive Officer For further information, please contact: Magnus Brännström, Chief Executive Officer Tel: +41 798 263 754Gabriel Bennet, Chief Financial Officer Tel: +41 798 263 769Nathalie Redmo, Sr. Manager IR Tel: +41 799 220 173 This information is information that Oriflame Holding AG is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:15 CET on February 16, 2017. Oriflame Holding AGBleicheplatz 3, CH-8200 Schaffhausen, Switzerlandwww.oriflame.comCompany registration no CHE-134.446.883

Kuehne + Nagel ordering 326 trolleys from FlexQube

Anders Fogelberg, CEO of FlexQube, comments: "This is the first major transaction we undertake together with STILL GmbH after we signed our agreement for the distribution and sale for them in September 2016. FlexQube already has a few thousand wagons in operation of different customers with the Liftrunner transport solution from STILL. But this is the first business transaction where we sell carts to a third party logistics company, a phenomenon that is becoming more and more common in the industry. There is one major thing to take note of in this business for FlexQube. When companies take over materials handling in contracts over a number of years, they need access to solutions that can be adapted and adjusted to the rapid changes in volume, mix and product. In order to offer the most competitive offerings companies also need to invest in technology that make material handling as efficient, safe and ergonomic as possible. Something that we, FlexQube, think we succeeded with in this project.” “As part of transforming logistics operations and line feeding processes for our customer Kuehne + Nagel will use a combination of a market leading material handling train from STILL and FlexQube together with applicable concepts for material trolleys, to streamline material management and minimize forklift use on location. This will allow us to increase efficiency and improve scalability as well as improve health and safety aspects of the operations”, says Håkan Nydén, Director Contract Logistics at Kuehne + Nagel Sweden. About FlexQube FlexQube is a Swedish-American company that provides a robust, modular and flexible concept to design and build industrial trolleys and racking. The company has manufacturing facilities in Sweden and the USA and distribution in North America and Europe. 2015 and 2016 were FlexQube named one of Sweden's most promising and innovative technology companies through the "33 list" as Business Week and New Technology compiles. Growth during the last three years has been more than 100% on average and FlexQube has some of the world's largest and most prominent manufacturers in the automotive, energy, aerospace, appliance, and engineering industries as clients. Some examples include Autoliv, Dräxlmaier, Kuehne-Nagel, Scania, Whirlpool, Eberspächer, Oshkosh and Cummins. About Kuehne + Nagel With approximately 69,000 employees at more than 1,200 locations in over 100 countries, the Kuehne + Nagel Group is one of the world’s leading logistics companies. Its strong market position lies in the seafreight, airfreight, contract logistics and overland businesses, with a clear focus on providing IT-based integrated logistics solutions. Further information can be found at  www.kuehne-nagel.com  For more information, contact CEO Anders Fogelberg anders.fogelberg@flexqube.com+1 678 701 58 55 +46 702 86 06 74

Year-end report 2016 and quarterly report October – December 2016

Fourth quarter 2016:  · Revenues for the fourth quarter increased by 23.9% to SEK 400 (323) million · Operating profit amounted to SEK 156 (122) million, an increase of 28.1% · Operating margin was 39.0 (37.7)%  · Profit after tax amounted to SEK 150 (116) million, an increase of 29.6% · Earnings per share amounted to SEK 0.62 (0.48) after dilution  · 13 new customer agreements were signed, 12 new customers’ casinos were launched Full year 2016: · Revenues for the full year increased by 28.5% to SEK 1,455 (1,132) million · Operating profit amounted to SEK 536 (402) million, an increase of 33.4% · Operating margin was 36.8 (35.5)% · Profit after tax amounted to SEK 504 (374) million, an increase of 34.9% · Earnings per share amounted to SEK 2.10 (1.56) after dilution · 45 new customer agreements were signed and 34 new customers’ casinos were launched · Proposed cash distribution to shareholders of SEK 2.25 (1.33) per share · At the end of 2016, NetEnt had 31 signed customers that had not yet been launched Important events in the fourth quarter:  · Retail deal signed with Gauselmann for gaming machines market in Italy  · Retail agreement entered with Paddy Power for gaming machines in Great Britain · NetEnt games launched on the regulated markets in Bulgaria and Portugal  · Contract signed with Codere regarding online games distribution in Mexico Comments by Per Eriksson, President and CEO: Another record year for NetEnt2016 was another exciting year for NetEnt with new record levels in revenues, earnings and cash flow. The year featured many new customers, new regulated market entries and successful game launches for NetEnt. Revenues for the full year increased by 28.5 percent to 1,455 SEKm. Operating profit and profit before taxes amounted to SEKm 536 and SEKm 546 respectively, and the operating margin improved to 36.8 percent. We believe in corporate social responsibility as a condition for long-term sustainability of our business, and focus on growing on regulated markets. During the year, we became members of the World Lottery Association (WLA), a member-based organization that promotes the interests of state-authorized lotteries around the world. Following new licenses and certifications, our games were launched on the regulated markets in Romania, Bulgaria and Portugal. We signed a total of 45 new customer agreements, the highest number ever, and we launched our games with 34 new customers. During the year, we made several larger investments – we continued to enhance our platform and developed a mobile solution for Live Casino Roulette, which we think will support future growth for us in this segment. The game trilogy NetEnt Rocks was very successful and Guns N’ Roses was named best game of the year at the EGR Operator Awards in London. We also launched a range of other innovative, best-in-class games such as Aloha, Drive, Warlords and Little Red Riding Hood, all of which became great successes among customers and players. In addition to offering the best games in the industry, we also manage all gaming transactions for our customers through so-called hosting. Our games are available 24/7, all year around. In 2016, we managed almost 36 billion transactions in our systems, which is 19 times more than the total number of transactions on the New York Stock Exchange during the same period. High growth and good profitability in the fourth quarterThe fourth quarter developed well, revenues increased by 23.9 percent in SEK and by 18.5 percent in EUR compared to the very strong fourth quarter of 2015. The operating margin improved to 39.0 percent, mainly due to better scalability in the business. Great Britain continues to offer great growth potential for us and in December, it became our largest geographical market for the first time. Mobile games continue to be an important growth driver and accounted for 43 percent of revenues in the quarter. We signed new retail deals for gaming machines with Gauselmann in Italy and Paddy Power in the UK. We also took our first step into Latin America by extending our partnership with Codere to include the regulated online casino market in Mexico. Future outlookFor the first quarter of 2017, we expect revenues to be in line with the fourth quarter of 2016. For the rest of 2017, we see conditions for continued solid growth supported by a strong pipeline of new games, growing market shares in the UK, mobile growth, new customers to launch, as well as our expansion in North America. We increase the number of employees, enhance our product offering and integrate more customers on new regulated markets. With this in mind, we foresee higher costs and an ongoing need to invest during 2017. These are all projects that will enable continued solid growth for NetEnt going forward. Presentation of earnings reportOn Thursday, February 16, 2017, at 9.00 a.m. the earnings report will be presented by CEO Per Eriksson live via webcast. The presentation can be followed in real-time on NetEnt’s website at https://www.netent.com/en/section/invest/. For additional information please contact:Per ErikssonPresident and CEOPhone: +46 8 5785 4500per.eriksson@netent.com This information is information that NetEnt AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7:30 CET on February 16, 2017.

Munksjö Oyj’s Financial Statements Bulletin 2016: Profitability target of 12% reached, record high full-year results and cash flow

MUNKSJÖ OYJ, FINANCIAL STATEMENTS BULLETIN, Helsinki, Finland, 16 February 2017 at 07:30 AM CET Munksjö Oyj’s Financial Statements Bulletin 2016: Profitability target of 12% reached, record high full-year results and cash flow Highlights of the fourth quarter 2016 ·  Net sales were EUR 282.4 (290.0) million. ·  Adjusted EBITDA was EUR 36.1 (22.1) million and the adjusted EBITDA margin was 12.8% (7.6%). Items affecting comparability (IAC) amounted to EUR -6.6 (0.0) million, mainly related to the planned combination.  ·  Operating result was EUR 16.4 (8.5) million and net result EUR 11.8 (7.2) million. ·  Earnings per share (EPS) were EUR 0.23 (0.14). ·  Operating cash flow was EUR 41.3 (44.5) million.  ·  On 7 November 2016, Munksjö announced the plan to combine with Ahlstrom Corporation and create a global leader in sustainable innovative fiber-based solutions.   Highlights of January-December 2016 ·  Net sales were EUR 1,142.9 (1,130.7) million. ·  Adjusted EBITDA was EUR 136.7 (93.6) million and the adjusted EBITDA margin was 12.0% (8.3%). Items affecting comparability (IAC) amounted to EUR -6.6 (-7.3) million, mainly related to the planned combination.  ·  Operating result was EUR 74.9 (32.7) million and net result EUR 43.3 (22.8) million. ·  Earnings per share (EPS) were EUR 0.85 (0.44). ·  Operating cash flow was EUR 114.3 (55.5) million. ·  The Extraordinary General Meeting (EGM) approved the combination with Ahlstrom on 11 January 2017. ·  The EGM also authorised the Board of Directors to resolve on an extra payment of funds from the company's reserve for invested unrestricted equity as return of equity of maximum EUR 0.45 per share. KEY FIGURES Oct-Dec Jan-DecMEUR 2016 2015 Change, % 2016 2015 Change, % Net   sales 282.4 290.0 -3% 1,142.9 1,130.7 1%EBITDA   36.1 22.1 63% 136.7 93.6 46%(adj.*)EBITDA   12.8 7.6 12.0 8.3margin, %(adj.*)EBITDA 29.5 22.1 33% 130.1 86.3 51%EBITDA   10.4 7.6 11.4 7.6margin, %Operating   23.0 8.5 171% 81.5 40.0 104%result (adj.*)Operating   8.1 2.9 7.1 3.5margin, %(adj.*)Operating   16.4 8.5 93% 74.9 32.7 129%resultOperating   5.8 2.9 6.6 2.9margin, %Net   result 11.8 7.2 64% 43.3 22.8 90%Earnings   per 0.23 0.14 66% 0.85 0.44 93%share (EPS),EURInterest 169.5 227.4 -25% 169.5 227.4 -25%-bearing   netdebt *Adjusted for items affecting comparability (IAC)  Unless otherwise indicated, the figures in parentheses refer to the figures for the equivalent period in 2015. This financial report is unaudited. It is published in Swedish, Finnish and English. In case of any discrepancies between the three versions, the Swedish text shall prevail. Comment from Munksjö’s President and CEO, Jan Åström  “I am proud of our team and what we have achieved in 2016. We reached our ambitious target, set in 2013, of an EBITDA margin of 12 per cent. We announced the plan to combine Munksjö and Ahlstrom through a merger to create a global leader in sustainable and innovative fiber-based solutions, and we communicated new expected targets including an EBITDA margin target of above 14 per cent for the combined company. The combination is expected to create significant value for the stakeholders through stronger global growth opportunities and improved operational efficiency. During 2016, the adjusted EBITDA reached EUR 136.7 (93.6) million, an improvement of EUR 43 million or 46 per cent. All four business areas have executed on their respective profitability improvement plans and approximately half of the result improvement is based on our own actions to increase efficiency. The rest was mainly attributable to favourable cost conditions. Market demand has remained stable on a good level in all key businesses. Some geographical markets, such as Brazil, have still been impacted by macroeconomic uncertainty during 2016 but we have been able to compensate this with exports to other markets. Our long-term market growth expectation remains intact at between 2-4 per cent annually, as the demand for several of the end-use applications of our solutions is supported by global megatrends such as urbanization and globalisation. Our strong performance in 2016 has strengthened the company. I am now looking forward to the next big step in the development through the merger with Ahlstrom that is expected to be completed early in the second quarter of 2017. The preparations for the integration process are proceeding according to plan and together we will improve our competitiveness further and create a strong growth platform for the future.” Outlook  The demand outlook for 2017 for Munksjö’s specialty paper products is expected to remain stable at the current good level and to reflect the seasonal pattern.  The annual maintenance and vacation shutdowns in the second and third quarter as well as the seasonal shutdowns at the end of 2017 are expected to be carried out to about the same extent as in 2016. The next maintenance shut down at the pulp production facility in Aspa in Sweden will be carried out in the fourth quarter of 2017. The cash flow effect of current capital expenditure for fixed assets in 2017 is expected to be approximately EUR 40 million and, in addition, the cash flow impact of the strategic investment in the Arches mill is expected to be approximately EUR 14 million. The outlook for the financial year 2017 is given for Munksjö as a stand-alone company with its current operations. The Munksjö Group  Oct-Dec Jan-DecMEUR 2016 2015 Change, % 2016 2015 Change, % Net   sales 282.4 290.0 -3% 1,142.9 1,130.7 1%EBITDA   36.1 22.1 63% 136.7 93.6 46%(adj.*)EBITDA   12.8 7.6 12.0 8.3margin, %(adj.*)EBITDA 29.5 22.1 33% 130.1 86.3 51%EBITDA,   10.4 7.6 11.4 7.6margin %Operating   23.0 8.5 171% 81.5 40.0 104%result (adj.*)Operating   8.1 2.9 7.1 3.5margin, %(adj.*)Operating   16.4 8.5 93% 74.9 32.7 129%resultOperating   5.8 2.9 6.6 2.9margin, %Net   result 11.8 7.2 64% 43.3 22.8 90%Capital   10.7 8.9 20% 39.2 39.8 -2%expenditureEmployees,   2,752 2,749 0% 2,755 2,774 -1%FTE * Adjusted for items affecting comparability (IAC) Fourth quarter 2016  · Total group delivery volumes decreased. The positive volume development in most of the product segments, especially the Brazilian paper business in Business Area Release Liners, did not compensate for the lower volume for the specialty pulp business and the Decor business, where the comparison period was historically strong and included a large year-end delivery. ·  EBITDA adjusted for IAC increased to EUR 36.1 (22.1) million and the adjusted EBITDA margin was 12.8% (7.6%). The positive result effect was driven by profitability improvement actions, lower variable costs and higher production. ·  The seasonal shutdowns in the fourth quarter were shorter compared to 2015 particularly in the Business Area Graphics and Packaging and in the Brazilian paper business in Business Area Release Liners where seasonal shutdowns in 2015 were prolonged. ·  IAC amounted to EUR -6.6 (0.0) million, whereof approximately EUR 4 million were related to the planned merger with Ahlstrom. Furthermore, approximately EUR 2 million were related to the terminated long-term share-value-based incentive program. ·  The operating result was EUR 16.4 (8.5) million and net result EUR 11.8 (7.2) million. ·  In the reporting period the currency hedging result impacting operating profit amounted to EUR -0.8 (-0.2) million. Exchange gains on financial assets and liabilities were EUR 1.6 (1.4) million and are reported in financial items. January-December 2016 · Total group delivery volumes increased in most of the product segments and were stable in decor papers. The delivery volume development was particularly strong in the specialty pulp business and the Brazilian paper business in Business Area Release Liners. · Net sales increased to EUR 1,142.9 (1,130.7) million, as higher volumes compensated for the lower average price, mainly driven by the lower sales price for long fibre specialty pulp and a different product mix compared to last year. ·  EBITDA adjusted for IAC increased to EUR 136.7 (93.6) million and the adjusted EBITDA margin was 12.0% (8.3%). Higher delivery volumes had a positive effect of EUR 10 million. This was offset by EUR 11 million as an effect of the lower average price. Lower variable costs, driven mainly by operational efficiency related actions, the lower energy price and lower raw material prices had a positive result effect of EUR 54 million. Higher fixed costs had a negative result effect of EUR 10 million, mainly as a result of accruals for incentive plans and increased manning related to higher production volumes. ·  Out of the total profitability improvement, amounting to EUR 43 million, approximately half was related to actions related to the plan to reach the profitability target. ·  The annual maintenance and vacation shutdowns in the second and third quarter were carried out to about the same extent as in 2015. The seasonal shutdowns in the fourth quarter were shorter compared to 2015 particularly in the Business Area Graphics and Packaging and in the Brazilian paper business in Business Area Release Liners where seasonal shutdowns in 2015 were prolonged.  ·  IAC amounted to EUR -6.6 (-7.3) million, whereof approximately EUR 4 million were related to the planned merger with Ahlstrom. Furthermore, approximately EUR 2 million were related to the terminated long-term share-value-based incentive program. The IAC in the comparison period 2015 was mainly related to restructuring actions.  ·  The operating result was EUR 74.9 (32.7) million and net result EUR 43.3 (22.8) million. ·  In the reporting period, the currency hedging result impacting operating profit amounted to EUR -1.7 (-4.9) million. Exchange losses on financial assets and liabilities were EUR 1.5 (gains of 9.5) million and are reported in financial items. Combination with Ahlstrom On 7 November 2016, Munksjö Oyj and Ahlstrom Corporation announced a plan to merge the two companies. The combination will create a global leader in sustainable and innovative fiber-based solutions. The combination is expected to create significant value for the stakeholders in the combined company through stronger global growth opportunities and improved operational efficiency. The combined company’s growth ambitions will be supported by a strong balance sheet and strong cash flow generation.  ·  Munksjö and Ahlstrom will merge through an absorption merger whereby Ahlstrom’s shareholders will receive Munksjö shares as merger consideration. ·  Ahlstrom’s shareholders will receive 0.9738 new shares in Munksjö for each share held in Ahlstrom as merger consideration, corresponding to an ownership in the combined company of approximately 47.2% for current Ahlstrom shareholders and approximately 52.8% for current Munksjö shareholders. Unaudited pro forma financials of the combined company and certain other information, such as composition of the management team can be found in the merger prospectus, published on 16 December 2016. Munksjö entered on 10 November 2016 into a facilities agreement for the merger and the combined company with Nordea and SEB as the joint underwriters. The new financing consists of approximately EUR 560 million multicurrency term and revolving credit facilities with maturities ranging between three and five years; and EUR 200 million bridge facility for Ahlstrom, which will be assumed by Munksjö as from the date of completion of the merger with amended terms and commitments reduced to EUR 100 million. The syndication of the term loan facilities and the revolving credit facility was concluded on 23 December 2016 and is provided by SEB, Nordea and Danske Bank as bookrunners. BNP Paribas, OP Corporate Bank and Swedbank joined as Mandated Lead Arrangers and Citi, Commerzbank, Crédit Agricole and DNB Bank joined as Lead Arrangers. Financial targets for the planned combined company are expected to include an EBITDA margin above 14 per cent over a business cycle, a net gearing below 100 per cent, as well as a stable and annually increasing dividend. Profitability target reached  Munksjö’s profitability target, set in 2013, to reach an EBITDA margin of 12 per cent at the end of 2016 was achieved according to plan. The drivers for the profitability improvement included continued operational efficiency, profitable growth, product and service quality leadership and utilising the position as a market and innovation leader. Within operational efficiency, the majority of the planned actions included measures to adjust the cost structure. Of the realised actions in the financial result in January-December 2016, the majority were related to operational efficiency. Further information on the actions related to the profitability improvement plan and their effect on the financial result can be found under the heading Munksjö Group. Events after the end of the reporting period  The Extraordinary General Meetings of both Munksjö Oyj and Ahlstrom Corporation were held in Helsinki on 11 January 2017. Munksjö’s EGM resolved, inter alia, to approve the combination of Ahlstrom’s and Munksjö's business operations through a statutory absorption merger of Ahlstrom into Munksjö and approve the merger plan. The EGM also resolved to authorise the Board of Directors to resolve on an extra payment of funds from the company's reserve for invested unrestricted equity as return of equity of maximum EUR 0.45 per share. The merger, which is expected to be completed at the beginning of the second quarter of 2017, is subject to among other things approval by relevant competition authorities. Webcast and conference call  A combined news conference, conference call and live webcast will be arranged on the publishing day 16 February 2017 at 10:00 a.m. CET (11:00 a.m. EET, 8:00 a.m. GMT) at restaurant Savoy (Eteläesplanadi 14, 7th floor, Helsinki). The report will be presented by President and CEO Jan Åström. The event will be held in English. The conference call and live webcast can be followed on the Internet and an on-demand version of the webcast will be available on the same webpage later the same day. To join the conference call, participants are requested to dial one of the numbers below 5-10 minutes prior to the start of the event. Webcast and conference call information Finnish callers: +358 (0)9 7479 0404Swedish callers: +46 (0)8 5065 3942US callers: +1 719 457 2086UK callers: +44 (0)330 336 9412Conference ID: 7977721 Link to the webcast: http://qsb.webcast.fi/m/munksjo/munksjo_2017_0216_q4/#/webcast For further information, please contact:  Jan Åström, President and CEO, tel. +46 10 250 1001 Pia Aaltonen-Forsell, CFO, tel. +46 10 250 1029

YEAR-END REPORT FOR THE SHORTENED FISCAL YEAR 1 APRIL - 31 DECEMBER 2016

“Record quarter ends the year!”1 OCTOBER – 31 DECEMBER 2016 (3 MONTHS) · Net sales in the third quarter rose by 30 percent to SEK 611.5 million (472.1), of which organic growth totalled 21 percent and acquired growth totalled 8 percent. · EBITA rose by 80 percent to SEK 75.8 million (42.1) and EBITA-margin amounted to 12.4 percent (8.9). · Profit after tax rose by 81 percent and amounted to SEK 49.1 million (27.2). · Cash flow from operating activities amounted to 96.4 million (62.1). · Two acquisitions have been carried out during the quarter, Svan Care AB and Biolin Scientific AB, with a combined annual sales of about SEK 135 million and one new business, Medline, has been integrated into existing companies which adds another SEK 40 million in annual sales.  1 APRIL – 31 DECEMBER 2016 (9 MONTHS) · Net sales during the financial year rose by 34 percent to SEK 1,485.6 million (1,109.7), of which organic growth totalled 13 percent and acquired growth totalled 20 percent. · EBITA rose by 54 percent to SEK 153.7 million (100.1) and EBITA-margin amounted to 10.3 percent (9.0). · Profit after tax rose by 58 percent and amounted to SEK 93.0 million (59.0). · Earnings per share amounted to SEK 3.87 (3.31). For the 12-month period, earnings per share amounted to SEK 4.87 (4.40). · The equity ratio amounted to 45.5 percent (22.2). · Return on working capital (P/WC) amounted to 62.1 percent (65.8). · During the financial year the Company carried out a rights issue of SEK 300 million to existing shareholders. · Four acquisitions have been carried out during the financial year with a combined annual sale of about SEK 185 million and two new operations have been integrated into existing companies which adds another SEK 90 million in annual sales. After the financial year, one acquisition has been carried out which adds approximately SEK 30 million in annual sales. · The Board of Directors proposes a dividend of SEK 1.50 per share for the shortened fiscal year. Stockholm 16 February 2017AddLife AB (publ)TeleconferenceInvestors, analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be given in Swedish and take about 20 minutes, after which there will be an opportunity to ask questions. AddLife is an independent player in the Life Science sector, offering high-quality products, services and advice to the private and public sectors, above all in the Nordic region. AddLife has about 550 employees in some 30 subsidiaries that operate under their own brands. The Group has annual sales of about SEK 1.9 billion. Addlife shares are listed on NASDAQ Stockholm. This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on February 16, 2017.

Year-end Report January-December 2016

October – December 2016• Net sales decreased with 6 percent to SEK 579 million (613)• Operating profit before depreciation increased to SEK 28 million (25)• Non-recurring items amounted to SEK -11 million (-12)• Adjusted EBIT before depreciation increased to SEK 39 million (37)• Operating profit increased to SEK 15 million (1)• Earnings after tax amounted to SEK -1 million (-13)• Earnings per share amounted to SEK -0.01 (-0.08)• Cash flow after investing activities amounted to SEK 23 million (5) January – December 2016• Net sales decreased with 9 percent to SEK 2,135 million (2,345)• Operating profit before depreciation decreased to SEK 61 million (70)• Non-recurring items amounted to SEK -18 million (-36)• Adjusted EBIT before depreciation decreased to SEK 79 million (106)• Operating profit increased to SEK 9 million (-5)• Earnings after tax amounted to SEK 297 million (-64)• Earnings per share amounted to SEK 1.42 (-0.41)• Cash flow after investing activities amounted to SEK 30 million (-75) Bong is one of the leading providers of specialty packaging and envelope products in Europe and offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.1 billion and about 1,500 employees in 15 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its shares are listed on Nasdaq Stockholm (Small Cap). For further information, please contact Håkan Gunnarsson, CEO for Bong AB.  Tel (switchboard) 46 44-20 70 00   This information is information that Bong AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8am CET on February 16 2017.   

Nexam Chemical Holding AB (publ) Year End Report 1 January – 31 December 2016

Fourth quarter at a glance Operational: · Receives order of SEK 5.3 million concerning the high performance product NEXIMID®. Largest order in the company history. · Signs supply agreement with Diab concerning the NEXAMITE®-technology for the production of PET-foam. Financials:                                                                                                            · Net sales for the fourth quarter totaled SEK 2,097,000 (2,513,000). · The operating loss for the fourth quarter SEK -6,431,000 (-4,923,000). · In comparison to the beginning of the year, cash and cash equivalents amounted to SEK 133,147,000 (36,305,000). · Cash flow from operating activities was SEK -5,210,000 (-2,936,000). Lund 16 February, 2017 The Board of Directors These financial statements have not been audited by the Company´s auditor. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com This information is information that Nexam Chemical Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on February 16, 2017. ____________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com (http://file/////TELLUS/styrelsen/A.%20Pressmeddelanden%20och%20nyheter/Pressmeddelanden/Eng/www.nexamchemical.com). The company´s Certified Adviser is FNCA Sweden AB.

Evolution Gaming: Year-end report 2016

Fourth quarter of 2016 (Q4 2015) · Operating revenues increased by 53% to EUR 34.3m (22.4) · EBITDA increased by 39% to EUR 13.0m (9.3), corresponding to a margin of 38% (42) · Profit for the period was EUR 9.0m (6.9) · Earnings per share reached EUR 0.25 EUR (0.19) · Mobile penetration amounted to 46% (28) Full-year 2016 (2015) · Operating revenues increased by 51% to EUR 115.5m (76.4) · EBITDA increased 44% to EUR 44.6m (31.0), corresponding to a margin of 39% (41) · Profit for the period was 31.7 MEUR (20.0) · Earnings per share reached 0.88 EUR (0.56) · The Board of Directors proposes a dividend of EUR 0.45 per share (0.32) Events during the fourth quarter of 2016 · Demand remains strong for tables and environments Events following the balance sheet date · Cecilia Lager new Board Member · Launch of a new game category – Live Lucky Wheel CEO Martin Carlesund comments: 2016 marked Evolution Gaming’s 10thyear in business and I am happy to report that we wrapped up a very successful year with a strong quarter. Sales increased by 53 percent compared with the fourth quarter of 2015. Adjusted for expenses related to the upcoming move to the main market, EBITDA amounted to EUR 13.4 million, corresponding to a margin of 39 percent and an increase of 44% compared to the fourth quarter of 2015. Live Casino continues to strengthen its position among operators as well as players. Our focus on the quality of the user experience, offering the broadest product portfolio for all devices and delivering a leading service to our customers are some of the factors behind our strong results in 2016. The year ended with continued solid demand for our services and a very high pace of delivery. The fourth quarter is also seasonally positive with a high level of activity from our customers. In addition to several new customers, existing customers are continuing to expand their offerings. This quarter, new dedicated environments were launched for 888, Virgin Games and bwin, among others. Existing customers are also choosing to expand into more markets where, for example, the aforementioned bwin launched its offering in Denmark during the quarter. We have also expanded further in our latest studio at Grand Casino Bucharest. Another growth driver is the heavy increase in mobile gaming – in the fourth quarter, almost half of the gaming revenues generated via Evolution’s platform derived from mobile devices. The equivalent number is above 50% among our largest customers. Extensive development is also taking place on the product side. The roll-out of Live Ultimate Texas Hold’em to operators is continuing. We have also launched another derivative of our world leading Live Baccarat product, Baccarat Control Squeeze, where the player is given even more opportunity to actively participate in the course of the game. After the end of the quarter, we have also launched an entirely new game, Dream Catcher, inspired by popular entertainment shows. It is the world’s first game in the Live Lucky Wheel category, which reinforces our position as the market’s prime innovator in the Live segment. At the publishing of this report, this year’s ICE, Europe’s largest gaming trade fair, has just been held. As a temperature gauge on the industry, I can report that this was the most intense exhibition to date, with a very large interest in our services. Apart from premiering the above-mentioned Dream Catcher, Dual Play Baccarat was also one of our main attractions. This is our second Dual Play game, further strengthening our offer to the land-based segment.  2017 will be an exciting year for Evolution. We will continue to work according to our strategy where product innovation, regulated markets and land-based solutions are key areas. In addition to our commercial focus, we are also preparing the company for a move to Nasdaq Stockholm in the second quarter of the year. Together with my colleagues, I want to thank you for the past year. We look forward to Evolution’s continued success with confidence.

Sobi™ publishes its report for the fourth quarter and full year 2016

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) today announces its results for the fourth quarter and full year 2016. Revenues for the full year totalled SEK 5,204 M, an increase of 61 per cent compared to 2015. Revenues for the quarter were SEK 1,292, an increase of 59 per cent. Product sales for the full year amounted to SEK 4,548 M, an increase of 77 per cent, based on strong performance across the portfolio and the launch of our new haemophilia products, Elocta® and Alprolix®. Business highlights Q4 2016 · European Commission approved the transfer of the marketing authorisation for Alprolix to Sobi · European Commission granted SOBI003 orphan designation for the treatment of MPS IIIA (Sanfilippo A Syndrome) · European study of real-life haemophilia treatment emphasises the need to improve standard of care · In collaboration with Bioverativ, data were presented reinforcing the long-term safety and efficacy of Elocta and Alprolix · Sobi entered into a distribution agreement with Horizon Pharma for Ravicti® and Ammonaps® Financial summary Q4 2016 (Q4 2015) · Total revenue of SEK 1,292 M (814), an increase of 59 per cent (54 per cent at CER) · Product revenue of SEK 1,144 M (698), an increase of 64 per cent (58 per cent at CER) · Gross margin of 67 per cent (64) · EBITA of SEK 210 M (90) · Earnings per share 0.37 SEK (-0.04) Financial summary FY 2016 (2015) · Total revenue of SEK 5,204 M (3,228), an increase of 61 per cent · Product revenue of SEK 4,548 M (2,568), an increase of 77 per cent · Gross margin of 70 per cent (62) · EBITA of SEK 1,543 M (433) · Ended the year with a cash position of SEK 786 M · Earnings per share 3.01 SEK (0.24) “2016 was a highly significant year for Sobi. We delivered strong financial performance across the portfolio, we established a platform for transformational growth through the launch of two innovative state-of-the-art treatments for haemophilia in Europe and the Middle East, and we took several important steps forward with our pipeline of innovative therapies for rare diseases”, says Sobi’s CEO and President Geoffrey McDonough. Financial summary Q4 Q4 Full Full year year Amounts in SEK 2016 2015 Change 2016 2015 Change M Total 1,292 814 59% 5,204 3,228 61% revenues(1) Gross profit 860 520 65% 3,651 2,007 82% Gross margin 67% 64% 70% 62% EBITA 210 90 1,543 433 EBIT 100 17 1,133 146 (Operating profit/loss) Profit/loss 100 -10 809 65 for the period (1)Full year 2016 revenues include a one time credit in Q1 of SEK 322 M relating to the first commercial sales of Elocta, and a one time credit in Q2 of SEK 386 M relating to first commercial sales of Alprolix. Outlook 2017* Sobi expects revenues for the full year to be in the range of SEK 5,800 to 6,000 M. Gross margin is expected to be in the range of 66 to 68 per cent. Sobi expects EBITA for the full year to be in the range of SEK 1,600 to 1,700 M. *At current exchange rates  --- Sobi's report for the fourth quarter and FY 2016 can be found on http://www.sobi.com/Investors--Media/Financial-Reports/ About Sobi™ Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.  For more information please contact   Media relations Investor relations Linda Holmström, Senior Jörgen Winroth, ViceCommunications Manager President, Head of Investor Relations +46 70 873 40 95 +1 347-224-0819, +1 212-579 -0506, +46 8 697 2135 linda.holmstrom@sobi.com  jorgen.winroth@sobi.com  This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of Linda Holmström, Senior Communications Manager, at 08:00 am CET on 16 February 2017. 

Sobi™ expands haemophilia B development portfolio by adding rFIXFc-XTEN to its collaboration agreement with Bioverativ

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) today announces that it has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ. Sobi has the right to include the rFIXFc-XTEN fusion molecule into its collaboration agreement with Bioverativ. By making a one-time payment to Bioverativ Sobi gains an opt-in right to participate in the final development and commercialisation of this product candidate. The opt-in right may be exercised by Sobi in connection with the submission of the marketing authorisation application for rFIXFc-XTEN with the European Medicines Agency. In September 2014, Sobi elected to add the rFVIIIFc-VWF-XTEN fusion molecule for the potential treatment of haemophilia A to its collaboration agreement with Bioverativ.  “Sobi is committed to help address the unmet needs for people affected by haemophilia and we are pleased to engage with this innovative product candidate which has been designed for the subcutaneous treatment of haemophilia B,” says Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi. “We are inspired by the collaboration we have with Bioverativ to support people living with haemophilia. We have a longstanding relationship and this decision further adds to our common aspirations.” - - - About haemophilia BHaemophilia B is caused by having substantially reduced or no factor IX activity, which is needed for normal blood clotting.[i] (https://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/012_XTEN/012e_XTEN_170216_1.docx#_edn1) The World Federation of Hemophilia estimates that approximately 28,000 people are currently diagnosed with haemophilia B worldwide.[ii] (https://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/012_XTEN/012e_XTEN_170216_1.docx#_edn2) People with haemophilia B may experience bleeding episodes in joints and muscles that cause pain, decreased mobility and irreversible joint damage. In the worst cases, these bleeding episodes can cause organ bleeds and life-threatening haemorrhages. Injections of factor IX temporarily replace clotting factors necessary to resolve bleeding and, when used prophylactically, to prevent new bleeding episodes.i About the Sobi™ and Bioverativ collaborationSobi and Bioverativ collaborate on the development and commercialisation of Alprolix and Elocta/ELOCTATE®. Bioverativ has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory, and has manufacturing responsibility for ELOCTATE and Alprolix. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Bioverativ was created as a spin-off from Biogen’s haemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts, USA. During a temporary transition period, which includes time to allow Bioverativ to establish certain licenses and consents related to ELOCTATE® and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products. About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more informationplease contact  Media relations   Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor Relations+ 46 708 73 40 95, + 46 +1 347-224-0819, +1 212-5798 697 31 74   -0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmström, Senior Communications Manager, at 08:15 am CET on 16 February 2017. ---------------------------------------------------------------------- [i] (https://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/012_XTEN/012e_XTEN_170216_1.docx#_ednref1) World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: January, 13, 2017. [ii] (https://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/012_XTEN/012e_XTEN_170216_1.docx#_ednref2) World Federation of Hemophilia. Report on the Annual Global Survey 2013. Available at: http://www1.wfh.org/publications/files/pdf-1591.pdf. Accessed on: January 13, 2017. 

Starbreeze AB (publ) Year-End Report 2016

The full year-end report in Swedish is available at www.starbreeze.com/investor-relations/. The English version of the report will be available within a week. Financial statements in English are available at the end of this document. CHANGED FISCAL YEAR  Note that in accordance with the decision taken on the Annual General Meeting in November 2015, this is the fourth quarterly report after changing the company’s fiscal year to calendar year. The comparative period Q4 2015 corresponds to October-December 2015, previously Q2 2015/2016.  FOURTH QUARTER (OCTOBER - DECEMBER 2016) · Net revenue amounted to SEK 99.4 million (SEK 48.9 million), representing a growth of 103 %. Sum of revenues and capitalized development amounted to SEK 165.5 million (SEK 73.6 million). · During the quarter, PAYDAY 2 represented SEK 37.2 million (SEK 47.7 million) of net revenue. · During the quarter, Dead by Daylight represented SEK 54.6 million (SEK 0.0 million) of net revenue. · Operating income before depreciation and amortization, EBITDA, amounted to SEK 38.8 million (SEK 15.2 million), implying a margin of 23.4 percent. · Income before tax amounted to SEK 32.3 million (SEK 14.0 million). · Net income for the period amounted to SEK 30.2 million (15.4 million). · Earnings per share before dilution were SEK 0.11 (SEK 0.07) and earnings per share after dilution were SEK 0.11 (SEK 0.07). · Cash flow from operating activities amounted to SEK 12.9 million (SEK -3.0 million). · As of December 31, cash and cash equivalents totaled SEK 669.4 million (SEK 85.4 million).  FISCAL YEAR (JANUARY – DECEMBER 2016) · Net revenue amounted to SEK 345.5 million (SEK 218.4 million), representing growth of 58 %. Sum of revenues and capitalized development amounted to SEK 523.0 million (SEK 299.6 million). · Operating income before depreciation and amortization, EBITDA, amounted to SEK 81.2 million (SEK 49.5 million) equivalent to an EBITDA margin of 15.5 %. · Income before tax amounted to SEK 55.9 million (SEK 43.1 million). · Net income for the period amounted to SEK 57.1 million (SEK 39.4 million). · Earnings per share before dilution were SEK 0.22 (SEK 0.20) and earnings per share after dilution were SEK 0.22 (SEK 0.20). KEY EVENTS DURING THE FOURTH QUARTER (OCTOBER – DECEMBER 2016) · In October, Starbreeze carried out a direct share issue to institutional investors, where Första AP-fonden, a major Swedish pension fund, subscribed for a majority of the shares issued. A total of 16,452,991 shares were issued at a price of SEK 23.40, equivalent to a total amount issued of   SEK 385 million. In connection with the new issue, Första AP-fonden also acquired 1,850,000 shares from Indian Nation AB, the company of Starbreeze Chairman Michael Hjorth. · In October, Starbreeze acquired Nozon, a Belgian Visual Effects (VFX) studio and the developer of the PresenZ technology. The PresenZ technology, which was released in 2015, makes it possible to convert 3D films to VR films, and thereby overcome the technical differences between film and game environments. This occurs through interactive parallax in virtual reality and delivers high quality blockbuster computer graphics with true immersive feeling. Since 1998, Nozon has steadily grown to become a well-known, and award winning VFX studio thanks to the company’s creative/artistic approach and technology development. The consideration amounted to EUR 7.1 million, of which EUR 4.6 million was in cash and EUR 2.5 million in newly issued Starbreeze B shares. In addition, the parties also agreed on a 10-year earnout period, based on revenue from the PrezenZ technology. After the acquisition, Starbreeze’s has deepened its analysis of the PresenZ technology, which has resulted in the decision to include all the potential earnout in the calculation of goodwill from the acquisition. The goodwill is estimated at SEK 257.5 million as of December 31, 2016. · In December, Starbreeze agreed to acquire 90.5 percent of the shares in the Indian production company Dhruva Interactive. The total consideration amounted to USD 8.5 million, of which    USD 7.0 million was in cash and USD 1.5 million in newly issued Starbreeze B shares. The deal is planned to be completed in 2017 and had no impact on earnings during 2016. Dhruva Interactive is a highly reputed and best-of-breed art production house, with whom Starbreeze has a long-standing relationship. Founded in 1997, Dhruva is India’s leading game developer with over 320 employees, providing art production services to the global games industry. Dhruva has three studios in India. · During the quarter, Carnegie Investment Bank was appointed as advisor for the company’s relisting to Nasdaq Stockholm’s main market. Starbreeze intends to complete the relisting during 2017. · In November, a new brand was announced in the Publishing division. The new label Starbreeze IndieLabs aims to help projects that are smaller in scope to reach the market. Together with the Croatian studio Lion Game Lion, Starbreeze has agreed that the company will invest USD 300,000 to bring the game AntiSphere to PC and other platforms. Per the agreement Starbreeze will receive 30 percent of revenues, after the initial investment has been fully recouped by Starbreeze. Lion Game Lion and Soap Interactive in turn will retain 100 percent of the IP rights. AntiSphere is a top-down competitive arena battle game in which players use their skills in order to catch each other, and win the match. · In November, Starbreeze entered its second IndieLabs project with the Dutch studio KeokeN Interactive to publish the title “Deliver Us The Moon”. Starbreeze will invest USD 500,000 to bring the game to PC and other platforms. Starbreeze will be able to recoup 120 % of its investment, and will subsequently retain 50 percent of the revenues after distribution fees. KeokeN will retain 100 % of the IP rights. Deliver Us The Moon is set in the near future where the earth’s resources are nearly depleted. A brave astronaut will take the great step and travel to the moon in a do-or-die secret mission to save humanity. AFTER THE QUARTER · In early January, Starbreeze announced that the first pilot center for IMAX VR Experience had opened in Los Angeles, in close proximity to the popular shopping area - The Grove and Farmers Market. In the center, visitors will be able to test high quality VR experiences in StarVR, which is produced in collaboration with Acer. Experiences available for StarVR include John Wick Chronicles: Arcade Edition and the range will be gradually extended as new VR experiences in both film and games become available. StarVR was positively received by visitors and along with John Wick Arcade Edition, is currently one of the most popular VR experiences in the center. · After the opening of the first IMAX VR Experience center in Los Angeles, Starbreeze announced that the company is negotiating with IMAX regarding the continuation of the agreement on premium experiences in IMAX VR Centers, which was announced in May 2016. In light of the decision of IMAX to broaden its offering to include widely available VR experiences during the launch of the center, Starbreeze anticipates that the form of collaboration will be adapted accordingly. · The VR game John Wick: Chronicles was released on Steam for HTC Vive on February 9, in connection with the premiere of the movie John Wick: Chapter 2. The game was available for pre-order for USD 19.99 via the platform from October 6, 2016. · In January, Starbreeze signed an agreement with Behaviour Digital regarding a digital version of Dead by Daylight for PlayStation 4 and Xbox One. To date, more than 1.8 million copies of the game’s PC version have been sold on Steam. The development costs for the modifications required for the console version will be shared equally between the parties. The revenue sharing model follows the existing agreement. In February, Starbreeze signed a distribution agreement with Digital Bros’ subsidiary 505 Games regarding physical distribution of Dead by Daylight for PlayStation 4 and Xbox One. Furthermore, this means that 505 Games will pay an advance royalty of USD 2.5 million, which will be shared between Starbreeze and Behaviour. The agreement does not cover the Asian and Nordic markets. The console version of the game is expected to be released during the second quarter of 2017. · In February, Starbreeze signed an agreement with Double Fine Productions to publish the game Psychonauts 2. Starbreeze will invest USD 8 million to bring the game to PC and console platforms together with Double Fine Productions. The release is expected to occur sometime during 2018. The development of the game was previously funded by Double Fine Productions and through equity crowdfunding via the Fig service. Starbreeze will be able to recoup 100 % of its full investment including marketing costs and will receive an initial revenue share of 85 % after distribution fees and Fig crowdfunding revenue share. Starbreeze share of revenues will become 60 % after the investment is recouped, after distribution fees and Fig crowdfunding revenue share. Psychonauts 2 is a third-person action/adventure game where players control Razputin Aquato   – a newly graduated Psychonaut with powerful psychic abilities. STARBREEZE KEEPS DELIVERING CEO BO ANDERSSON KLINT GIVES HIS COMMENT We’re proud to yet again show a triple digit growth for this quarter and the highest EBITDA since the launch of PAYDAY 2. It is a solid performance that shows our ability to deliver profitability while we are scaling our business to secure future growth. PAYDAY The PAYDAY franchise generated SEK 37.2 million (SEK 47.7 million) in total whereof SEK 0.0 million (SEK 14.4 million) in production support. As the sole owner of the PAYDAY IP, we no longer receive any production support revenues. We’re additionally still awaiting 505 to recoup USD 5 million on console, while we get 100% of the healthy PC sales. Moreover, we expect 505 to have reached their USD 5 million recoup in Q1 2017 as we see impressive PAYDAY performance through digital distribution on consoles following the lastest update. DEAD BY DAYLIGHT We’re over the moon with Dead by Daylight, a complete success both strategically and financially. The game has now sold over 1.8 million units on PC and contributes with SEK 54.6 million to Starbreeze net revenues in Q4, making it the best quarter through the game’s lifetime. An impressive trend that we, together with Behavior, will nurse carefully as we expand the product to consoles in Q2 2017. To date, the game has generated over 267 MSEK in gross sales on Steam. STARBREEZE FINANCES We’re also delighted to see that both our acquisitions, ePawn and Nozon, for the first time are contributing to top-line. Both businesses are now fully integrated and run at full speed within Starbreeze. As we continue our steady growth we need to invest in our key assets PAYDAY, OVERKILL's The Walking Dead, Valhalla engine, StarVR and in our very important publishing business. Consequently, our operating expenses, excluding royalties to publishing partners, have increased with SEK 46.7 million or 78 % compared to Q4 2015. The incremental spend is in all material aspects still derived from employee related expenses as we continue to ramp up the teams for delivering on our plans. Despite the increase in costs we show a remarkable profitability with an EBITDA margin reaching  23.4% underpinned by a strong development of our top line but also boosted by a stronger US dollar.   Boosted by successful financing activities during the third quarter, we’re ending the year with a cash position of SEK 669.4 million (SEK 85.4 million). To be clear, these funds will not be put in the bank to rest, they will continue to build our momentum. Hence we expect it to be reduced over time. Worth noting is also that we now have positive cash flow from our operating activities amounting to         SEK 12.9 million (SEK -3.0 million). When closing the fourth quarter we also close the financial year 2016 where net revenues reached SEK 345.5 MSEK (SEK 218.4 million) which is 62 % better than the financial year when we launched PAYDAY 2. EBITDA reached SEK 81.2 million (SEK 49.5 million) and net profit SEK 57.1 million (SEK 39.4 million). Our core business is doing very well. VR-CENTER IN LOS ANGELES As the first phase of building and operating a pilot VR center, mimicking our VR arcade concept StarCade, with IMAX is underway, we have entered into negotiations with IMAX about the future sale of content and StarVR-headsets into this business. At the VR center, we operate under our original agreement and have two pods equipped with the latest iteration of our StarVR HMD showcasing John Wick Chronicles Arcade Edition in collaboration with Lionsgate. Since January, we have thoroughly enjoyed having customers and potential partners visit the center to experience both the hardware as well as our content, something that has strengthened our view that location-based VR at this time is the best way for consumers to experience high-quality VR. Our goal is to sell StarVR systems to as many different location-based businesses, theme parks and B2B projects as possible. Our aim is to sell a broader range of headsets and systems through our joint venture with Acer under the brand StarVR. STARVR EVOLUTION While we, just as planned, have not yet started shipping larger volumes of StarVR, the current interest from multiple markets and from prominent brands and business sets us up well for the mass production phase beginning later in 2017. We focus on distributing and prioritizing the current development version of the headset to key partners, ensuring that we are compatible with leading industry systems and standards to fully enable us to lead the charge once we deliver the first full production unit. We estimate approximately two more development iterations during the year, where we trust that the third iteration will include Tobii’s proprietary eye tracking. Durability, field of view, hygiene, resolution, refresh rates and weight are all key aspects that we improve constantly and according to plan. The roadmap of StarVR is clear, we’re still targeting B2B partners as our primary business, and we keep delivering as planned at our decided phase. We aim to make the development of StarVR and sales of VR content a significant business for us down the line. We secure this through making early investments and strategic collaborations. This will educate us internally how to master the experience design and optimize our production. Once the market is mature, we’ll be in a pole position. For the fourth quarter StarVR with related activities account for less than 10% of Starbreeze operating expenses. NOZON’S PRESENZ While we’re integrating all of our recent acquisitions with Starbreeze vision to build future ecosystems, Nozon’s Presenz technology is generating quite the buzz in Hollywood. Nozon is now working hard together with our business development team to produce its first showcase VR short movie that we believe will build the foundation for a major cogwheel in our VR offering. Using PresenZ, movie studios can use their CG assets from feature films repurposing them easily for VR movies without losing visual fidelity. We strongly believe that together with the high-resolution of StarVR, this can be a groundbreaking technology for movie and entertainment production everywhere.   PAYDAY MOBILE, BCN STUDIO As a separate note to this report, we also just announced that we’ve opened a new office in Barcelona, Spain. The Barcelona Studio consists of a handful of very talented individuals that have been with us in Stockholm for quite some time. Together with old friends and now new colleagues joining us from a prominent mobile developer, they form our task force to steer our mobile projects with a 100% focus. The bulk of the development will mainly be outsourced but we require a dedicated team from Starbreeze to make sure we are on point and deliver with the same focus as our other products. Starbreeze Barcelona will closely monitor the wrap up of Geminose and also focus its efforts on PAYDAY: Crime War. After a due diligence of the progress on the mobile version of our beloved PAYDAY franchise, we found a lack of focus on our product. As we want to see this game realized as badly as many of our fans, we’ve moved production to another studio, BadFly Interactive. As part of a work-for-hire partnership, BadFly have hit the ground running and we look forward to sharing more from the game in the months to come. The project has already accelerated considerably and is now fully playable in multiplayer with the games backend in place. The following months will be dedicated to building more content and polishing the gameplay format to maximize the fun of the final product. In 2017 we also continue our full productions of RAID, OVERKILLS The Walking Dead, CROSSFIRE Co-Op and Geminose. Our lineup is strong and our teams dedicate their full energy in making the games as high-quality as recent products such as the PAYDAY and Dead by Daylight DLC releases. Our success is of course shared by and thanks to our partners. Lately we had the pleasure to work with Universal on our PAYDAY Scarface DLCs in December. Additionally, we’ve continued our extremely successful partnership with Lionsgate on two DLCs for PAYDAY and the release of the stand-alone VR game John Wick Chronicles on Steam and in the IMAX VR center. These collaborations are tremendously important to us as we establish Starbreeze as a trusted partner for top-tier brands as well as it gives us an ever-growing community of fans from near and far enjoying and talking about Starbreeze products. Our publishing portfolio has grown to secure a steady flow of products, big and small, for the upcoming year. We are proud to have signed up Double Fine with Tim Shafer leading the development of their new AAA game Psychonauts 2. We are constantly looking to attract leading teams to our publishing business and 2017 will see a number of these projects initiated by Starbreeze. It is with great satisfaction that we also can announce that PAYDAY 3 production is officially initiated and at a full design stage. I’d like to especially clarify, that this project will enjoy as much time as we deem needed. It will be done when it’s done. This is our single most important brand today and the cornerstone of our business and we will treat it accordingly. Updates in the near future might be scares and far between. You simply don’t rush PAYDAY 3. With a team of over 550 talented developers, post the acquisition of Dhruva, we are well staffed for the full productions going forward. With this strategic acquisition our capacity is very satisfying, meanwhile we keep recruiting more game developers to secure quality and talent for the future. Our AAA game productions and our innovative VR pipeline is providing our developers with real challenges and exciting careers. At Starbreeze, we look forward to keep delivering on our games, services and strategy for 2017 and beyond. Let’s do this!### This information is information that Starbreeze AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 16 February, 2017 For more information, please contact:Starbreeze Investor Relations Contact: Maeva Sponbergs, +46 (0)8 209 208 or ir@starbreeze.com  About Starbreeze  Starbreeze is an independent creator, publisher and distributor of high quality entertainment products. With studios in Stockholm, Paris, Los Angeles, Barcelona and Brussels, the company creates games and other virtual reality entertainment products, based on proprietary design and licensed content. Starbreeze's most recent games include PAYDAY 2®, John Wick VR shooter and upcoming survival co-op FPS OVERKILL’s The Walking Dead. Under its publishing initiative, Starbreeze has together with Canadian studio Behaviour Digital successfully launched horror thriller Dead by Daylight.x Starbreeze has set out to develop truly immersive virtual reality experiences, by integrating software and hardware in its StarVR® head mounted display, which is produced together with Acer, displaying a unique field of view and a mission to bring top-end VR to large audiences. Together with IMAX, Starbreeze aspires to dominate the location based VR market with the IMAX VR centers. The first IMAX VR center opened in Los Angeles in January 2017.  Headquartered in Stockholm, Sweden, Starbreeze's shares are listed on Nasdaq Stockholm First North Premier under the tickers STAR A and STAR B with the ISIN-codes SE0007158928 (A share) and SE0005992831 (B share).  Remium Nordic is the company's Certified Adviser. For more information, please visit http://www.starbreeze.com, http://www.starvr.com, http://www.overkillsoftware.com  

Beijer Ref Q4 2016

Net sales for the fourth quarter of 2016 increased by 8.5 per cent compared with the corresponding period in the previous year and amounted to SEK 2,199M (2,027). The increase is mainly due to the acquired companies, HRP and Realcold. Good development for Commercial & Industrial refrigeration. Slightly weaker development for HVAC. Operating profit for the fourth quarter of 2016 amounted to SEK 145M (134). It is an improvement of 8.0 per cent compared with the same period last year. Profit for the quarter amounted to SEK 100M (84), an increase of 18.6 per cent compared with the same period last year. Profit per share amounted to SEK 9.17 (8.64). The Board of Directors proposes that the Annual Meeting of shareholders resolves that an increased dividend of SEK 5.50 (5.25) per share shall be paid. Comments by the CEO Stable quarter ends a good year Beijer Ref ended 2016 with a stable quarter and a profit increase. The development was especially positive during November and December and we are of the opinion that this trend will continue into the new year. Our largest market segment, Commercial & Industrial refrigeration, enjoyed a positive development during the quarter, whilst HVAC was slightly weaker than in the corresponding quarter of the previous year. Viewed over the full year, however, HVAC enjoyed a stronger development than Commercial & Industrial refrigeration. Strong quarter in Central Europe In Central Europe, the restructuring work with HRP in the United Kingdom is beginning to generate an effect. We were delayed by the examination by the Competition & Markets Authority in the UK (CMA), but were able to complete our work of integrating HRP during the autumn and contributed to a positive result for the fourth quarter. The other companies in the region also enjoyed a positive development.    In the Nordic countries, the result was slightly lower than for the corresponding period in the previous year. This is mainly because the comparative figures for the corresponding quarter in the previous year were unusually high.    The result in Southern Europe was affected by the fact that we took on costs in order to achieve better logistics and a more cost-efficient organisation in France. In addition, demand in the market for indoor climate control slowed down slightly. On a full year basis, however, the region reports a positive stable development.    Asia Pacific developed strongly in line with forecasts and Africa shows a stable positive development. During the quarter, we opened an operation in Tanzania, which becomes our seventh market in Africa.    Taken together, it is gratifying that we have reversed the development in the newly-acquired company in the United Kingdom. This acquisition now shows positive results. Important resolution in Kigali  At a summit meeting in the capital of Rwanda, Kigali, in October, 170 countries agreed to phase out hydrogen fluoride carbon gases (HFC gases), which contribute to global warning. A decision to phase out HFC has already been taken within the EU, but through the agreement in Kigali the phasing out of HFC will also be initiated in other large markets such as the USA and Japan starting as early as 2019. Other countries in the agreement will follow in accordance with an established timetable, with a final start in 2028 in countries such as India and Pakistan. Through our broad offer of eco-friendly alternatives to HFC solutions, the decision provides good opportunities for Beijer Ref in a growing global market. Continued investment in OEM  During the quarter, we continued to expand the range of products manufactured internally and will launch new products during 2017. This operation is now increasing more rapidly than the traditional distribution operation. The OEM investment strengthens our offer in the market towards, among others, food stores. The OEM offer is important in enabling us to meet the increasing demand for eco-friendly solutions which we see in Europe and also increasingly in Australia and New Zealand.    We are also continuing our work in digitalising our operation, which will lead to cost savings and increased efficiency in the long term. Our local presence is decisive for good customer relations, but through the digitalisation we also see new market opportunities.    Taken together, I look back on a good last quarter of 2016 and a year that has involved an all-time-high for both sales and results. Beijer Ref’s Board of Directors proposes an increased dividend to SEK 5.50 (5.25), which should be seen as a confirmation of yet another good year for the Group. We stand well equipped to face the future and are looking forward to 2017 with confidence. Per Bertland Fourth quarter of 2016 Sales  Beijer Ref increased its net sales by 8.5 per cent to SEK 2,199M (2,027) for the fourth quarter of 2016. The sales increase emanates mainly from the acquired companies, HRP and Realcold. When adjusted for exchange rate fluctuations and acquisitions, the organic sales change was -1.0 per cent. The decrease in organic sales is attributable to the weaker HVAC market in Europe. In 2015, the HVAC market in Europe was strongly influenced by the heat wave, the effects of which on demand continued into the fourth quarter and gave strong comparative figures in 2016. The market segment, Commercial & Industrial refrigeration, increased by one per cent. During the year, net sales increased by 8.2 per cent to SEK 9,045M (8,361). When adjusted for exchange rate fluctuations and acquisitions, the organic sales change was 2.8 per cent. Results  The Group’s operating profit amounted to SEK 145 M (134) for the fourth quarter, equivalent to an increase of 8.0 per cent. The increase in profit is partly explained by the contribution from the acquired companies, HRP and Realcold. The operating margin in the quarter is on a par with the same period in the previous year, 6.6 per cent (6.6). When adjusted for exchange rate fluctuations and acquisitions, the organic change in operating profit was -1.7 per cent for the quarter, for the same reason as sales. For the full year, operating profit increased by 4.5 per cent to SEK 593M (567). When adjusted for exchange rate fluctuations and acquisitions, the organic operating profit increase was 2.7 per cent. The Group’s financial income/expense amounted to SEK -33M (-42) for the year. Profit before tax was SEK 560M (525). Profit for the period was 399M (373). Profit per share amounted to SEK 9.17 (8.64). Dividend  The Board of Directors proposes that the Annual Meeting of shareholders resolves that a dividend of SEK 5.50 (5.25) per share shall be paid for the 2016 financial year. This is equivalent to a total of SEK 232.7M if the shares currently held by the company are excluded. Cash flow  Cash flow from the current operation before change in working capital was SEK 481M for the 12 months of 2016 compared with SEK 488M for the corresponding period in the previous year. During 12 months, the working capital has increased by SEK 416M (-7), partly as a result of the increased business volume and the acquired companies, HRP and Realcold. This gives a cash flow from the current operation of SEK 65M compared with SEK 495M in the previous year. Investments  The Group’s capital expenditure including business combinations amounted to SEK 80M (237) for the year. The difference when compared with the previous year is due to minor influence from acquisitions. Significant events during the year During the first quarter, the UK Competition & Markets Authority (CMA) began an examination of our acquisition of HRP Ltd with 15 branches in the United Kingdom. On 8 June, CMA announced that it had no objections to the transaction. The planned restructuring work could therefore begin. HRP is included in the consolidated accounts as from June.   Risk assessment  The operation of the Beijer Ref Group is affected by a number of external factors, the effects of which on the Group’s operating profit can be controlled to a varying degree. The Group’s operation is dependent on the general economic trend, especially in Europe, which controls the demand for Beijer Ref’s products and services. Acquisitions are normally linked with risks such as, for example, staff defection. Other operating risks, such as agency and supplier agreements, product responsibility and delivery undertaking, technical development, warranties, dependence on individuals, etc., are continually being analysed and, when necessary, action is taken to reduce the Group’s risk exposure. In its operation, Beijer Ref is exposed to financial risks such as currency risk, interest risk and liquidity risk. The parent company’s risk picture is the same as that of the Group. For further information see the Group’s Annual Report. Malmö, 16 February 2017 Beijer Ref AB (publ) Per Bertland, CEO For further information, please contact:  Per Bertland, CEO – switchboard +40 35 89 00 Jonas Lindqvist, CFO – switchboard +40 35 89 00 This interim report has not been the subject of examination by the Company’s Auditors. This information is information that Beijer Ref AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 16 February 2017. Beijer Ref in short The Beijer Ref Group is focused on trading and distribution operations within refrigeration products, air conditioning and heat pumps. The product programme consists mainly of agency products from leading international manufacturers and, in addition, some manufacture of own products, combined with service and support for the products. The Group creates added value by contributing: technical competence to the products; accounting for knowledge and experience about the market; and by providing efficient logistics and warehousing.      Operations are carried out by region within the Beijer Ref, which comprises Beijer Ref ARW (Air conditioning, refrigeration, wholesale) and Toshiba’s distribution operation within air conditioning and heating. The Beijer Ref Group is a leading operator within the refrigeration sector in Europe and has a significant position within air conditioning in Europe. The operation is split into six geographic segments: Nordic countries, Southern Europe, Central Europe, Eastern Europe, Africa and Asia Pacific. Growth is achieved both organically and through the acquisition of companies which supplement existing operations. Seasonal effects  Beijer Ref’s sales are seasonally dependent as demand for refrigeration and air conditioning is at its peak during the warm months of the year. It means that demand in the northern hemisphere is at its peak during the second and third quarters whilst demand in the southern hemisphere is at its peak during the first and fourth quarters. Financial calendar  •     The Annual Report for 2016 will be published in March 2017. •     The Interim Report for the first quarter 2017 will be published on 24 April 2017. •     The Interim Report for the second quarter 2017 will be published on 14 July 2017. •     The Interim Report for the third quarter 2017 will be published on 20 October 2017. The Annual Meeting of shareholders will be held on 6 April 2017. This document is a translation of the Swedish language version. In the event of any discrepancies between this translation and the original Swedish document, the latter shall be deemed correct. www.beijerref.com 

New White Wolf Games Arrive Today with new Vampire and Mage stories (in the World of Darkness)

STOCKHOLM, SWEDEN (16th of February 2017) White Wolf Publishing today releases Vampire The Masquerade: We Eat Blood and Mage The Ascension: Refuge, two all-new interactive fiction games for Android, iOS, and PC. These classic roleplaying games enter the digital age with two new titles inspired by choose your own adventure books, written and illustrated by award-winning authors and artists. In Vampire The Masquerade: We Eat Blood you’re a young artist who wakes up at night to find you’re no longer human…but exactly what are you and why are you so ravenously hungry for blood?!? Told entirely through an innovate mobile messaging perspective, We Eat Blood is a sharp, mature, and terrifying story about your first nights as unwilling predator and prey. Will you join ancient vampire conspiracies, or will you turn the tables on oppressive authority and seek your own future? The temptation is real. The game is written and illustrated by Zak Sabbath and Sarah Horrocks. In Mage The Ascension: Refuge you play a volunteer at a European camp for Syrian refugees, and suddenly you discover that magic is real, you can use it, and you’re in the middle of a secret magical war for the fate of the world. The game lets you experience today’s social and political upheavals while learning that you can shape reality itself through sheer force of belief. Your actions and choices will have profound consequences on the world and people around you. Safety or sacrifice? Let them in or build the wall? The choice is yours. The game is written by noted Swedish author Karin Tidbeck. “The World of Darkness has always been about mature, intelligent stories,” said White Wolf Creative Director Martin Ericsson. “These new games uphold that tradition, but we put a very modern twist on it: we see our games as a way not only to entertain, but to look closely at contemporary issues, and ask some of the big questions of our time.” “We are absolutely delighted to see the first games from the new White Wolf based on our most popular brands reach our fans on both mobile and Steam,” said White Wolf CEO Tobias Sjögren. “We know we can create great entertainment as well as serve the responsibility any content creators have helping the audience reflect on the world around them. These games show we are keen on trying new formats and that stories in World of Darkness doesn’t shy away from tough questions or contemporary issues.” These game releases are the first digital game releases in over a decade for this acclaimed story world, and this release marks the start of White Wolf’s emergence as a transmedia entertainment company. White Wolf are working on a 5th edition of the Vampire: The Masquerade tabletop RPG books and recently announced a video game adaptation of Werewolf: The Apocalypse. Learn more about Vampire the Masquerade: We Eat Blood and Mage the Ascension: Refuge at White Wolf’s website: www.white-wolf.com.

Public transport supplier Pilotfish Networks AB is acquiring Appello Technologies AB

Pilotfish supplies a combination of a standardised communication platform and a range of services which in various ways improve productivity within the public transport system. At present, public transport in Scandinavia and in Europe in general is undergoing a rapid transition, with major challenges in the form of increased competition, new technology, electric vehicles and new information technologies. Cloud-based applications and services, standardised platforms and efficient autonomous vehicles are important tools for meeting the rapid changes which are currently taking place within the public transport sector. Executive Director of Pilotfish, Tomas Gabinus, says that “Appello has a fantastic team, which with its expertise within the fields of application development, maps and navigation services - used by millions of end-users - is a perfect complement to Pilotfish’s current team”. Tomas adds that “we furthermore intend to continue to develop Appello’s navigation service Wisepilot, which is supplied internationally to a range of telecommunications operators”. Lars Szakaly, Executive Director of Appello, remarks that “we at Appello look forward to working together with Pilotfish on continuing our collective journey as suppliers of modern applications for public transport”. For more information please contact: Tomas Gabinus, Executive Director, Pilotfish Networks AB. Tel.: +46 (0)31 3396674. Email: tomas.gabinus@pilotfish.se Pilotfish’s ambition is to achieve a higher level of competitiveness for bus and train operators within the public transport sector. Pilotfish’s approach is centred on structured digitalisation based around an open communication platform which can be supplemented with various user-friendly applications for utilization via the implementation of strategies aimed at continuous improvements. Pilotfish’s tender is based upon standards and architectures which are administered by the European Committee for Standardization’s ITxPT (Information Technology for Public Transport).

Stora Enso plans to shut down one SC paper machine at Kvarnsveden Mill in Sweden

Stora Enso will start co-determination negotiations with employees at its Kvarnsveden Mill in Sweden regarding a plan to reorganise the mill, including a permanent closure of paper machine (PM) 8. The planned actions would affect a maximum of 140 employees. The paper machine has an annual capacity of 100 000 tonnes of super-calendered uncoated magazine paper (SC) and it is planned to be shut down by the end of the second quarter of 2017. The plan would result in annual cost savings of EUR 12 million. Stora Enso will book restructuring charges of approximately EUR 17 million as an item affecting comparability (IAC) in its Q1/2017 results, of which about EUR 14 million will be cash costs. The planned closure would not have material impact on Stora Enso’s sales or operational EBIT. “We plan to reorganise Kvarnsveden Mill to ensure its competitiveness in the structurally declining paper market. This plan includes the permanent shutdown of PM8, which, due to its small size and technical age, is unfortunately no longer competitive in the current market conditions. We appreciate the efforts taken by the employees, and regret that this plan would be necessary to support the competitiveness of Kvarnsveden Mill going forward,” says Kati ter Horst, EVP Paper division. The closure of PM8 at Kvarnsveden Mill would not impact Stora Enso’s SC paper offering. In Europe, Stora Enso continues to produce SC paper at Kvarnsveden Mill PM12 as well at Maxau Mill in Germany and Langerbrugge Mill in Belgium. The group also serves its SC customers from Dawang Mill in China. No decisions regarding the planned reorganisation or employee impact will be taken until the co-determination negotiations have been concluded. Production at Kvarnsveden Mill would continue on two lines, PM10 for improved newsprint paper and PM12 for SC papers. For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228Liisa Nyyssönen, SVP Communications, Paper division, tel. +358 40 544 3491 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 25 000 people in more than 35 countries, and our sales in 2016 were EUR 9.8 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com (http://www.storaenso.com/)

Sectra Tiger approved for NATO SECRET

The ability to transfer information quickly and securely, without the risk of eavesdropping, can be vitally important for authorities, defense organizations and critical societal functions. Sectra Tiger/S 7401 offers the highest level of protection against eavesdropping attacks, even from state actors, and is a unique solution that is approved for both mobile and fixed communication at the NATO SECRET security level. Sectra Tiger/S 7401 was developed by Sectra under guidance from the Netherlands National Communications Security Agency (NL-NCSA). This approval confirms that the long and fruitful cooperation between Sectra and NL-NCSA meets the highest requirement for communication security.  Thanks to cooperation with customers and national security authorities in numerous countries, Sectra’s various solutions for secure communications have now been delivered to more than half of the EU’s member states, for national use and within the context of the EU and NATO. Users include government officials, officials in the diplomatic corps, decision-makers in defense and critical infrastructure, and military personnel in the field. Common to these is that they use security-approved products to communicate securely and that they have high demands on flexibility and mobility.  About Sectra Tiger/S 7401The secure mobile phone Sectra Tiger/S 7401 is the top tier of an ecosystem of security-approved products for secure communications. The system also covers solutions for secure smartphone use and secure fixed telephony. By using Sectra Tiger Ecosystem, an organization can assign secure communication solutions based on an individual’s communication and security requirements. Sectra Tiger/S 7401 also enables secure communications between different security domains. This means a user can securely communicate with colleagues in NATO, the EU and their respective national networks, with a single telephone, which is unique in the crypto industry. Download press images: communications.sectra.com/news-and-media/image-bank 

Airport operator Avinor extends its investment in IFS Applications

By upgrading to IFS Applications 9, Avinor will be able to leverage its layered application architecture and new support model, which will ensure that the company is always benefitting from the latest updates and enhancements in a cost-efficient way. In addition, the upgrade will give Avinor extended capabilities to monitor and document that work processes are carried out in accordance with the industry’s stringent safety requirements. IFS Applications 9 will also empower Avinor employees with the role-based and customizable IFS Lobby™ interface. “We chose to upgrade to IFS Applications 9 because we see great benefit in running evergreen ERP in the future,” Avinor CIO Brede Nielsen said. “Our goal is to remain the leader in terms of service delivery, safety, quality, and cost efficiency. In an increasingly complex industry, a comprehensive ERP suite is one of the most important enablers for achieving operational excellence.” Glenn Arnesen, CEO of IFS in Scandinavia, added, “Avinor plays a pivotal role in ensuring Norway’s airports run smoothly, making process efficiency and safety of the utmost importance. IFS Applications 9 will give Avinor a solid platform for ensuring business transparency and control in an always-updated, flexible environment. We are proud of the renewed trust that Avinor has placed in our solutions and we look forward to continuing our mutually beneficial partnership.” The two companies’ business relationship dates back to 1996, when IFS Applications was chosen as the central maintenance system for Oslo Airport Gardermoen. In 2012 (http://www.ifsworld.com/corp/news-and-events/newsroom/2014/10/21/13/06/2012-12-20-avinor/), Avinor chose to deploy IFS Applications 8 as its central ERP solution to manage and control its varied business processes across a network of 46 airports all over Norway. In 2013 (http://www.ifsworld.com/corp/news-and-events/newsroom/2014/10/21/12/47/2013-07-09-avinor/), the company opted to expand its IFS portfolio with additional functionality for HSEQ (health, safety, environment, quality) reporting. Another area where Avinor already enjoys major benefits, thanks to IFS Applications, is within procurement. The procurement solution is used for achieving a more precise ordering of security personnel, something that used to be a major cost and was sometimes problematic because of the airports’ diverse needs. The solution, together with process improvement, has contributed to substantial savings. Learn more about how IFS supports business in the civil aviation sector: www.ifsworld.com/corp/industries/aerospace-and-defense/civil-aviation-sector/.

Deveo combines forces with a global cloud computing powerhouse

Helsinki, Finland, February 2017: Code hosting and collaboration platform, Deveo, has joined forces with Alibaba Cloud, the cloud computing arm of Alibaba Group, to become   the first repository platform within the Alibaba Cloud Marketplace. With free private repositories, support for Git, Mercurial, and Subversion version control systems, and WebDAV, for storing binary files, Deveo offers a unique private hosting environment. “We are glad to partner with Alibaba Cloud to deliver the best tools for the developers to use in the cloud.” explained Deveo CEO, Ilmari Kontulainen. “The first step was adding Deveo to Alibaba Cloud’s marketplace, but we look forward to discussing a more in-depth collaboration to offer the whole DevOps tool stack on the cloud with a click of a button.”Deveo has been creating proprietary software to assist high-profile enterprises for the last 10 years, as part of the leading Finnish DevOps organization, Eficode. In 2014, the team launched their code hosting and collaboration platform as a standalone application, and while retaining enterprise users, set their sights on the wider industry.“Deveo's sister company has already introduced disruptive innovation in the mobile payment sector.” said Kontulainen. “We are hoping to find disruptive innovations in the DevOps tool sector together with Alibaba Cloud.”   Contact: Ilmari Kontulainen, ilmari@deveo.com, +358 440 715518Deveo Pohjoinen rautatienkatu 25, 00100 Helsinki, FinlandMore about Deveo: https://deveo.comAssets available: http://bit.ly/2fcAhBT   About DeveoBefore Deveo was founded in 2014, the founding team were building custom-tailored software production solutions for customers, including some of the world's largest companies. The small team of 8 work in a fully distributed company, with employees all over Europe, from the UK to Romania. The team are united by 5 core values of simplicity, transparency, customer centricity, curiosity and initiative, and are on a mission to streamline software development.

Summons to the Annual General Meeting of shareholders in Castellum AB (publ)

At the Annual General Meeting of shareholders in Castellum AB (publ), on Thursday, March 23, 2017, following proposals will, inter alia, be presented: · A distribution of SEK 5.00 per share, distributed to the shareholders in two equal payments of SEK 2.50 per share. The first record day for distribution is proposed to be Monday, March 27, 2017 and the second record day for distribution is proposed to be Monday, September 25, 2017. · An amendment of the Articles of Association regarding the term of office at the election of auditor. · Re-election of the existing Board members Charlotte Strömberg, Per Berggren, Anna-Karin Hatt, Christer Jacobson, Nina Linander, Johan Skoglund and Christina Karlsson Kazeem. Charlotte Strömberg is proposed to be re-elected as Chairman of the Board of Directors. Further, remuneration to the members of the Board of Directors is proposed to be the following(2016 remuneration within brackets).   -   The Chairman of the Board of Directors: SEK 825,000 (SEK 720,000). -   Each of the other members of the Board of Directors: SEK 350,000 (SEK 315,000). -   Member of the Remuneration Committee, including the Chairman: SEK 30,000 (SEK 30,000). -   Chairman of the Audit and Finance Committee: SEK 100,000 (SEK 50,000). -   Each of the other members of the Audit and Finance Committee: SEK 50,000 (SEK 35,000). The proposed total remuneration to the members of the Board of Directors, including remuneration for committee work, accordingly amounts to SEK 3,215,000 (SEK 2,820,000). It is proposed that the auditor’s fee shall be paid as per approved accounts. ·  In accordance with the Audit and Finance Committee’s recommendation, Deloitte is proposed as auditor in Castellum for a one-year term of office until the end of the Annual General Meeting 2018. If the Annual General Meeting resolves to elect Deloitte as auditor, Deloitte has announced that the current authorised auditor in the company, Hans Warén, will be the main responsible auditor at Deloitte.  ·  A new Election Committee shall be established in preparation for the Annual General Meeting 2018. For this purpose the Chairman of the Board of Directors will contact the three largest ownership registered or otherwise known share­holders as per the last share trading day in August 2017 and to invite them to each appoint one member of the Election Committee. The names of the members of the Election Committee shall be made public no later than six months prior to the next Annual General Meeting. ·  Authorisation for the Board of Directors to resolve to acquire and transfer the company’s own shares until the next Annual General Meeting of shareholders. Appendix: the Summons  For further information, please contact Charlotte Strömberg, Chairman of the Board of Directors. Phone +46 702 77 04 03 Henrik Saxborn, CEO, Phone +46 31-60 74 50 www.castellum.se  Castellum is one of the major listed real estate companies in Sweden. The fair value of the real estate portfolio amounts to approx. SEK 71 billion, and comprises of commercial properties for office, retail, warehouse and logistics with a total lettable area of approx. 4.3 million sq.m.  Castellum own and manage properties through one common brand in five geographical regions with strong local presence. The five geographical regions are: Central, North, Stockholm, West and Öresund.  Castellum is represented in the Dow Jones Sustainability Indices (DJSI), which includes the companies in all industries in the world with best performance in terms of sustainability. Further Castellum sustainability performance recently has been awarded two top distinctions: First Prize for sustainability reporting in Europe from EPRA and Global Sector Leader, handed out by GRESB which means that Castellum is ranked first in the world within the office- and industrial-properties sector. Further The Castellum share is listed on Nasdaq Stockholm Large Cap.  Castellum AB (publ), Box 2269, SE-403 14 Gothenburg | Org nr/Corp Id no SE 556475-5550 | Phone +46 31 60 74 00 Fax +46 31 13 17 55 

ABB to deliver digital substation for one of India’s largest IT parks

ABB will deliver a 110 kilovolt (kV) digital substation to Technopark, one of the largest Information Technology (IT) parks in India, located in the southern state of Kerala and spanning an area of 930,000 square meters. Due to the nature of the industry, the campus is highly dependent on reliable, round the clock power to serve the 350 companies employing more than 50,000 people. Technopark is currently in an expansion mode and is envisioned to become a self-contained township with potential to employ a hundred thousand people working in the fields of IT, biotechnology and nanotechnology, increasing the need for reliable power supplies for commercial and residential consumers. “This will be among the first digital substations in India and supports the country’s vision of smarter grids and cities” said Claudio Facchin, president of ABB’s Power Grids division. ”It highlights the increasing digitalization of the grid, a key focus area of our Next Level strategy and reinforces our digital thrust based on our common ABB Ability offering.” A digital substation is more compact, flexible, reliable, safer, cost effective over the lifecycle and simpler to maintain and extend than a conventional one. It is another example highlighting the integration of information and operational technologies (IT and OT) and will leverage digital communications via fiber optic cables that will replace traditional copper connections using analog signals. This will improve flexibility, availability, reliability and safety, while reducing installation costs and environmental impact. The digital substation will also enable the drive for power management efficiencies by turning real time data into actionable intelligence and bringing cost efficiencies. It will be IEC 61850 compliant, ensuring an open communication architecture. Using fiber optic cabling instead of copper enables reduced cost through the direct savings on copper, optimized panel design and less civil work required to lay the cables. Thousands of traditional analog copper signaling wires between the High Voltage equipment and the control room are also substituted with a few fiber optic digital communication buses (process bus). All this reduces installation cost. Digitizing signals at their source reduces the risk of electrical hazards to operators, creating a safer work environment. The substation equipment is also enabled for digital communication, which allows Technopark to monitor and maintain the equipment in an easier manner through real time data. A key component of the digital substation is ABB’s Standalone Merging Unit (SAM600), built to withstand the harshest environments. It fits alongside primary equipment, collecting information close to the source in the field, and converting it into IEC 61850 digital format for control, monitoring and protection applications. 

Year-End Report 2016

· Profit after tax for the year increased by SEK 835 million to SEK 5,284 million (4,449). The increase is due mainly to higher unrealized changes in the value of the property holdings. · Gross profit rose by 8 per cent to SEK 1,262 million (1,172). The increase can be attributed mainly to higher rental revenue. · Consolidated net revenue amounted to SEK 1,790 million (1,689), an increase of 6 per cent. · Profit after tax for the year was SEK 4,120 million (3,470), equivalent to SEK 19.98 per share (16.82). · The Board proposes an increase in the dividend to SEK 3.30 per share (3.10). · The fair value of the property holdings was set at SEK 36.5 billion (31.7), resulting in a net asset value of SEK 138 per share (118). The unrealized change in value of the property holdings for the year was SEK 4,160 million (3,427). · The equity ratio was 61 per cent (61), the net loan-to-value ratio was 15 per cent (17) and the interest coverage ratio multiple was 8.6 (9.1). · The rental vacancy level at the year-end was 3.9 per cent (4.5). Excluding projects in progress, the rental vacancy level was 2.6 per cent (3.2). Stockholm, February 16, 2017 HUFVUDSTADEN AB (publ) The Board   Appendix:Year-End Report 2016 Questions can be answered by Ivo Stopner, President, or Åsa Roslund, CFO, telephone +46 (0)8-762 90 00.   The information in this Interim Report is information that Hufvudstaden AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was published under the auspices of the above contact person on February 16, 2017 at 11:30am.

Oriflame Capital Markets Day 2017: Celebrating 50 years and looking forward

Today, 16 February 2017, Oriflame will hold a Capital Markets Day in Stockholm, with the purpose of presenting the Group’s strategy and how the company will continue its profitable growth journey and deliver on its financial targets. Magnus Brännström, CEO & President, and Gabriel Bennet, CFO, will together with other members of the Senior Management team give further details on the current strategic priorities and view of the market. “We believe Oriflame is in a good position to benefit from the sharing economy and as digitalization continues to gain speed our business model has never been more relevant. 2017 marks the 50th anniversary of Oriflame and we are reaching this milestone stronger than ever before, equipped with an underlying momentum, a strong financial position and a geographical footprint that enables long-term profitable growth. We will continue to deliver on our growth strategy to sharpen our offering and improve our effectiveness – ready to meet an ever-changing world during the next 50 years”, said Magnus Brännström, CEO & President. Increased market disclosureDuring the day, Oriflame will present an increased level of market disclosure to include the Company’s three largest markets per Business Area as per the 2016 year-end sales results. The new details are presented below. Latin America +------------+----------------+-------------------------+-----------------+|Market |Sales 2016 (€m) |% of Business Area Sales |% of Group sales |+------------+----------------+-------------------------+-----------------+|1. Mexico  | 81.2 | 55% | 7% |+------------+----------------+-------------------------+-----------------+|2. Colombia | | | |+------------+----------------+-------------------------+-----------------+|3. Peru  | | | |+------------+----------------+-------------------------+-----------------+ Europe & Africa +-----------+----------------+-------------------------+----------------+|Market |Sales 2016 (€m) |% of Business Area Sales |% of Group sales|+-----------+----------------+-------------------------+----------------+|1. Poland  | 47.6 | 14% | 4% |+-----------+----------------+-------------------------+----------------+|2. Romania | | | |+-----------+----------------+-------------------------+----------------+|3. Morocco | | | |+-----------+----------------+-------------------------+----------------+ CIS +--------------+----------------+-------------------------+-----------------+|Market  |Sales 2016 (€m) |% of Business Area Sales |% of Group sales |+--------------+----------------+-------------------------+-----------------+|1. Russia  | 210.7 | 65% | 17% |+--------------+----------------+-------------------------+-----------------+|2. Ukraine  | | | |+--------------+----------------+-------------------------+-----------------+|3. Kazakhstan | | | |+--------------+----------------+-------------------------+-----------------+ Asia & Turkey +-------------+----------------+-------------------------+-----------------+|Market |Sales 2016 (€m) |% of Business Area Sales |% of Group sales |+-------------+----------------+-------------------------+-----------------+|1. China  | 139.1 | 32% | 11% |+-------------+----------------+-------------------------+-----------------+|2. Indonesia | | | |+-------------+----------------+-------------------------+-----------------+|3. India  | | | |+-------------+----------------+-------------------------+-----------------+ Financial TargetsThe long-term financial targets of local currency sales growth of approximately 10 percent per annum and an operating margin of 15 percent remain. As part of the Capital Markets Day, a roadmap of how to reach the operating margin target will be presented. PresentationsThe Capital Markets Day presentations will be available at http://investors.oriflame.com/ from 11:30 CET. Recordings of the presentations will be posted on Oriflame’s website after the event. For additional information, please contact:Nathalie Redmo, Sr. Manager Investor Relations, +41 799 220 173 This information is such that Oriflame Holding AG is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.30 CET on Thursday, 16 February 2017. Founded in 1967, Oriflame is a beauty company selling direct in more than 60 countries. Its wide portfolio of Swedish, nature-inspired, innovative beauty products is marketed through approximately 3 million independent Oriflame Consultants, generating annual sales of around €1.2 billion. Respect for people and nature underlies Oriflame’s operating principles and is reflected in its social and environmental policies. Oriflame supports numerous charities worldwide and is a Co-founder of the World Childhood Foundation. Oriflame is a Swiss company group listed on the Nasdaq Stockholm Exchange. For more information about Oriflame, please visit www.oriflame.com.

ALE and Hoist Group Enter Partnership to Address the Hospitality and Healthcare Markets

“Hoist Group is focused on making fully integrated, reliable and competitive solutions available to our customers, ones which ensure high quality services along with end user satisfaction. Combining the knowhow and technology of both ALE and our business will allow us to offer a wider range of solutions, open new areas of development and reinforce our leadership as the one and only hospitality partner for hotels”, says Marc Valentin, CTO at Hoist Group. The partnership creates a full end-to-end solution for the hospitality and healthcare EMEA market combining the Hoist Group Fusion Platform capabilities (guest and internet access, video content, centralised management, TV services, Digital Signage, PMS for hospitality & healthcare) with the Alcatel-Lucent Enterprise network LAN and WiFi, communications phones and cloud offers. As well, the two companies will offer integration and customisation capabilities via an enhanced go-to-market and geographical coverage beyond the original scope of EMEA.  “The hospitality and healthcare markets are key verticals for ALE. We have over 20 years of success with customers in these industries. The partnership with Hoist Group is an essential step forward in further developing our market relevance as well as distribution coverage. It will allow us to create enhanced end-to-end solutions and services for customers in these key vertical markets”, concludes Thierry Bonnin, WW senior Vice President verticals & Strategic partnerships.

Major Shareholder Announcement regarding Nordic Waterproofing Holding A/S

Axcel IV K/S (Danish company registration number 32 90 65 16) has today divested its entire shareholding of 1,821,826 shares in Nordic Waterproofing Holding A/S and therefore no longer holds any shares or voting rights in Nordic Waterproofing Holding A/S. Axcel IV K/S 2 (Danish company registration number 33 42 65 69) has today divested its entire shareholding of 1,447,699 shares in Nordic Waterproofing Holding A/S and therefore no longer holds any shares or voting rights in Nordic Waterproofing Holding A/S. As a result of the divestments, AXIII MPH Invest ApS (Danish company registration number 28 85 73 14) today no longer indirectly controls any shares or voting rights in Nordic Waterproofing Holding A/S. AXIII MPH Invest ApS controls AXIII MP Holding ApS (Danish company registration number 28 86 09 86) who in turn controls Axcel Management A/S (Danish company registration number 28 30 18 55). Axcel Management A/S is the advisor to and exercised the voting rights of Axcel IV K/S, Axcel IV K/S 2, and AX Management Invest II K/S, (Danish company registration number 32 90 66 56), who were the direct holders of the shares. Following the reportable transactions described above as well as a divestment of all shares held in Nordic Waterproofing Holding A/S by AX Management Invest K/S, (Danish company registration number 32 90 66 72) and AX Management Invest II K/S, carried out in relation to the above, Axcel does not hold any shares or voting rights in Nordic Waterproofing Holding A/S. This information is information that Nordic Waterproofing Holding A/S is obliged to disclose pursuant to the Danish Securities Trading Act. The information was released for public disclosure, through the agency of the contact person below.The information was submitted for publication at 12:15 p.m. CET, on 16 February 2017.

ExpreS2ion’s Chief Scientific Officer, Dr. Wian de Jongh, to Speak at ISBiotech 7th Spring Meeting in Washington D.C. – March 6-8

Abstract Drosophila S2 insect cell expression is less known than the extensively used Spodoptera (Sf9/Sf21) or Trichoplusia ni (Hi-5) insect cell based baculovirus expression system (BEVS). Nevertheless, it has been used in research for almost 40 years. The cell line was derived from late stage Drosophila melanogaster (fruit fly) embryos by Schneider in the 1970s, who named the cell line Drosophila Schneider line 2 (synonyms: S2, SL2, D.mel. 2). The S2 expression system has been used for antigen manufacture up to and including Phase II clinical trials, and was used, among others, for production of Dengue antigens tested in a Phase I clinical trial by Merck Inc. ExpreS2ion has developed S2-based production processes for two malaria vaccine clinical trials with The Jenner Institute, Oxford University (Rh5, blood-stage malaria) and Copenhagen University (VAR2CSA, pregnancy-associated malaria). The pregnancy-associated malaria vaccine is currently in a Phase Ia trial in Germany, and will be followed by a Phase Ib trial in Benin. The blood-stage malaria vaccine has recently completed cGMP manufacture and the Phase I/IIa trial started in October 2016. Furthermore, transmission blocking malaria vaccine candidates (Pfs25, Pfs48/45, Pfs230C) are also under development. Antigen expression screening, process development, and GMP manufacture for these malaria programs will be discussed.

Dometic Nomination Committee’s Board proposal for the 2017 Annual Shareholders’ Meeting

The Nomination Committee’s proposal to the 2017 annual shareholders’ meeting is that the number of Board members should continue to be seven. The proposal is for Fredrik Cappelen, Rainer E. Schmückle, Magnus Yngen and Erik Olsson to be re-elected and Heléne Vibbleus, Peter Sjölander och Jacqueline Hoogerbrugge to be elected as new members. The annual shareholders’ meeting will be held in Stockholm on April 7, 2017. For more information, please contact:Simon Blecher, Chairman of the Nomination CommitteeEmail: simon.blecher@carnegiefonder.se Erika Ståhl, Head of Business Control & Investor RelationsTel: +46 8 501 025 24Email: ir@dometicgroup.com This information is information that Dometic Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.20 CET on February 16, 2017. ABOUT DOMETIC GROUP Dometic is a global market leader in branded solutions for mobile living in the areas of Climate, Hygiene & Sanitation and Food & Beverage. Dometic operates in the Americas, EMEA and Asia Pacific, providing products for use in recreational vehicles, trucks and premium cars, pleasure and workboats, and for a variety of other uses. Dometic offer products and solutions that enrich people’s experiences away from home, whether in a motorhome, caravan, boat or a truck. Our motivation is to create smart and reliable products with outstanding design. We operate 22 manufacturing/assembly sites in nine countries, sell our products in approximately 100 countries and manufacture approximately 85% of products sold in-house. We have a global distribution and dealer network in place to serve the aftermarket. Dometic employs approximately 6,500 people worldwide, had net sales of SEK 12.4 billion in 2016 and is headquartered in Solna, Sweden.

Panoro Energy (Oslo Ticker: PEN): Invitation to Fourth Quarter 2016 conference call February 23, 2017

Panoro Energy’s Q4 2016 report will be published on Thursday, February 23, 2017 and will be available on our website http://www.panoroenergy.com at 07:00 a.m. CET. Panoro will hold a conference call at 10:00 a.m. CET on Thursday, February 23, 2017 during which management will discuss Panoro's 2016 fourth quarter results. The participants are invited to ask questions on the Q4 report after conclusion of the discussion. Participants are asked to dial in five to ten minutes prior to the start time using the numbers and password below: Local - Oslo, Norway                                    +47 21 563 318 Toll Free – Norway                                         800 19 457 Local – New York, USA                                +1 212 999 6659 Toll Free – USA                                             +1 866 966 5335 Local – London, UK                                      +44 (0) 20 3003 2666 Toll Free – UK                                                0808 109 0700 Password:                                                      Panoro Participants dialling in from outside these countries may use the UK or USA number. A replay of the audio will be available shortly after the call is finished and will remain on our website for approximately 14 days. For more information please contact: Qazi QadeerChief Financial Officer+44 203 405 1060info@panoroenergy.com About Panoro Energy Panoro Energy ASA is an independent E&P company based in London and listed on the Oslo Stock Exchange with ticker PEN. The Company holds high quality production, development, and exploration assets in West Africa, namely OML 113 offshore western Nigeria and the Dussafu License offshore southern Gabon. In addition to discovered hydrocarbon resources and reserves, both assets also hold significant exploration potential. For more information, please visit the Company’s website at www.panoroenergy.com.  

Saab Partners With Hindustan Aeronautics Limited for Transfer of Technology

Announced at Aero India 2017, the contract - valued at ZAR112 million (USD8.5 million) - will see the transfer of technology for in-country maintenance of Saab’s Integrated Defensive Aids Suite (http://saab.com/air/electronic-warfare/self-protection-systems/idas/) (IDAS) system in India. IDAS has been selected as the electronic warfare (EW) self-protection system for Indian Air Force and Indian Army Aviation Corps variants of the HAL Dhruv Advanced Light Helicopter. . The maintenance ToT provides for the supply and commissioning of test infrastructure at HAL Hyderabad along with documentation and training of HAL personnel in both Centurion, South Africa, and Hyderabad. “The export of this technology to India bodes well for future manufacturing and skills transfers, and for building an ongoing mutually beneficial partnership in line with the ‘Make in India’ initiative,” says Trevor Raman, President and CEO of Saab Grintek Defence. The ToT programme will run for 24 months and will qualify HAL Hyderabad as a Saab-approved IDAS repair facility. HAL will focus on maintenance and repair of IDAS equipment for the Indian end-users. Saab will continue to support HAL Hyderabad with critical spares and proprietary components for the entire service life of IDAS. The contract follows a long term business agreement signed by SGD and HAL in 2005, which provides for the delivery of IDAS equipment by SGD, based on annual orders. Series production of IDAS systems at SGD is currently underway with more than 200 ordered to date. For further information, please contact:Saab Press Centre,+46 (0)734 180 018presscentre@saabgroup.com www.saab.comwww.saab.com/YouTubeFollow is on twitter: @saab Saab is a global company with operations and employees in about 35 countries around the world. Through innovative, collaborative and pragmatic thinking, Saab constantly develops, adopts and improves new technology to meet customers’ changing needs.

Tieto new Data-Driven Businesses unit aims to bring Artificial Intelligence to healthcare

Tieto’s newly established Data-Driven Businesses wants to help Nordic society to pursue the significant opportunities of the data-driven world. In support of this goal, Tieto is also investigating the opportunities Artificial Intelligence can present in various sectors. The company has earlier announced the appointment of Artificial Intelligence as a member of the leadership team of its new Data-Driven Businesses unit in order to study the effects of truly data-driven decision-making.  – Tieto sees data as the new water – the prime driver for human experience and economic value in the future – and aims to co-innovate new and unforeseen data-driven services with the help of new cutting-edge technologies like Artificial Intelligence. In our vision of the future, we see that every industry has the potential to become AI-filled as AI can be used to extract value from all kinds of data, comments, Ari Järvelä, Head of Tieto Data-Driven Businesses.  Today’s announcement speeds ups Tieto’s possibilities to create data-driven services specifically in the healthcare sector. In the Nordics Tieto has a long history as healthcare and social care solution provider and as a part of Tieto's Data-Driven Businesses strategy the company is also seeking further opportunities and partnerships in the healthcare sector.  Microsoft AI in Health Partner Alliance provides resources for healthcare and social care solution providers to apply AI to healthcare.   – Without AI solutions it is impossible to solve the huge challenges facing our society. Tieto's aim in the health and wellbeing sector is to drive personalized but efficient data-driven models by maximizing the wellbeing of individuals while reducing the costs of public healthcare and social care services. For every citizen this means personalized, faster and more personalized services, says Matti Ristimäki, Director, Data-Driven Businesses in Public, Health and Wellbeing, Tieto.  Tieto has actively collected innovators, teams and startups to join forces in creating data-driven future business. The company fosters a strong drive for co-innovation and ecosystems globally.  Supporting resources:  Blog: Harnessing the new era of data in health for more human centric wellbeing by Matti Ristimäki:   https://enterprise.microsoft.com/en-us/articles/industries/health/harnessing-new-era-data-in-health-for-more-human-centric-wellbeing/  Tieto the first Nordic company to appoint Artificial Intelligence to the leadership team of the new data-driven businesses unit https://www.tieto.com/news/tieto-the-first-nordic-company-to-appoint-artificial-intelligence-to-the-leadership-team-of-the-new  Read more about New Data-Driven Businesses: www.tieto.com/data-driven  For more information: Jessica Diktonius, Head of Media Relations and Reputation Management, jessica.diktonius[at]tieto.com, +358 40 70  991 76  TIETO OYJ  DISTRIBUTION  Principal media  Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal, by combining our software and services capabilities with a strong drive for co-innovation and ecosystems. www.tieto.com.

BJÖRN BORG AB YEAR END-REPORT JANUARY – DECEMBER 2016

1 OCTOBER – 31 DECMEBER, 2016              · The Group’s net sales increased by 12.3 percent to SEK 171.4 million (152.6). Excluding currency effects, sales rose by 10.2 percent. · The gross profit margin was 48.0 percent (51.8). Excluding currency effects, the margin was 49.9 percent. · Operating profit amounted to SEK 21.4 million (14.6). · Profit after tax was SEK 17.9 million (7.3). · Earnings per share before and after dilution amounted to SEK 0.74 (0.34). 1 JANUARY – 31 DECEMBER, 2016 · The Group’s net sales increased by 10 percent to SEK 631.6 million (574.3). Currency effects were marginal. · The gross profit margin was 50.3 percent (52.4). Excluding currency effects, the margin was 50.7 percent. · Operating profit amounted to SEK 64.2 million (58.6). · Profit after tax amounted to SEK 46.9 million (41.6). · Earnings per share before and after dilution amounted to SEK 1.88 (1.79) · The Board of Directors has decided to propose to the Annual General Meeting a distribution of SEK 2.00 (2.00) per share, totaling SEK 50.3 million (50.3).  QUOTE FROM THE CEO “We finished the year very strongly, and two years and four months after the launch of our business plan, Northern Star, we closed the books on another year in which we improved our key indicators,” said CEO Henrik Bunge.    For further information, please contact:Henrik Bunge, CEO, telephone +46 8 506 33 700Daniel Grohman, CFO, telephone +46 8 506 33 700Björn Borg is required to make public the information in this interim report according to the EU’s Market Abuse Regulation.The information was released for publication on February 17, 2017 at 7:30 am (CET).

Arise announces a fully supported rights issue of convertible bonds to proactively develop its position and strengthen its financial flexibility.

Pursuant to the authorisation of the General Meeting held on 3 May 2016, the Board of Directors of Arise AB (publ) (“Arise” or “the Company”) decided on 17 February 2017 that the Company is to raise a convertible loan of a nominal maximum of approximately MSEK 245 with preferential rights for existing shareholders. Preferential rights issue in brief · The purpose of the preferential rights issue (“the Rights Issue”) is to provide the conditions required to proactively develop the Company’s market position: · Increase growth in development and management, including through acquisitions · Create readiness to exploit consolidation opportunities · Increase value creation potential in the project portfolio as a result of greater financial flexibility The Rights Issue will also strengthen the Company’s financial flexibility and thus provide the opportunity to manage assets based on a position of financial strength and to reduce capital costs · Entitlement to subscribe for the convertible bonds with preferential rights will accrue to the Company’s existing shareholders, but excludes the Company’s treasury holding of 54,194 shares. The Company will, in connection with this, apply to admit subscription rights and the convertible bonds for trading on Nasdaq Stockholm · Existing shareholders Claesson & Anderzén with companies, AB Traction, Briban Invest AB and Peter Gyllenhammar via company, who hold 36.85 % of the shares in the Company, have signed subscription undertakings and underwriting agreements corresponding to approximately MSEK 177.8. In addition, Tredje AP-fonden, who holds approximately 9.99 % of the shares in the Company, has signed a Letter of Intent to subscribe for approximately MSEK 24.5. Furthermore, Swedbank AB (publ) has signed an underwriting agreement corresponding to approximately MSEK 42.4. Accordingly, the Rights Issue is 100 % supported by subscription undertakings, underwriting agreements and the Letter of Intent · The record date for participating in the Rights Issue is 24 February 2017 and the subscription period will be 28 February to 16 March 2017 · The convertible loan carries an annual rate of interest of 5.75 %, with quarterly coupon payments · Holders of convertible bonds are entitled, during the period from two banking days after the convertible bonds have been registered with the Swedish Companies Registration Office up to and including 28 February 2022, to convert all or portions of their convertible bonds to new ordinary shares in Arise at a conversion price of SEK 22 · The loan falls due for payment on 31 March 2022 unless it is converted prior to this date Daniel Johansson, CEO of Arise AB comments: “It is very gratifying that some of our major shareholders have chosen to support this issue. The issue is 100 % supported by the combination of subscription undertakings, a Letter of Intent and underwriting agreements. We will now boost growth together with our customers and the issue provides us with a stronger financial position from which to take action.”  Background and motiveArise is one of Sweden’s leading operators of onshore wind power. At the end of 2016, the Company’s portfolio of managed wind power totalled approximately 655 MW, of which 241 MW is owned by Arise and approximately 415 MW is managed on behalf of external customers. Total production from own and co-owned production in a normal year amounts to 628 GWh. Arise is thereby a significant supplier of renewable power in the Nordic market. Arise also has an extensive project portfolio of approximately 1,000 MW in Sweden. In Scotland, preliminary project planning work is underway on projects with a combined output of about 150 MW for which the company has signed leasehold agreements. Given that production of electricity from wind power is becoming increasingly cost effective and that there is a political desire in Sweden to continue to support the expansion of renewable energy based on the recently published agreement on Swedish energy policy, the Company’s aim is to further expand its project portfolio. Over the past two years, Arise has successfully developed and built a number of wind farms on behalf of investors and also sold several already operational wind farms. Arise’s customers are investors in wind power that either want to acquire wind farms or that require the Company’s assistance with the financial and technical management of wind farms. It has gradually become clear that Arise has the ability and the credibility required for being a successful developer of projects for various types of investors. The purpose of the Rights Issue is to provide the conditions required to proactively develop the Company’s market position: i) enhance growth in development and management, including through acquisitions, ii) create readiness to exploit consolidation opportunities, and iii) increase value creation potential in the project portfolio as a result of greater financial flexibility. The Rights Issue will also strengthen the Company’s financial flexibility and thus provide the opportunity to manage assets based on a position of financial strength and to reduce capital costs. This means that part of the proceeds from the Rights Issue will be used towards final payments on the bond loans that fall due for payment in 2017. The Rights Issue allows Arise to be opportunistic in its project-development business in which the Company sees business opportunities in the prevailing market climate, and in the ownership of wind farms and related financing. Terms of the preferential rights and convertible bonds in briefPursuant to the authorisation of the General Meeting held on 3 May 2016, the Board of Directors of Arise has decided that the Company is to raise a convertible loan of a nominal maximum of approximately MSEK 245. Entitlement to subscribe for convertible bonds with preferential rights will accrue to the Company’s shareholders, with three shares entitling subscription to one convertible, each with a nominal value of SEK 22. Accordingly, the nominal amount of the convertible loan will total a maximum of SEK 244,741,750. The convertible bonds will be issued at a nominal amount. The record date for entitlement to participate in the issue is 24 February 2017. Subscription is to take place between 28 February and 16 March 2017. The convertible subordinated loan carries an annual rate of interest of 5.75 %, with quarterly coupon payments. Holders of convertible bonds are entitled, during the period from two banking days after the convertible bonds have been registered with the Swedish Companies Registration Office up to and including 28 February 2022, to convert all or portions of their convertible bonds to ordinary shares in the Company at a conversion price of SEK 22. The convertible subordinated loan falls due for payment on 31 March 2022 unless it is converted prior to this date. On the condition of full subscription to the Rights Issue and full conversion of the convertible bonds thereby issued, Arise’s share capital will increase by SEK 889,970.00 on the basis of the issue of 11,124,625 ordinary shares. Subscription undertakings and underwriting agreementsAs stated above, existing shareholders who hold 36.85 % of the shares in the Company have signed subscription undertakings and underwriting agreements corresponding to approximately MSEK 177.8. In addition, a shareholder who holds 9.99 % of the shares in the Company has signed a Letter of Intent to subscribe for approximately MSEK 24.5. Furthermore, approximately MSEK 42.4 is underwritten by an external party. Subscription undertakings and underwriting agreements thus total approximately MSEK 220.2, corresponding to 89.99 % of the Rights Issue. Including the Letter of Intent, this corresponds to the total volume of the Rights Issue. The complete terms, conditions and instructions of the convertible bond issue and other information about Arise will be provided in the prospectus that will be published prior to the subscription period. +-----------+--------------------------------------------------------------+|Preliminary|Event   ||timetable | ||Date   | |+-----------+--------------------------------------------------------------+|20 February|Expected publication of the prospectus (but no later than 27 || |February) |+-----------+--------------------------------------------------------------+|22 February|Last day of trading including rights to receive subscription || |rights in the issue of convertible bonds |+-----------+--------------------------------------------------------------+|23 February|First day of trading excluding rights to receive subscription || |rights in the issue of convertible bonds |+-----------+--------------------------------------------------------------+|24 February|The record date for entitlement to participate in the issue of|| |convertible bonds |+-----------+--------------------------------------------------------------+|28 February|Subscription period ||– 16 March | |+-----------+--------------------------------------------------------------+|28 February|Trading in subscription rights ||– 14 March | |+-----------+--------------------------------------------------------------+|28 February|Trading in paid subscribed convertible bonds ||– 27 March | |+-----------+--------------------------------------------------------------+|21 March |Announcement of the final outcome of the issue of convertible || |bonds |+-----------+--------------------------------------------------------------+      AdvisorsSetterwalls Advokatbyrå is acting as legal advisor and Swedbank AB (publ) is financial advisor to Arise in connection with the convertible bond issue. Invitation to a conference call in connection with Arise’s 2016 Year-End ReportArise’s 2016 Year-End Report will be released on Friday, 17 February, 2017 at around 8:00 a.m. CET. At 11:00 a.m. CET on the same day, a conference call will be held, hosted by Daniel Johansson, CEO and Linus Hägg, CFO, who will present the report to the stock market and media. After the presentation, those attending will be invited to ask questions. The dial in number for the conference call is:Sweden                                         08 50 510 036UK: (local):                                    020 3059 8125Other countries:                            + 44 20 3059 8125Password:                                      Arise A presentation will be held during the telephone conference. Presentation material is available at: http://www.investis-live.com/arise/587f532e7b6fba170040b9b8/ioj2a After the meeting, a recording of the presentation will be available at the same link.    Invitation to a conference call due to the Rights Issue on 22 February at 10:00 a.m. CETDue to the Rights Issue, Arise will hold a company presentation via a conference call on 22 February at 10:00 a.m., hosted by Daniel Johansson, CEO and Linus Hägg, CFO. After the presentation, those attending will be invited to ask questions. The dial in number for the conference call is: Sweden:                               +46 (0) 8 535 211 70   For further information, please contact:Daniel Johansson, CEO of Arise, +46 702 24 41 33. This information is information that Arise AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 17 February 2017.     About ArisArise is one of Sweden´s leading wind power companies, with the business concept to develop, build and manage onshore wind farms for its own account and on behalf of investors. The company is listed on NASDAQ Stockholm. Arise AB (publ), P.O. Box 808, SE-301 18 Halmstad, Sweden, telephone +46 (0)35 20 20 900, corporate id .no. 556274-6726E-mail info@arise.se, www.arise.se  Important informationThis announcement is not and does not form a part of any offer for sale of securities. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Japan, Hong Kong, Singapore, South Africa, New Zealand, Australia or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. Any offering of securities referred to in this announcement will only be made by means of the prospectus announced herewith. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Such statements are statements that are not historical facts and may be identified by words such as “regard”, “estimate”, “expect”, “anticipate”, “assume”, “predict”, “intend”, “may”, "continue", “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

Interim Report January 1 – December 31, 2016

The fourth quarter in figures · Net sales amounted to TSEK 1,935 (1,181). · The loss after tax amounted to TSEK 14,623 (11,154). · The loss per share amounted to SEK 1.77 (1.35). · The cash flow from current operations was negative in the amount of TSEK 13,032 (13,864). · Significant margin improvement with gross margin increasing to 35.0% in Q4 (18.4%). The full year in figures · Net sales amounted to TSEK 6,436 (4,151). · The loss after tax amounted to TSEK 53,086 (41,532). · The loss per share amounted to SEK 6,41 (6.01). · The cash flow from current operations was negative in the amount of TSEK 47,850 (46,588). · Significant margin improvement with gross margin increasing to 34.5% (2.5%).  Important events during the quarter · Our primary market Germany continues to show good growth with sales in value up by 54% and electrode sales volume up by 93% in the quarter. · Significant resources invested in the PMA process, with continued progress. Ongoing work to provide replies to feedback from the FDA within several areas. · A nominating committee has been appointed for the AGM 2017. · In the period the management team was strengthened with Niklas Jakobsson, responsible for QA and regulatory issues and with Anna Danström head of manufacturing and logistics. · The semi-automated electrode production process now validated.  · First delivery of Nevisense View in the period.   Important events after the end of the period · DermoScan and SciBase agree to co-promote an integrated solution for digital dermoscopy and Nevisense. +---------------------------+-------+-------+-------+-------+| |Oct 1 - Dec 31 |Jan 1 - Dec 31 |+---------------------------+-------+-------+-------+-------+|THE GROUP |2016 |2015 |2016 |2015 |+---------------------------+-------+-------+-------+-------+|Net sales, SEK ths |1 935 |1 181 |6 436 |4 151 |+---------------------------+-------+-------+-------+-------+|Gross margin, % |35,0% |18,4% |34,5% |2,5% |+---------------------------+-------+-------+-------+-------+|Equity/Asset ratio, % |90,8% |95,1% |90,8% |95,1% |+---------------------------+-------+-------+-------+-------+|Net indebtness, multiple |0,10 |0,05 |0,10 |0,05 |+---------------------------+-------+-------+-------+-------+|Cash equivalents, SEK ths |84 955 |133 736|84 955 |133 736|+---------------------------+-------+-------+-------+-------+|Cashflow from operating |-13 032|-13 864|-47 850|-46 588||activities, SEK ths | | | | |+---------------------------+-------+-------+-------+-------+|Earnings per share (before |-1,77 |-1,35 |-6,41 |-6,01 ||and after dilution), SEK* | | | | |+---------------------------+-------+-------+-------+-------+|Shareholder's equity per |11,19 |17,59 |11,19 |21,09 ||share, SEK* | | | | |+---------------------------+-------+-------+-------+-------+|Average number of shares, |8 285 |8 285 |8 285 |6 910 ||000'* | | | | |+---------------------------+-------+-------+-------+-------+|Number of shares at closing|8 285 |8 285 |8 285 |8 285 ||of period, 000'* | | | | |+---------------------------+-------+-------+-------+-------+|Share price at end of |19,00 |31,00 |19,00 |31,00 ||period, SEK | | | | |+---------------------------+-------+-------+-------+-------+|Average number of employees|23 |15 |21 |14 |+---------------------------+-------+-------+-------+-------+|*Adjusted for in May 2015 | | | | ||performed reversed split, | | | | ||40:1 | | | | |+---------------------------+-------+-------+-------+-------+ Comment by CEO Simon Grant  In the last quarter we were happy to see continued sales growth, driven by increased Nevisense usage. Compared to the same period 2015 our sales increased by 64 percent and reached MSEK 1.9, which is a new all-time high.  We also sold 5,600 electrodes, an increase of 106 percent. The sales for the full year 2016 amounted to over MSEK 6.4, which is an increase with 55 percent compared to 2015. The volume of sold electrodes (tests) increased by 87 percent to 15,200. Germany continues to be our growth engine and it is encouraging to see that we have a growing number of high-volume users there. As you know, our business model requires an initial device sale but the potential lies in the sale of single-patient electrodes when the device is used. The first Nevisense View delivered In December Nevisense View, a new device combining our EIS-method with the documentation of clinical images, became commercially available. With Nevisense View it is possible to import clinical and dermoscopic images of lesions and store them together with patient data and the EIS test results. For clinicians, this can have significant benefits. It can improve workflow, facilitate full documentation of suspicious lesions and help monitor difficult to diagnose lesions. In December we delivered the first Nevisense View to Belgium. Since then we have also sold units in Sweden and we see an increasing interest from these as well as from other markets, including Germany. As part of the release of Nevisense View, we also released a major update of Nevisense itself. This included both an update in the Nevisense hardware but also significant improvements in the system software. We have, for example, added inbuilt network connectivity (Wi-Fi and Ethernet), improved patient data management and the body map, and added follow-up functionality. Germany is the engine but there are other interesting markets Germany is, as you know, our largest and most important market and we continue to grow at a rapid pace there. During the quarter sales increased by 54 percent and the volume of sold electrodes by 93 percent compared to the same period 2015. We see now over one thousand patients tested each month in Germany. We also see a growing number of clinics with more than one system, which is positive as it is a sign that they see the benefits of Nevisense. In total we now have fifteen customers in Germany with two, three or even four Nevisense systems. The German market success is driven by market conditions and our direct sales presence. There are many private dermatology clinics, there is reimbursement coverage for EIS-measurements and good acceptance for the method. In January 2017 we entered into a co-promotion agreement with DermoScan GmbH. This co-operation provides an opportunity to reach Dermoscan’s customer base of several hundred clinics.  We will be able to offer an integrated solution for each other’s products and that will both improve workflow and save time for clinics. DermoScan will market Nevisense towards both their existing as well as new customers with Germany as the initial focus. With Nevisense View we see improved opportunities for our offer on the Belgian and Swiss markets and we will subsequently increase our efforts there. We also see and increased interest in Nevisense View in Sweden. In the USA the process to achieve a PMA approval continues to move forward. During the period we have provided additional complementary information, as is the normal process. We receive on-going feedback and we stand by our hope that we will receive an FDA approval by the end of the second quarter 2017.     Moving forward in electrode production In the period we finalized the validation of the semi-automated production process, which now is ready for implementation. We now have a short-term focus on increasing production capacity and yield. We’re now looking forward to a spring where sales and the on-going PMA process will continue to be our main priorities. We will work to support the sales channels as they introduce Nevisense View and we are also looking forward to our cooperation with DermoScan. We believe that the cooperation offers good opportunities for us to reach new groups of customers and increase the knowledge of SciBase, Nevisense and the EIS-method. Simon Grant, CEO The Year-end report 2016 is found in its entirety below For further information please visit www.scibase.com or contact: Simon Grant, CEOTel: +46 72 887 43 99E-mail: simon.grant@scibase.com This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 17, 2017. Contact person: Michael Colérus, CFOTel: +46 70 341 34 72E-mail: michael.colerus@scibase.com (simon.grant@scibase.com) About Skin CancerSkin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly. About SciBase and NevisenseSciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.

Alligator Bioscience AB Full Year 2016 Report

Summary · During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this were new shares issued that provided the company 350 000 TSEK before underwriting expenses. · The company's project portfolio has continued to develop according to plan including the start of dosing in a second phase I clinical trial that is done by Janssen Biotech. · The Board of Directors proposes that no dividend shall be paid for the year 2016. Conference call for investors, analysts and the mediaThe 2016 Financial Statement will be presented by Alligator’s CEO, Per Norlén and members of the management group on Friday February 17, 2017, at 10.00 (CET).Phone numbers for participants from:Europe: +44 (0) 2030089803, Sweden: +46 856642696, US: +1 8558315946The recorded conference call will be available on Alligators website after completion of the conference, www.alligatorbioscience.com Fourth quarter 2016 in summary  · During the quarter, the company's shares were listed on the Nasdaq Stockholm Mid Cap. · In connection with this, a new share issue which provided the company TSEK 350 000 before underwriting expenses was done. · In October began dosing in a second phase I clinical trial with ADC-1013. This second study includes intravenous dose escalation and is done by Janssen Research & Development LLC. · Net sales for the period amounted to TSEK 6 433 (512). · Result for the period amounted to TSEK -19 352 (-39 450) which corresponds to a result per share before and after dilution with SEK -0,31 (0,67). · Cash flow amounted to TSEK 310 886 (-28 690) and cash and cash equivalents at the end of the quarter amounted to TSEK 659 136 (365 605). January - December 2016 in summary · Alligator’s clinical study with ADC-1013 was expanded in the first quarter resulting in a milestone payment of 5 MUSD following the terms in the partnership agreement with Janssen Biotech Inc. · Janssen started in October a phase I clinical trial with ADC-1013. · Cell-line development for manufacturing of clinical materials for ATOR-1015 began in January. · Result for the period amounted to TSEK -48 356 (207 377), which is equivalent to earnings per share before and after dilution of SEK -0,80 (3,81 and 3,70 respectively). · Cash flow for the period amounted to TSEK 287 135 (326 232). · During the second quarter, the participation in the Biosynergy project was written down with TSEK 22 120. · During 2016 has Alligator increased the share of expenses invested in R&D to 64,3% (54,6%). · The number of employees has increased during 2016, mainly within R&D, and the company is well prepared for further development in 2017. Events after the end of the period · In January 2017 has 700 000 warrants been converted to an equal number of shares. Financial summary (Group)  +---------------------------+-------+--------+-------+--------+| |October-December|January-December|+---------------------------+-------+--------+-------+--------+| |   2016|   2015 |   2016|   2015 |+---------------------------+-------+--------+-------+--------+|Net sales, TSEK (SEK | 6 433| 512| 58 240| 289 797||thousand) | | | | |+---------------------------+-------+--------+-------+--------+|Profit/loss for the period,|-19 352| -39 450|-48 356| 207 377||TSEK | | | | |+---------------------------+-------+--------+-------+--------+|Cash flow for the period, |310 886| -28 690|287 135| 326 232||TSEK | | | | |+---------------------------+-------+--------+-------+--------+|Cash and cash equivalents, |659 136| 365 605|659 136| 365 605||TSEK | | | | |+---------------------------+-------+--------+-------+--------+|Equity ratio, % | 96%| 95%| 96%| 95%|+---------------------------+-------+--------+-------+--------+|R&D costs as % of operating| 68,5%| 47,3%| 64,3%| 54,6%||costs excluding impairments| | | | |+---------------------------+-------+--------+-------+--------+|Earnings per share before | -0,31| -0,67| -0,80| 3,81||dilution, SEK | | | | |+---------------------------+-------+--------+-------+--------+|Earnings per share after | -0,31| -0,67| -0,80| 3,70||dilution, SEK | | | | |+---------------------------+-------+--------+-------+--------+|Average number of employees| 35| 26| 31| 27|+---------------------------+-------+--------+-------+--------+  For further information, please contact:Rein Piir, VP IR, rein.piir@alligatorbioscience.com, +46 (0) 46 286 42 80Per Norlén, CEO, per.norlen@alligatorbioscience.com, +46 (0) 46 286 42 80Per-Olof Schrewelius, CFO, per-olof.schrewelius@alligatorbioscience.com, +46 (0) 46 286 42 85 This information is such information as Alligator Bioscience AB (publ) is obligated to disclose in accordance with EU market abuse regulation. The information was submitted, through the above contact persons, for publication on 17 February 2017 at 08:00 (CET)

Lynparza positive in metastatic BRCA breast cancer

This announcement contains inside information 17 February 2017, 07:00 GMT LYNPARZA MEETS PRIMARY ENDPOINT IN PHASE III TRIAL IN BRCA-MUTATED METASTATIC BREAST CANCER Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy First positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer AstraZeneca today announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways." Initial findings from the OLYMPIAD study indicate that the safety profile of Lynparza was consistent with previous studies.   A full evaluation of the OLYMPIAD data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting. AstraZeneca will be working with regulatory authorities to make Lynparza available to patients with this type of breast cancer. About Metastatic Breast Cancer Approximately one in eight women are diagnosed with breast cancer. Of these patients, approximately one-third are either diagnosed with or progress to the metastatic stage of the disease.[i] Despite treatment options increasing during the past three decades there is currently no cure for patients diagnosed with metastatic breast cancer. Thus, the primary aim of treatment is to slow progression of the disease for as long as possible, improving or at least maintaining a patient's quality of life. About OLYMPIAD OLYMPIAD is a randomised, multi-center Phase III trial assessing the efficacy and safety of Lynparza (300 mg twice daily) to 'physician's choice' chemotherapy (capecitabine, vinorelbine, eribulin) in 302 patients with HER2-negative metastatic breast cancer with germline BRCA1 or BRCA2 mutations, which are predicted or suspected to be deleterious. The international study was conducted in 19 countries from across Europe, Asia, North America and South America. The primary endpoint of the trial was progression-free survival (PFS) as measured by a Blinded Independent Central Review (BICR). Secondary endpoints include overall survival (OS), time to second progression or death (PFS2), objective response rate (ORR), and effect on health-related quality of life (HRQoL). About Germline BRCA mutations BRCA1 and BRCA2 are human genes that produce proteins responsible for repairing damaged DNA and play an important role maintaining the genetic stability of cells. When either of these genes is mutated, or altered, such that its protein product either is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.[ii] Specific inherited mutations in BRCA1 and BRCA2 increase the risk of female breast and ovarian cancers, and they have been associated with increased risks of several additional types of cancer. Together, BRCA1 and BRCA2 mutations account for about 20 to 25 percent of hereditary breast cancers[iii] and about 5 to 10 percent of all breast cancers[iv]. In addition, mutations in BRCA1 and BRCA2 account for around 15 percent of ovarian cancers overall[v]. Breast and ovarian cancers associated with BRCA1 and BRCA2 mutations tend to develop at younger ages than their nonhereditary counterparts. About Lynparza Lynparza (olaparib) is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP) inhibitor that may exploit tumour DNA damage response (DDR) pathway deficiencies to preferentially kill cancer cells. Lynparza is the foundation of AstraZeneca's industry-leading portfolio of compounds targeting DNA damage response (DDR) mechanisms in cancer cells. Lynparza is currently approved by regulatory health authorities in the EU for use as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. It is also approved in the US as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA- test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Lynparza is currently being investigated in another separate non-metastatic breast cancer Phase III study called OLYMPIA. This study is still open and recruiting patients internationally. About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that have the potential to transform patients' lives and the Company's future. With at least 6 new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advancing Oncology as one of AstraZeneca's six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology. By harnessing the power of four scientific platforms -- immuno-oncology, the genetic drivers of cancer and resistance, DNA damage response and antibody drug conjugates -- and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. Media EnquiriesEsra Erkal-Paler UK/Global +44 203 749 5638Vanessa Rhodes UK/Global +44 203 749 5736Karen Birmingham UK/Global +44 203 749 5634Rob Skelding UK/Global +44 203 749 5821Jacob Lund Sweden +46 8 553 260 20Michele Meixell US +1 302 885 2677Investor RelationsThomas Kudsk Larsen +44 203 749 5712Craig Marks Finance, Fixed Income, M&A +44 7881 615 764Henry Wheeler Oncology +44 203 749 5797Mitchell Chan Oncology +1 240 477 3771Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970Nick Stone Respiratory +44 203 749 5716Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711US toll free +1 866 381 7277 Adrian Kemp Company Secretary, AstraZeneca PLC ---------------------------------------------------------------------- [i] Dr Joyce O'Shaughnessy; Extending Survival with Chemotherapy in MBC" The Oncologist 2005:10 [ii] NCI website - BRCA Fact-sheet … https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet Last accessed January 2017 [iii] Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Research 1999; 1(1):14-17. [iv] Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: New genetic developments, new therapeutic avenues. Human Genetics 2008; 124(1):31-42. [v] Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104(12):2807-16.

MEDIVIR AB – FINANCIAL STATEMENT, JANUARY – DECEMBER 2016

Significant events during the fourth quarter · Medivir focuses research and development operations exclusively on oncology and reorganises in order to achieve significant cost savings. As a result of the operative transformation a non-recurring sum of SEK 49.1 million was charged to the profit/loss for the period and of SEK 52.6 million for the full year. · Medivir divests its pharmaceutical company, BioPhausia (Nordic Brands), to Karo Pharma for SEK 908 million and reports a consolidated capital gain of SEK 534.8 million, thereby applying IFRS 5 (see p. 12). · Medivir strengthens its clinical pipeline by entering into an agreement on the acquisition of a portfolio of clinical phase oncology programmes, which has increased its intangible fixed assets by SEK 89 million and current receivables by SEK 22 million. October – December 2016 · Net turnover for the continuing operations totalled SEK 9.9 million (34.5 m), SEK 5.6 million (31.1 m) of which comprised royalties for simeprevir. · Revenues from Medivir’s continuing pharmaceutical sales totalled SEK 2.9 million (2.9 m), of which SEK 2.9 million (2.7 m) derived from sales of OLYSIO®. · The profit after tax for the continuing operations was SEK -121.3 million (-56.9 m). · Basic and diluted earnings per share totalled SEK -4.50 (-2.11) and SEK -4.50 (-2.11), respectively. · The cash flow from operating activities amounted to SEK -69.6 million (-37.6 m). January – December 2016 · Net turnover for the continuing operations totalled SEK 93.0 million (474.3 m), SEK 60.3 million (418.6 m) of which comprised full year royalties for simeprevir. · Revenues from Medivir’s continuing pharmaceutical sales totalled SEK 12.3 million (53.9 m), of which SEK 12.0 million (53.0 m) derived from sales of OLYSIO®. · The profit after tax for the continuing operations was SEK -294.9 million (31.7 m). · Basic and diluted earnings per share totalled SEK -10.94 (1.09) and SEK -10.94 (1.08), respectively. · The cash flow from operating activities amounted to SEK -180.1 million (307.4 m). +-------------------------------+--------+-------+-------+-------+|Summary of the Group’s figures | Q4 | Q1-Q4 ||(SEK m) | | |+-------------------------------+--------+-------+-------+-------+|Continuing operations | 2016| 2015| 2016| 2015|+-------------------------------+--------+-------+-------+-------+|Net turnover | 9.9| 34.5| 93.0| 474.3|+-------------------------------+--------+-------+-------+-------+|Gross profit | 7.7| 30.0| 77.1| 436.0|+-------------------------------+--------+-------+-------+-------+|Operating profit before | -120.7| -51.9| -278.9| 95.7||depreciation and amortisation | | | | ||(EBITDA) | | | | |+-------------------------------+--------+-------+-------+-------+|Operating profit (EBIT) | -128.9| -60.4| -312.4| 55.4|+-------------------------------+--------+-------+-------+-------+|Profit/loss before tax | -129.9| -67.8| -306.7| 46.2|+-------------------------------+--------+-------+-------+-------+|Profit/loss after tax | -121.3| -56.9| -294.9| 31.7|+-------------------------------+--------+-------+-------+-------+|Operating margin, % |-1,306.1| -175.3| -335.7| 11.7|+-------------------------------+--------+-------+-------+-------+|Basic earnings per share, SEK | -4.50| -2.12| -10.94| 1.09|+-------------------------------+--------+-------+-------+-------+|Diluted earnings per share, SEK| -4.50| -2.12| -10.94| 1.08|+-------------------------------+--------+-------+-------+-------+|Net worth per share, SEK | 64.38| 54.04| 64.38| 54.04|+-------------------------------+--------+-------+-------+-------+|Return on equity | -30.5| -15.5| -18.5| 1.8|+-------------------------------+--------+-------+-------+-------+|Cash flow from operating | -69.6| -37.6| -180.1| 307.4||activities | | | | |+-------------------------------+--------+-------+-------+-------+|Cash and cash equivalents at | 1,698.5|1,077.9|1,698.5|1,077.9||period end | | | | |+-------------------------------+--------+-------+-------+-------+|R&D spending/total opex, % | 65.9| 77.8| 78.8| 73.1|+-------------------------------+--------+-------+-------+-------+ Conference call for investors, analysts and the mediaThe financial statement for January – December 2016 will be presented by Medivir’s President & CEO, Niklas Prager.Time: Friday, 17 February 2017, at 14.00 (CET).Phone numbers for participants from:Sweden 08- 566 426 91Europe +44 20 3008 9804USA +1 855 753 2235The conference call will also be streamed via a link on the website: www.medivir.comThe presentation will be available on Medivir’s website after completion of the conference. CEO’s commentsWe took several significant steps in the restructuring of Medivir during the fourth quarter. In all essentials, we completed the transformation of the company that had been in progress throughout the year. A key part of this transformation was the focusing of the company’s operations exclusively onto research and development in the field of oncology. This focus was given extra emphasis with the acquisition of two oncology projects in late development phases, both of which have considerable potential. The acquisition strengthens and balances our research portfolio and gives us a wider range of projects in different phases, shifting the company’s primary focus from early stage research to clinical development.As a further step in this process, we also divested BioPhausia with its drug portfolio Nordic Brands. After having considered and prepared a separate stock exchange listing of BioPhausia, we judged that a sale to Karo Pharma AB was the best alternative for our shareholders. An Extraordinary General Meeting in early February 2017 endorsed the Board’s proposal that the net proceeds from the sale of SEK 870 million should be distributed to Medivir’s shareholders in the form of a voluntary redemption programme.We also reorganised the company’s early stage research and administrative functions during the quarter. It is estimated that this will give annual savings totalling approximately SEK 110 million.Furthermore, we continued to make progress in our research projects during the quarter, both in our internal portfolio and in partner projects. I would like to make particular mention of the fact that we selected two new candidate drugs from our own research portfolio that have now proceeded to preclinical development: MIV-323 for the treatment of RSV infections and MIV-818 for the treatment of liver cancer. In keeping with our new exclusive oncology focus, we will continue to pursue the development of MIV-818 in-house, while for that of MIV-323 we will be seeking a partner.Along with MIV-802 for the treatment of hepatitis C, which we licensed out to Trek Therapeutics in the third quarter of 2016, these projects are clear indications of the improved productivity of our early stage research operations and ability to continue to produce new, well-differentiated candidate drugs in areas of great unmet medical needs on the basis of our own technology platform.The osteoarthritis trial MIV-711 proceeded according to plan and is now fully enrolled. As before, we expect to report data from the study during the third quarter of 2017.In November our partner, Janssen Research & Development, announced that they are building on earlier interesting results by initiating a phase IIb study with the combination of simeprevir, odalasvir and AL-335 for the treatment of hepatitis C.Q4 royalties attributable to the hepatitis C drug OLYSIO® (simeprevir) amounted to SEK 5.6 million as a result of the decline in global net sales.The extensive transformation we have now achieved gives me great hope for the future. Our strong, balanced research and development portfolio with a focus on oncology, based on our exciting technology platforms for protease inhibitors and nucleosides/nucleotides, has considerable potential to create long-term value for the shareholders and will generate a continuous news flow in 2017 and the years to come. It is therefore with a sense of pride and great confidence that I feel spring 2017 is the right time to hand over the baton to a new CEO, Christine Lind. I would like to take this opportunity to thank all our engaged shareholders, the Board of Medivir, all our employees and business partners for the stimulating and intense years at the helm of Medivir and I wish the company every success in the future. As a shareholder, I will be following the progress with great interest! Niklas PragerPresident and CEO  Upcoming reporting dates:Interim Report (January – March 2017)28 April 20172017 Annual General Meeting3 May 2017Interim Report (January – June 2017)25 July 2017Interim Report (January – September 2017)26 October 2017 For further information, please contact:Niklas Prager, President & CEO, phone: +46 (0) 8 407 64 30Ola Burmark, CFO, mobile: +46 (0)725-480 580.This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 17 February 2017.About MedivirMedivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Dome Energy resumes drilling program in Orangefield, Texas

Dome Energy AB. (https://www.domeenergy.com) (herein after “Dome” and/or “the Company”) today announces that they resumes the drilling program in Orangefield, Texas. ·  Program in Orangefield with a planned drilling start in March for the two first wells ·  Hager # 39 and # 40 are planned to be drilled to a depth of 5,000 ft ·  Estimated investment $550,000 per well ·  The first two of more than 20 possible wells to be drilled in Orangefield Paul Morch, CEO: “It is with the great pleasure to announce that we are resuming our drilling program in Orange Field, which initially started in the end of 2014. We succeeded then with the first well, Hager #37, which has proven to be very favorable from a financial point of view. We are now continuing on the southern point of the lease, to see if we can repeat the success on this, for us so fortunate, land. We have started to plan the drilling localization, and estimate to start drilling within a few weeks. We will return with more information on the start of the drilling and thereafter with regular progress reports.”   For further information please contact:Paul MorchPhone: +1 713 385 4104E-mail: pm@domeenergy.com   This information is the kind of information that Dome Energy AB (publ) is obliged to publicize according to EU Market Abuse Regulations (MAR). The information was publicized, by the above contact person February 17, 2017 08.30 CET.  About Dome EnergyDome Energy AB. is an independent Oil & Gas Company publicly traded on the Nasdaq First North exchange in Sweden (Ticker: DOME (http://www.nasdaq.com/symbol/els/dome)). Mangold Fondkommission AB, phone: +46 8 503 01 550, is the Company’s Certified Adviser. Headquartered in Houston, Texas, the Company’s focus is on the development and production of existing onshore Oil & Gas reserves in the United States. For more information visit www.domeenergy.com.

Pioneering Healthcare Company changes name from Brainshake to “Nightingale Health”

After three years of fast growing business in the medical research market, the company known as Brainshake has unveiled its new company name, Nightingale Health. This coincides directly with the company’s move in 2017 to clinical testing in Europe. With its unique, proprietary and powerful blood testing re-invention, Nightingale aims to solve the world’s biggest health problem. The technology has been proven to advance research in chronic diseases such as heart disease and diabetes, and is supported by over 100 peer-reviewed biomedical publications. When asked about the new name, CEO Teemu Suna said: “We have been laser focused on this revolutionary product and as we move to making it widely available, we wanted a name that truly reflects our mission, passion and values. The Nightingale bird in the Finnish translation literally means “representing many voices”. At the same time, Florence Nightingale was one of the original pioneers of modern medicine; instead of taking medical interventions as the only solution, she introduced better hygiene and nursing practice for disease prevention. In addition, she popularized visual data mapping, she was a believer in better healthcare for all. She took action, did not accept the status quo and innovated new thinking. As an inclusive and pioneering company, we are inspired by her work”. The company will refresh its brand look and feel and as CCO Kristiina Tolvanen explains: “We are proud to pioneer new solutions in everything we do. And this will be reflected in our identity over the coming months”. The company simultaneously remains tirelessly focused on making their unique blood analysis solution scale with affordability, clinical integration and scalability as core foundations. Nightingale’s mission is to make life defining choices possible so rather than just diagnosing and treating diseases, we will be able to take preventive actions. Recently, Nightingale Health’s blood analysis technology has been chosen from hundreds of applications to be presented at MIT Solve event at United Nations headquarters in March. Further information: Teemu Suna, CEO, Co-founder teemu.suna@nightingalehealth.com +358 40 196 1669 Solve at the United Nations -event: http://solve.mit.edu/events/solve-at-the-united-nations Nightingale Health Ltd.  Nightingale Health (formerly known as Brainshake) is a pioneering healthcare company aiming to solve the world’s biggest health problem with its unique, proprietary and powerful blood testing re-invention. The technology has been proven to advance scientific research in chronic diseases and is supported by over 100 peer-reviewed biomedical publications. Early prediction and prevention of heart disease and diabetes is at the core of the technology. Nightingale’s mission is to make life defining choices possible, so that in the future we are no longer just told and diagnosed, we can predict our health.

Seqr partners with Facestore launching in 25,000 online stores

Seqr, the innovative and easy mobile payment solution developed by Seamless, has partnered with Facestore to launch a new official payment method for consumers on the giant social commerce platform. Facestore will launch Seqr as a secure online payment method to its 25,000 online stores in Portugal. This partnership will provide merchants using the Facestore distribution platform to offer the Swedish payment option to its customers - not only does Seqr provide merchants with the lowest transaction costs in the market, compared to credit card services, but also benefits consumers with a new secure and easy way to pay. E-commerce has shown massive growth over the past few years. This deal will both enhance our e-commerce offering to both merchants and consumers and will help the Swedish company Seqr to reinforce and build awareness within the mobile payment industry in Portugal.”, says João Pedro Duarte, Country Manager of Seqr Portugal. While traditional e-commerce payment methods charge retailers with extensive costs, Seqr is based on a low cost transaction system. Furthermore, Seqr offers more security, since it doesn’t require any private information while paying. “Our infrastructure is solid, it supports more than 675,000 active sales outlets and manages 5,3 billion transactions every year.”, concludes João Pedro Duarte. With Seqr any consumer is able to make Seqr ‘Tap and Pay’ payments at any retailer that accepts contactless payments worldwide or via QR code at participating retailers. Seqr is designed for everyday payments simply using a smartphone, it enables consumers to pay for goods, either in physical stores, digital stores, on social media and even outdoor. “Enhancing the presence of Seqr in e-commerce was one of the priorities when we partnered with Facestore.”, cites João Pedro Duarte. Paulo Solinho Barbosa, CEO of Facestore says: “Supporting more than 25,000 stores including brands as: Aldo, Rally de Portugal, NICI, Impala, among others, is extremely valuable. We want to offer the best technological solutions to our clients, in order to enable them to be more competitive.” Seqr is now available as a payment method to anyone who uses Facestore. In order to use it, simply  download the app in the Google Play (https://play.google.com/store/apps/details?id=com.seamless.seqr) Store, App Store (https://itunes.apple.com/lu/app/seqr/id494224742?mt=8) or Windows Phone Store (https://www.microsoft.com/pt-pt/store/p/seqr/9wzdncrdhh22) and join the most innovative payment system.

Summa Equity’s first fund closes at SEK 4.5 billion

Summa Equity was founded in 2016 by five partners brought together by a shared vision of building a leading specialised private equity firm in the Nordic lower mid-market. The firm focuses on capturing the investment opportunity provided by thematic megatrends that are expected to drive long term growth. Reynir Indahl, Managing Partner, Summa Equity comments: “Our investment strategy is designed to address the challenges associated with generating long-term profitability in a volatile market underpinned by low economic growth. In the process we hope to be part of developing innovative solutions to some of the most pressing challenges of our time. The closing of our first fund brings us closer to realising this vision and marks the beginning of an exciting journey.” Summa Equity Fund I is backed by a broad investor base comprising endowments, foundations, pension funds, insurance firms and funds of funds across the Nordics, Europe and North America. The Fund’s strategy will focus on investments related to four themes: resource scarcity, energy efficiency, changing demographics and tech-enabled businesses. The firm has offices in Stockholm and Oslo and the partners are Reynir Indahl, Jenny Keisu, Johannes Lien, Christian Melby and Tommi Unkuri. Two deals, Sortera and eGain, have already been completed for the fund: · Sortera is the market leader in collection and recycling of building material waste in Sweden’s largest urban areas. · eGain is a leading Nordic technology/service provider of remote optimisation and climate-based control of heating in multi-apartment buildings. Jenny Keisu, Partner and COO of Summa Equity, continues: “Sortera and eGain are great examples of the investment opportunities we see. They both have megatrend driven, resilient business models uncoupled from GDP growth and we have already identified a number of value creation initiatives that are being implemented to stimulate their respective growth strategies. A third investment is finalised and will be announced shortly providing a solid foundation for the fund.” Summa Equity’s investment philosophy also contributes to a strong environmental, social and governance (ESG) profile with the goal to generate long-term sustainable growth and profitability. As part of this commitment the firm will be the first Nordic Private Equity firm to report towards the UN Sustainable Development Goals. Summa Equity was advised by London-based Rede Partners, an independent fund raising and secondary adviser to the private equity industry. The legal advisors in connection with the fund raising were Mannheimer Swartling and Ropes & Gray. The new fund is domiciled in Sweden and is regulated as an AIF (Alternative Investment Fund) by the Swedish Financial Supervisory Authority. Ends Notes to Editors For more information, please contact: Jenny Keisu, Partner and COO, +46 72 24 24 144 About Summa Equity Summa Equity was formed in 2016 by partners with a shared vision of building a leading specialised private equity firm in the Nordic lower mid-market, positioned to capture the investment opportunity provided by the thematic megatrends expected to drive growth over the long term. The Firm focuses on sectors related to four megatrend driven themes: resource scarcity, energy efficiency, changing demographics and tech-enabled businesses. Summa Equity closed its first fund in February 2017 with commitments of SEK 4.5 billion.

Viking Line to invest in its Helsinki–Tallinn route, tripling departuresin July

The Helsinki–Tallinn route is by far one of the most popular with cruise passengers on the Baltic Sea. Many travel to Tallinn on business trips or to shop. In past years, aside from the usual service on the Viking XPRS, additional sailings were provided by the M/S Mariella and M/S Gabriella. This year, Viking Line also wanted to offer customers the chance to get to Tallinn even faster than before. The large amount of departures means it is possible to visit Tallinn easier than before. “Some people like to spend time on the vessel, while others want to get where they are going as fast as possible. So we decided to rent a vessel to make express sailings. This year we also want to start up the additional sailings beginning in the spring and continue them well into the autumn. There is such a great demand, and we do not want to leave anyone on shore”, says Kaj Takolander,Vice President Marketing and Sales at Viking Line. To Tallinn in less than two hours Travel time on the Viking FSTR from Helsinki to Tallinn is 1 hour and 45 minutes. Passengers can conveniently work on board since window seats on the upper deck are equipped with outlets for charging computers. Although the vessel travels the distance quickly, people have an opportunity to shop on board or relax in the restaurant and pub. The vessel has capacity for about 850 passengers and 120 cars. It also features an additional class, Club Lounge, where food and beverages are included in the ticket price. People can continue their journey by car from Tallinn to attractive Estonian destinations such as Vihula Manor, where they can enjoy a spa weekend, or the remote sandy beaches of the Baltic Sea. Naturally, Tallinn also offers city holidays with relaxation, shopping, culture and food experiences all day long. The last departures to Helsinki are in the evening. During the spring and autumn, the Viking FSTR will make four to six daily sailings in addition to the Viking XPRS’ usual four departures. In July, there will be a full 12 daily departures on the Helsinki–Tallinn route since the vessels that serve the Helsinki–Stockholm route will also make one return sailing to Tallinn during the day. The new departures will be bookable from March 15, 2017. The preliminary timetable, Viking Line reserves the right to changes:

CORRECTION OF PUBLISHING OF THE ANNUAL REPORT

By mistake in our Year-End-Report and on our web-site it says that the Annual Report will be available with effect of February 25th2016. That is not correct. Correct date is March 1st2017. The published date relates to previous year and has not been corrected in the Report 2017. We apologise for any confusion regarding this.Stockholm, February 17th 2017Timo Lindborg, CEOSotkamo Silver AB discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act.The official Stock Exchange Releases are given in Swedish and there may be differences in the translated versions.About Sotkamo Silver AB:Sotkamo Silver AB´s business concept is to exploit mineral deposits in the Nordic countries with positive social and environmental benefits. Sotkamo Silver owns mineral deposits, which contain silver and gold in Finland as well as zinc and gold in Norway. The Company’s main development project is the Silver Mine project in the municipality of Sotkamo.Sotkamo Silver applies SveMin’s & FinnMin’s respective rules of reporting for public mining & exploration companies. Sotkamo Silver has chosen to report mineral resources and ore reserves according to the internationally accepted JORC or NI 43-101 code. The company applies International Financial Reporting Standards (IFRS) as approved by the European Union.Number of shares and votes are 103,215,990 before the registration of this issue at the Swedish Companies Registration Office. Number of shares and votes after the registration of this issue is 113,527,267.The ticker symbol is SOSI in NGM Equity in Stockholm and SOSI1 in NASDAQ OMX Helsinki.ISIN-code for Sotkamo Silver shares is SE0001057910.ISIN- code for share warrants series 2016/2017 are SE0008373880Legal Entity Identifier (LEI): 213800R2TQW1OZGYDX93Read more about Sotkamo Silver on www.sotkamosilver.com or www.silver.fi Read more about Mining Associates on www.miningassociates.com (http://www.miningassociates.com)

Cloetta acquires Candyking

”The acquisition of Candyking will significantly strengthen Cloetta’s position in Denmark, Norway and the United Kingdom. Cloetta will be able to develop the Candyking brand and product offering, in order to offer an attractive customer and consumer experience. The acquisition will also strengthen our position in natural snacks with the Parrot brand. In addition, there are substantial cost synergies that make the acquisition attractive,” says Danko Maras, CFO and outgoing CEO a.i., of Cloetta. Candyking offers stores a complete concept in pick and mix candy including products, displays and accompanying store and logistic services. Candyking itself does not manufacture any products, instead they purchases products from different suppliers. The company currently supplies approx. 8,000 retail outlets in seven countries. Sweden, the United Kingdom, Norway and Denmark are the largest markets. Other markets are Finland, Ireland and Poland. In total Candyking have approx. 370 employees. Candyking’s total sales (including Danish tax) amounted to approx. SEK 1,300m on a rolling twelve month basis per the third quarter of 2016. Underlying EBITDA was approx. SEK 70m and underlying EBIT approx. SEK 30m. Candyking’s trademarks in confectionary are Candyking, Karamellkungen and Candyking Favourites. The company is also a leading pick and mix supplier within natural snacks in Sweden and Finland under the Parrot brand. The acquisition is expected to create substantial synergies that will gradually be realized during the years 2017 – 2020. Synergies will be created within administration, procurement, logistics, sales and through insourcing of production. The final outcome of the synergies is dependent on volume development. Cloetta intends to, following completion of the transaction, revert with information regarding expected synergies and non-recurring costs. The Cloetta group’s target of an underlying EBIT margin of 14 per cent stands firm. The transactionCloetta has agreed to acquire 100 per cent of the shares in Candyking as well as 100 percent of Candyking’s outstanding bond and other debt. The initial purchase price amounts to SEK 325m on a cash and debt free basis with a potential additional purchase price of maximum SEK 225m based on the result of Cloetta’s and Candyking’s combined sales volume of pick and mix in confectionary and natural snacks in the Nordic countries, the United Kingdom and Poland during 2018. The seller of the shares is Candyking’s CEO, Dani Evanoff. The majority of the initial purchase price and the potential additional purchase price will be allocated to the holders of Candyking’s SEK 750m bond loan. In connection with closing of the acquisition, Candyking’s bonds will be delisted from Nasdaq Stockholm. At the same time Cloetta will issue an earn-out instrument to the current bondholders that entitles to the future potential additional purchase price. The instrument will be registered at Euroclear in order to facilitate the distribution of any additional purchase price to the current bondholders. The transaction is subject to approval from the Swedish Competition Authority. FinancingThe acquisition will be financed by Cloetta using cash and its existing credit facilities. AdvisorsHandelsbanken Capital Markets has been financial advisor to Cloetta and Advokatfirman Cederquist has been legal advisor. KPMG contributed with support regarding financial due diligence. Conference call and web presentationA conference call and web presentation with Danko Maras, CFO and outgoing CEO a.i., will be held today at 15.00 p.m. Those who wish to participate are invited to dial in on telephone numbers. Phone numbersSE: +46856642690DK: +4535445575FI: +358981710493UK: +44 2030089802NO: +4723500254  Web presentationLink to the live broadcast will be published on www.cloetta.com The presentation will be in English. Make sure that you are connected to the conference by dialling in and register a few minutes before the conference begins. An audio recording of the conference call will be published on www.cloetta.com This information is such that Cloetta AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person set out below, for publication at 13.30 CET on 17 February 2017.

Candyking gets new owner

-          Shortly after my acquisition of Candyking, after a thorough dialogue with the creditors of the Company, the conclusion was that we needed to find a strong and long-term owner to the company. With this insight, dialogues with several potential purchasers on the market were initiated and Cloetta was deemed to be the best candidate in this process. A professional player with a strong interest for pick and mix confectionary and a strong focus on further developing its concept business within its group. I am convinced that Candyking will create added value for Cloetta, customers and our Nordic suppliers who during all years have supported Candyking for better or worse. Personally, I feel proud and relived to through this transaction perpetuate Karamellkungen which was founded in 1984 by Christer Forsman, says Dani Evanoff. The transaction is carried out on the basis of the discussions that have taken place between Candyking Holding AB (publ) (the “Company” or “Candyking”) and holders of the Company’s outstanding bond-loan in a nominal amount of MSEK 750 (the “Bonds”) regarding Candyking’s long-term financing (please refer to the press release on 13 January 2017 regarding the divestment of Candyking from Accent to Dani Evanoff). The agreement in relation to the acquisition has been entered into between a wholly owned subsidiary of Cloetta AB (publ) (“Cloetta”), a group of bondholders (together representing a qualified majority of more than 2/3 of the Bonds) and Dani Evanoff through his wholly owned company. Cloetta acquires, inter alia, all shares in Candyking and the Company’s mezzanine loan from Dani Evanoff as well as all outstanding Bonds from the bondholders.   The initial purchase price amounts to MSEK 325 on a cash and debt free basis and will be payable in connection with closing of the transaction. The purchase price after adjustments for cash and debt is estimated to approximately MSEK 307 in the agreement and will be finally determined in connection with closing. Based upon Cloetta’s and Candyking’s combined sales volume of pick and mix in confectionary and natural snacks in the Nordics, the United Kingdom and Poland during 2018, an additional purchase price of maximum SEK 225 million may become payable. The major part of the purchase price will be allocated to the bondholders. In connection with closing, Cloetta will issue an instrument relating to the right to the potential additional purchase price, which will be issued to the current bondholders in exchange for the existing Bonds (a so called “Mandatory Exchange” in accordance with the terms and conditions for the Bonds). Thereafter, the Bonds will be de-listed from Nasdaq Stockholm. The new instrument will be registered with Euroclear in order to facilitate the payment of the potential additional purchase price to the bondholders. Resolutions to approve the transaction, the exchange of instruments and other resolutions necessary in connection therewith will be resolved upon at a bondholders’ meeting which will be called upon shortly in accordance with the terms and conditions for the Bonds. Bondholders together representing a qualified majority of more than 2/3 of the Bonds have undertaken towards Cloetta to vote in favour of such resolutions. More information in relation to the transaction that may be of importance to the bondholders will be included in the notice. The transaction in subject to approval from the Swedish Competition Authority and approval of the bondholders at a bondholders’ meeting. Gernandt & Danielsson Advokatbyrå KB and Baker McKenzie are advisors to the bondholders, the Company and Dani Evanoff in connection with the transaction. In case of questions, please contact: Dani Evanoff +46 73-503 97 97 About this information Candyking Holding AB (publ) publishes this information in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.30 CET on 17 February 2017.   About Candyking Candyking was founded in 1984 and is a leading concept supplier of pick and mix candy in the Nordic countries, the United Kingdom, Ireland and Poland. Today, Candyking has more than 8,000 points of sale and offer stores an integrated concept which includes products, displays and accompanying store and logistic services. Candyking’s trademarks in confectionary are Candyking, Karamellkungen and Candyking Favourites. The company is also a leading pick and mix supplier within natural snacks in Sweden and Finland under the Parrot brand. More information is available at www.candyking.com.

Knorr-Bremse's offer for Haldex: Supplement to the offer document made public

On 5 September 2016, Knorr-Bremse AG ("Knorr-Bremse") announced a public offer to the shareholders of Haldex AB (publ) ("Haldex") to tender all shares in Haldex to Knorr-Bremse (the "Offer"). The offer document regarding the Offer was made public on 26 September 2016. On account of Haldex's annual statement January-December 2016, Knorr-Bremse has prepared a supplement to the offer document, which includes the above-mentioned document. The supplement has been approved and registered by the Swedish Financial Supervisory Authority. The supplement has been made public today and is, together with the offer document and the acceptance form, available on Knorr-Bremse's website www.knorr-bremseandhaldex.com and on SEB's website for prospectuses www.sebgroup.com/prospectuses. The supplement should be read in conjunction with the offer document dated 26 September 2016. In accordance with the Takeover Rules issued by Nasdaq Stockholm, shareholders who have accepted the Offer have the right to withdraw from the acceptance within five working days of the announcement of the supplement, i.e. up to and including 24 February 2017. In all other respects, the right to withdraw from the acceptance applies pursuant to the offer document. For other terms and information about the Offer please refer to the offer document. Knorr-Bremse AG  For additional information contact: Knorr-Bremse AG Dr. Detlef HugEmail: Detlef.Hug@knorr-bremse.comPhone: +49 89 3547 1402 Eva DopplerEmail: Eva.Doppler@knorr-bremse.comPhone: +49 89 3547 1498 Additional contacts for media in Germany FTI Consulting SC Carolin AmannEmail: Carolin.Amann@fticonsulting.comPhone: +49 69 92037 132 Thomas M. KrammerEmail: Thomas.Krammer@fticonsulting.comPhone: +49 89 71042 2116 Additional contacts for media in Sweden Comir Johan HähnelEmail: Johan.Hahnel@comir.sePhone: +46 8 31 17 70 This press release was submitted for publication on 17 February 2017 at 3:00 p.m. CET.  Important notice The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this announcement and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This announcement is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this announcement or any other document received in connection with the Offer to such persons. Statements in this announcement relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Knorr-Bremse AG. Any such forward-looking statements speak only as of the date on which they are made and Knorr-Bremse AG has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Special notice to shareholders in the United States  The Offer described in this announcement is made for shares of Haldex AB, a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which are different from those of the United States. The Offer is made in the United States in compliance with Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act"), subject to the exemptions provided by Rule 14d-1(d) under the U.S. Exchange Act and otherwise in accordance with the requirements of Swedish law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, the offer timetable, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. To the extent permissible under applicable law or regulation, Knorr-Bremse AG and its affiliates or brokers (acting as agents for Knorr-Bremse AG or its affiliates, as applicable) may from time to time, and other than pursuant to the Offer, directly or indirectly purchase, or arrange to purchase, shares of Haldex AB, that are the subject of the Offer or any securities that are convertible into, exchangeable for or exercisable for such shares. To the extent information about such purchases or arrangements to purchase is made public in Sweden, such information will be disclosed by means of a press release or other means reasonably calculated to inform U.S. shareholders of Haldex AB of such information. In addition, the financial advisors to Knorr-Bremse AG, may also engage in ordinary course trading activities in securities of Haldex AB, which may include purchases or arrangements to purchase such securities. Knorr-Bremse AG and/or its affiliates or brokers have purchased shares of Haldex AB during the period following the announcement of the Offer on 5 September 2016. NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THIS OFFER, PASSED UPON THE FAIRNESS OR MERITS OF THIS ANNOUNCEMENT OR DETERMINED WHETHER THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE IN THE UNITED STATES.

UPDATE ON STATUS OF THE REFINANCING OF FINANCIAL OBLIGATIONS

The Board of Directors (the “Board”) of EMAS Offshore Limited (the “Company”, together with its subsidiaries, the “Group”) refers to the announcement released by the Company dated 13 December 2016 (the “Announcement”) where the Company announced that the Group has signed a term sheet with all its financial lenders to refinance its financial obligations (“Refinancing”) over a period of 5 years from 12 December 2016 and the Refinancing will be subject to documentation and conditions that would be set out in definitive agreements (the “Definitive Agreements”) to be entered into between the parties within sixty (60) days from 12 December 2016. Unless otherwise defined, capitalised terms used herein shall have the same meanings ascribed to them in the Announcement.  The Board wishes to announce that the Company and all its financial lenders are still in the process of negotiating and finalising the Definitive Agreements. The Company has requested its financial lenders to grant an extension of time to finalise the Definitive Agreements within sixty (60) days from 10 February 2017. The Company will make further announcements in compliance with the listing requirements of the Oslo Bors, upon the execution of the Definitive Agreements and/or when there are material developments in respect of the Ongoing Initiatives. Shareholders of the Company (the “Shareholders”) are advised to exercise caution when trading in the Company’s shares as there is no certainty or assurance as at the date of this Announcement that the Definitive Agreements will be entered into or the Ongoing Initiatives will be undertaken or completed at all. When in doubt as to the action they should take, shareholders and potential investors should consult their financial, tax or other advisers. By Order of the Board Shannon OngCompany Secretary17 February 2017

Nel ASA: Awarded frame contract for multiple hydrogen fueling stations in California

(Oslo, 20 February 2017) Nel Hydrogen Solutions, a division of Nel ASA (Nel, OSE:NEL), has entered into a framework contract for the supply, construction and maintenance of H2Station® hydrogen fueling stations in California, following the California Energy Commissions Notice of Proposed Awards for the Grant Funding Opportunity GFO-15-605. “This framework contract represents a major milestone for Nel, and open significant opportunities in the fast developing US hydrogen market. We are very proud to have been exclusively chosen to deliver H2Stations to our customer in California. We look forward to working with our partner to roll out their Californian hydrogen fueling network”, says Mikael Sloth, Director of Business Development in Nel. On Friday 17 February 2017, the California Energy Commission (CEC) announced the Notice of Proposed Awards (NOPA) for the Grant Funding Opportunity GFO-15-605 on the construction and operation of fueling stations in California. Following the NOPA announcement, Nel and its partner finalized the framework contract for the exclusive supply, construction and maintenance for H2Station® hydrogen fueling stations in California. Rather than getting a direct allocation through Nel’s subsidiary Everfuel Inc., the allocation for H2Stations® came through a third party partner of Nel. The name of the partner will remain undisclosed until the details in the allocation document has been assessed. The exact value of the contract and delivery details will also be disclosed later. “This is our largest single order for fueling stations ever, and represents the best possible start of our entry into the Californian market. We look forward to supplying our partner with technology as well as support through service and maintenance. We are also in good dialogue with other applicants and are therefore in position to deliver even additional H2Station technology to other grants recipients”, says Jon André Løkke, Chief Executive Officer of Nel. ENDS For additional information, please contact: Jon André Løkke, CEO, +47 9074 4949 About Nel| www.nelhydrogen.com       Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

EDGEWARE YEAR-END REPORT JANUARY-DECEMBER 2016

FOURTH QUARTER 2016: (OCTOBER-DECEMBER)• Net sales amounted to SEK 84.6 million (64.8), up 30.6 percent.• Gross income was SEK 59.8 million (45.5), or a gross margin of 70.7 percent (70.2).• Operating income (EBIT) was SEK 10.0 million (4.6), or an operating margin of 11.8 percent (7.0).• Adjusted operating income (adjusted EBIT) was SEK 17.9 million (4.6), or an operating margin of 21.1 percent (7.0).• Profit for the period amounted to SEK 7.4 million (5.5).• Cash flow from operating activities before changes in working capital was SEK 12.8 million (8.0).• Profit for the period, before dilution was SEK 0.3 per share (0.2).• Profit for the period, after dilution was SEK 0.3 per share (0.2). JANUARY-DECEMBER 2016:• Net sales amounted to SEK 252.3 million (203.6), up 23.9 percent.• Gross income was SEK 175.6 million (140.9), or a gross margin of 69.6 percent (69.2).• Operating income (EBIT) was SEK 19.1 million (13.3), or an operating margin of 7.6 percent (6.5).• Adjusted operating income (adjusted EBIT) was SEK 34,3 million (13.3), or an operating margin of 13.6 percent (6.5).• Profit for the year amounted to SEK 15.7 million (10.8).• Cash flow from operating activities before changes in working capital was SEK 30.8 million (18.5).• Profit for the period, before dilution was SEK 0.6 per share (0.5).• Profit for the period, before dilution was SEK 0.6 per share (0.4). SIGNIFICANT EVENTS IN THE FOURTH QUARTER AND AFTER THE REPORTING PERIOD• Board of Directors decided on long-term financial targets at a Board meeting 26 October 2016.• On 9 December, Edgeware was listed on main list NASDAQ Stockholm at SEK 29 per share. Ahead of the listing a share split of 1:20 was carried out, a bonus issue of 11 093 855 shares with a par value of 0.05 increasing share capital by SEK 554 692.75, a new issue of 5 172 413 shares with a par value of 0.05 increasing share capital by SEK 258 620.65.• On 17th of February the appointment of the nomination committee in Edgeware was announced, which consists of representatives of the three largest shareholders as of 31 January, Amadeus Capital Partners (23.1%), Creandum (18.8%) and Swedbank Robur Fonder (8.7%). The owners are represented by Kent Sander, Daniel Blomquist and Annika Andersson. CEO COMMENTS: 2016 was a historic year for Edgeware. Strong growth, international customer successes, important product launches, a stronger organisation and a listing on Nasdaq Stockholm. The listing gave us new shareholders and provides us with valuable support in our continued growth journey, in a TV industry undergoing rapid transformation.Thanks to the Internet, viewers not only have much more content to choose from, they also have an opportunity to choose how and when they want to watch this content. From traditional linear TV viewing based on TV schedules to the TV of the future. In pace with this market transformation, Edgeware has grown ever stronger internationally. With a better and more complete product range, we offer attractive products and services that are in demand among telco and cable operators, as well as content providers. All with the aim of supplying an amazing TV experience to consumers worldwide. 366 eventful days2016 started with large-scale orders from customers in Central America. This was followed in the second and third quarter by smaller and larger orders from international customers. For example, solutions were supplied to TVB of Hong Kong that enabled this company to broadcast the Olympic Games over the Internet. This was an initiative that subsequently will lead to TVB abandoning its licence to broadcast traditionally TV in favour of focusing solely on high- resolution Internet-based TV. A similar trend within OTT/Broadcasters is continuing at a rapid pace, and represents a development that should benefit Edgeware’s streaming technology. During 2016, our technological know-how and products attracted considerable attention at several trade fairs. We received a number of industry awards for our innovativeness and we were contacted by multiple potential partners and customers. A strong fourth quarterThe fourth quarter was strong in many ways. Sales and profitability grew powerfully at all levels, but it is even more important that this is not down to just one or two customers. We noted a distinct reduction in our customer concentration during the year, whereby we now have several major customers and the numbers are increasing as we grow, thus providing stability and security. It is also invigorating to note that a number of our multi-year customers are returning to us to upgrade their capacity, install new functions and request more services. Existing customers account for two thirds of our business. This provides stability. It is also positive that our Service business is continuing to grow in pace with the company’s total sales. During the fourth quarter, we also presented a new transaction in Australia, the first in that country. While not being a particularly large transaction, it marked an important step into a new and significant market. The transaction could also lead to future orders, since the operator is part of a larger corporate constellation in the region. Historical date - IPO on 9 DecemberOur listing on NASDAQ Stockholm was a milestone for the company and the employees. The ownership spread provides us with key resources for continued growth and valuable room for manoeuvre. Being able to create our own future as a listed company makes us attractive for the skilled employees that we are now recruiting. We have already made considerable progress in a number of highly important recruitments. Although the IPO entailed intensive effort, the listing was implemented smoothly thanks to my skilled co-workers, the Board, the owners, banks and advisors. As a direct result of the market listing, the company has honed the efficiency of all internal functions, while also ensuring that the Board and corporate governance are stronger and more professional. I also want to take the opportunity to welcome all new shareholders. We look forward to 2017 with confidenceWe believe strongly in the financial targets we have set for Edgeware in connection with our IPO and we see every day that the estimated market growth becomes a reality. I personally am very proud of our company and all of our employees. Although we are still a small company, we have a diversity and global direction that is fascinating and generates considerable energy. I look forward with confidence to 2017, which will be an exciting year with new advances in the development of the TV of the future for the company, the employees and our customers. Joachim RoosCEO, Edgeware For further information, please contact:Joachim Roos, CEOTelephone: +46 73 612 68 40Steeve Führ, CFOTelephone: +46 73 612 68 40Gunilla Wikman, IR ManagerTelephone: +46 70 763 81 25 gunilla.wikman@edgeware.tv This information is such information that Edgeware AB is required to disclose pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication by the above mentioned contact person on 20 February 2017 at 7:30 a.m. CET.

The Nomination Committee´s proposal to Swedbank´s Annual General Meeting 2017

The Nomination Committee proposes election of Mats Granryd, Bo Johansson, Annika Poutiainen and Magnus Uggla as new members.   Mats Granryd (born 1962) has a background in the telecom industry, where he started his career with 15 years in different positions in Ericsson, both in Sweden and globally. In 2010 he was appointed CEO for Tele2, a position he left in 2015 when he was appointed Director General for GSMA (the interest group for the mobile industry). Mats Granryd is a member of the Board of Directors of Coor Service Management Holding AB. Bo Johansson (born 1965) has a solid background from the savings banks and Swedbank, where he has worked a large part of his professional career. He has been CEO for Swedbank Sjuhärad since 2002 and in 2015 he was appointed as Deputy Chair of Sparbankernas Riksförbund (interest group for the savings banks). Bo Johansson is also Chair of IF Elfsborg (football club). Annika Poutiainen (born 1970) has been head of market surveillance at Nasdaq Nordics, unit manager at Finansinspektionen (Swedish Financial Supervisory Authority), member of the consultative workgroup of the committee of corporate governance within the European Securities and Markets Authority, ESMA, and member of the Swedish Securities Council. Since 2014 she is an Industrial Advisor at JKL Group, mainly within financial communication. Annika Poutiainen is a member of the Board of Directors at Hoist Finance AB, Saferoad AS, eQ Oyj, and the Carpe Diem Foundation, with the purpose to run Fredrikshovs Slotts Skola. Magnus Uggla (born 1952) has more than 30 years of experience from Handelsbanken AB, of which the major part has been as  Deputy CEO and Head of Handelsbanken International, Head of Handelsbanken in Great Britain and regional manager for the Stockholm region. He retired from Handelsbanken in 2015. Magnus Uggla is member of the Board of Directors at Hoist Finance AB and AB Svensk Exportkredit.  Independence according to the Swedish Corporate Governance CodeAll proposed Board members, except Bo Johansson, are considered independent in relation to the bank and the bank’s management. All proposed Board members are considered independent in relation to the bank’s major shareholders. Furthermore, it is noted that, in order to reduce the potential risk for conflict of interest, Annika Poutiainen has announced that she intends to leave her assignment with Hoist Finance AB and that Magnus Uggla has announced that he intends to leave his assignment with Hoist Finance AB and AB Svensk Exportkredit.   Remuneration of the Board of Directors and Auditors.The Nomination Committee proposes to raise the remuneration to the Board of Directors calculated on an annual basis as follows, corresponding to an average raise of 4.90 percent: SEK 2 460 000 (2 430 000) to the Chair of the Board of Directors; SEK 825 000 (815 000) to the Deputy Chair of the Board of Directors; SEK 550 000 (525 000) to each of the ordinary members of the Board of Directors; SEK 350 000 (290 000) to the Chair of the Board’s Audit committee; SEK 225 000 (215 000) to each of the other members of the Board’s Audit committee; SEK 400 000 (290 000) to the Chair of the Board’s Risk and Capital committee; SEK 225 000 (215 000) to each of the other members of the Board’s Risk and Capital committee; SEK 100 000 (100 000) to the Chair of the Board´s remuneration committee; SEK 100 000 (100 000) to each of the other members of the Board’s remuneration committee. The Nomination Committee proposes that the auditor’s fee, shall be payable by approved account. Swedbank AB’s 2017 AGM will take place at Folkets Hus in Stockholm, on 30 March 2017. The Nomination Committee proposes Counsel (Sw. advokat) Wilhelm Lüning as Chair of the 2017 AGM. The Nomination Committee comprises the following: Jens Henriksson, Chair, appointed by owner-group Folksam, Lennart Haglund, Deputy Chair, appointed by Sparbanksgruppen, Ramsay Brufer, appointed by Alecta, Johan Sidenmark, appointed by AMF, Peter Karlström appointed by the owner-group Sparbanksstiftelserna and Lars Idermark, Chair of the Board of Directors of Swedbank AB. The entire proposal of the Nomination Committee will be included in the AGM notice and also be available on Swedbank’s website. For further information:Jens Henriksson, Chair of the Nomination Committee, telephone: +46 76 762 20 55Gabriel Francke Rodau, Head of Communication, Swedbank, telephone: +46 70 144 89 66

Summa Equity acquires Lin Education

Tommi Unkuri, Partner at Summa Equity, said: “We are very excited about concluding Summa Equity’ third investment, and the first one within the investment theme Changing Demographics. This investment also fits within another of our four themes, Tech-enabled business, where Education is a core segment. Through Lin Education we will contribute to the digitalisation of the Swedish educational system. In a time when learning is more important than ever, this is a field offering important challenges, but also huge opportunities. Being part of innovative solutions to some of the pressing challenges of our time, is a fundament in Summa Equity’s investment philosophy”. Josef Lind, Founder and CEO of Lin Education, said: “We are very pleased to have Summa Equity as our new majority owner and partner, as this will help Lin Education take the next steps in our development. We are looking forward to a collaboration whereby we will strengthen our offering, press ahead to lead the development in educational content, and further develop our organisation. In Summa Equity we find a fit not only for our business, but also for our people and stakeholders.” Lin Education was founded in 2007 by Josef Lind, and today has several hundred thousand digital tools and IT hardware (i.e. computers, laptops, tablets, etc.) in schools and preschools all over Sweden. Lin Education also offers learning, development and digitalisation training for its customers. Many thousand people are using the Lin Education’s proprietary digital content tools for learning. The company has some 90 employees working out of offices in Gothenburg, Stockholm, Malmö, Karlstad and Umeå. Revenue was SEK 569m in 2016. Summa Equity will support the continued development of Lin Education and assist the Company in further growth through investments to develop existing as well as new products. Lin Education is expected to benefit from the trend towards increasing digitalisation of learning, in schools and in other environments. Ends For more information, please contact: Tommi Unkuri, Lead Partner, Summa Equity, +46 70 508 1196, tommi.unkuri@summaequity.com Josef Lind, CEO, Lin Education, +46) 704 385 827, josef.lind@lineducation.se About Lin Education Lin Education is a Swedish Education Technology company founded in 2007 as distributor of IT hardware (i.e. computers, laptops, tablets) to Swedish schools. The Company has since also expanded into segments for digital content, training and supplementary services for a digital learning environment, and today has a position as a leader in the Swedish market for digitalisation of the educational system. Lin Education has demonstrated strong double digit revenue growth annually over the past three years. About Summa Equity Summa Equity was formed in 2016 by partners with a shared vision of building a leading specialised private equity firm in the Nordic lower mid-market, positioned to capture the investment opportunity provided by the thematic megatrends expected to drive growth over the long term. The Firm focuses on sectors related to four megatrend driven themes: resource scarcity, energy efficiency, changing demographics and tech-enabled businesses. Summa Equity closed its first fund in February 2017 with commitments of SEK 4.5 billion.

Autoliv declares increased dividend

The dividend will be payable on Thursday, June 1, 2017 to Autoliv shareholders of record on the close of business on Wednesday, May 17. The ex-date will be Monday, May 15 for holders of the common stock listed on the New York Stock Exchange and Tuesday, May 16 for holders of Swedish Depository Receipts (SDRs) listed on NASDAQ Stockholm. Shareholders AGM As previously announced, the Board of Directors has set Tuesday, May 9, 2017, as the date for the Annual General Meeting of Shareholders to be held in Chicago, IL, USA. Only shareholders of record at the close of business on March 13, 2017, will be entitled to be present and vote at the 2017 Annual General Meeting. Notice of the 2017 Annual General Meeting will be delivered to the holders of record in late March. All of the directors with terms expiring at the 2017 Annual Meeting (Robert Alspaugh, Jan Carlson, Aicha Evans, Leif Johansson, David Kepler, Franz-Josef Kortüm, Xiaozhi Liu, James Ringler, Kazuhiko Sakamoto and Wolfgang Ziebart) will be nominated for re-election at the 2017 Annual Meeting, with the exception of George Lorch, who has informed the Company that he will  not stand for re-election at the 2017 Annual Meeting, as he has reached the retirement age set forth in the Company’s Corporate Governance Guidelines. George Lorch has served as a director of the Company since 2003 and as Lead Independent Director since May 2014. At the conclusion of Mr. Lorch’s service, the Board will appoint a new Lead Independent Director. The Board will not fill the vacancy resulting from Mr. Lorch’s retirement and will accordingly reduce the size of the Board to ten directors, effective immediately following the closing of the polls for the election of directors at the 2017 Annual Meeting. Inquiries: Thomas Jönsson, Vice President Corporate Communications, Tel: +46 8 58 72 06 27 This information is information that Autoliv, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 08.30 AM CET on February 20, 2017.

Brighter signs agreement with Sonat for global logistics solution.

Brighter has selected Sonat as its development partner for the upcoming launch of Actiste®, Brighter’s connected diabetes solution. Sonat specializes in developing, managing and running logistics processes, and will together with Brighter develop a strong logistics platform that facilitates growth and international expansion. Under the agreement, Sonat will take on a partner role and drive the development of a logistics platform that enables rapid growth and expansion to new markets. Sonat will also act as an outsourced logistics function, which includes responsibility for forecasts, inventory control, availability, order planning, transportation administration, delivery monitoring and ongoing problem solving. “The Actiste launch is approaching, and it is crucial that we have professional partners in all of the relevant areas. Just like our production partner Sanmina, Sonat adds valuable expertise. That in combination with our agreements with Telia and Indosat Ooredoo will ensure a successful launch on applicable markets. Sonat’s clients include Apoteket, Svenska Retursystem and Varner Ibrahimovic, among others, and they have many times demonstrated their capability in terms of supplying world-class logistics solutions,” says Truls Sjöstedt, CEO and founder of Brighter. Cooperation with Sonat will be initiated immediately. With this partnership, Brighter, which is currently in the industrialization phase, has ensured all of the partnerships it requires for the initial launch of Actiste on selected markets. In July 2016, Brighter teamed up with Sanmina, its global manufacturing partner, and shortly after Brighter signed an agreement with Telia for subscription services in Sweden, with an option for the Nordic countries. Brighter has also signed an agreement with Indosat Ooredoo, an Indonesian mobile network operator. In addition, Brighter has an on-going close partnership with Ericsson regarding its Device Connection Platform. “This is an extremely invigorating assignment that we are looking forward to implementing. Over the course of 17 years, we have accumulated an enormous amount of expertise and experience. With Brighter, we have an opportunity to combine the hands-on aspect of our 4PL operations with our extensive strategic know-how. We have extensive experience from both large and small companies, some in the start-up phase and some more established, but all with the same growth aspirations as Brighter,” says Kjell Rundqvist, CEO of Sonat. For more information, please contact:Truls Sjöstedt, CEO     Tel: +46 709 73 46 00     Email: truls.sjostedt@brighter.se  Henrik Norström, COO     Tel: +46 733 40 30 45     Email: henrik.norstrom@brighter.se About Brighter AB.Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and care for the elderly, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on NASDAQOMX FIRST NORTH/BRIG. Brighter's Certified Adviser is Remium Nordic AB, +46 (0)8 454 32 50, CorporateFinance@remium.com, www.remium.com. This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on February 20, 2017.

Sivers IMA enters partnership with Integrated Device Technology

This new 60 GHz RFIC contains a beam forming transceiver including 16 Tx and 16 Rx channels. Sivers IMA will also be able to deliver a high gain patch antenna as part of the full solution. The partnership will produce a carrier-grade, high-speed mmWave V-band solution targeting data and telecommunication infrastructure applications for the networks of today and tomorrow. The leading use cases for this ground breaking technology are fixed wireless access (FWA), meshed networking and backhaul. ”We are very pleased and excited to join forces with IDT in conquering the growing IEEE 802.11ad infrastructure market and I am impressed by the joint work and cooperation performed by our teams so far,” says Anders Storm, CEO of Sivers IMA. “The combination of capabilities from the Sivers IMA and IDT products will create a solution exhibiting very high throughput, immunity against interference and outstanding link budget that will add value to any potential customer wanting to explore the use of the wide license free 60 GHz spectrum.” “This collaboration with Sivers IMA is a reflection of IDT’s strategic focus, investments, and commitment to mmWave enablement within wireless infrastructure,” said Sean Fan, vice president and general manager of IDT’s Computing and Communications Division. “We see great opportunities for utilizing the mmWave bands for access and backhaul applications.” The IDT and Sivers IMA combined solution will provide an optimized infrastructure solution unlike anything existing on the market today. For example, IDT’s RapidWave RWM6050 dual modem is designed in 28nm CMOS technology and offers unprecedented integration including  dual modems in a single chip, enabling many data and telecommunication infrastructure uses cases. Sivers IMA’s RFIC is developed in Silicon-Germanium technology, offering state-of-the-art RF performance packaged in an eWBL capsule for easy surface mounting. The Sivers IMA RFIC and the IDT RapidWave  RWM6050 is expected to sample to key customers in Q2 2017. Under the partnership, IDT will have access to resell the Sivers IMA RFIC, and Sivers IMA will sell the RWM6050 module solution to select customers. For more information: Anders Storm, CEO Tel: +46 70 262 6390 E-mail: anders.storm@siversima.com  Integrated Device Technology, Inc. develops system-level solutions that optimize its customers' applications. IDT's market-leading products in RF, real-world interconnect, wireless power transfer, serial switching, interfaces, automotive ASICs, battery management ICs, sensor signal conditioner ICs and environmental sensors are among the company's broad array of complete mixed-signal solutions for the communications, computing, consumer, automotive and industrial segments. Headquartered in San Jose, Calif., IDT has design, manufacturing, sales facilities and distribution partners throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market® under the symbol "IDTI." Additional information about IDT can be found at www.IDT.com. Follow IDT on Facebook, LinkedIn, Twitter, YouTube and Google+. Sivers IMA is a leading manufacturer of micro- and millimeter wave products for connecting and quantifying a networked world. Sivers IMA has a long history and is internationally renown as a reliable supplier of high quality components used in telecommunications links, RADAR sensors and test & measurement equipment. Headquarters is located north of Stockholm in Kista, Sweden. Learn more at http://siversima.com.

Contract Administration streamlines customer services with IFS Applications

Contract Administration, founded in 1991, provides outsourcing services in the area of human resources (HR) and payroll processes. The company has four offices in Poland (Warsaw, Wroclaw, Lodz and Cracow), two in Czech Republic (Prague and Brno) and one in Bratislava, Slovakia. Currently, Contract Administration services more than 500 customers of all sizes, primarily in the manufacturing, financial and services sectors in Poland. Prior to the implementation of IFS Applications, Contract Administration had been using another vendor’s ERP solution. The company decided to implement IFS Applications in order to regain control of their processes and to have the flexibility of adapting their services to their diverse customers’ needs. “IFS Applications enables us to provide compelling and advanced services to our customers, including co-sourcing. Offering customers the option to outsource the administration of certain elements of key processes in their ERP solution to a trusted partner like Contract Administration is not only cost effective but allows them to focus on what they do best—running their business. This type of collaboration creates time and cost savings for both us and our customers,” said Magdalena Aleksandrowicz, General Director at Contract Administration. Marcin Taranek, IFS CEE President added, “We are pleased that our solution helps Contract Administration to streamline operations and gain a competitive advantage on the growing market of outsourcing services that support all areas of enterprise management.”

Saab to Deliver CBRN Equipment to INTERPOL

Under the agreement with INTERPOL’s BioTerrorism Prevention Unit, Saab will supply a total of six sampling units, to be used in the field to combat bioterrorism. The delivery also includes a certified packaging container designed for safe transportation of CBRN samples and other hazardous materials from the field to the laboratory. Delivery will take place in March 2017. “With this order Saab further strengthens its position as a supplier of advanced CBRN solutions, while contributing to increased preparedness and keeping people and societies safe. Saab’s CBRN equipment provides first responders with all the tools they need to conduct efficient, proper and secure field collection, and safe transportation, of all types of toxic materials,” says Jonas Hjelm, head of Saab business area Support and Services. Bioterrorism refers to the malicious use of bacteria, viruses or biological toxins, to threaten or cause harm to humans, animals or agriculture, and there is a number of terrorist groups demonstrating an interest and intent to use biological materials as weapons. Saab offers a complete CBRN solution for protecting people and securing operational capabilities. Early warnings to units and personnel are a key factor in limiting CBRN threats. With Saab’s integrated solutions, CBRN specialists and decision-makers will have effective tools for detecting and identifying a wide range of threats and will receive all the support needed for fast and accurate early warning. Saab will assist the customer’s organisation in evaluating and integrating CBRN capabilities. Saab’s CBRN solutions include systems for Automatic Warning and Reporting (AWR), sampling equipment, certified transport packaging and a wide range of services and CBRN training and support solutions for individual protection. INTERPOL is the world’s largest international police organization, with 190 member countries. INTERPOL’s Bioterrorism Prevention Unit works with law enforcement, health, academia and industry, to tackle bioterrorism. Over the last few years, INTERPOL has increased its capacity to assist member countries in minimising and counteracting threats of a bioterrorism act and establish effective countermeasures as part of a global security strategy. INTERPOL’s BioTerrorism Prevention Unit, will primarily utilise Saab's CBRN products to train its various member countries. For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Eltel’s Q4 and FY 2016 operative EBITA significantly below previous guidance – Q4 report to be published one day earlier

Due to these circumstances, Eltel will publish its full-year 2016 and fourth quarter interim report one day earlier than communicated, on Tuesday 21 February 2017 at 7.00 CET. Eltel’s CEO Håkan Kirstein, interim CFO Lars Nilsson and Chairman of the Board Ulf Lundahl will host a presentation via audiocast in English starting at 9.00 CET. The interim report and the presentation will include structural measures and strategic revisions. The presentation will be audiocasted live on www.eltelgroup.com. For those who would like to participate on the telephone conference in connection with the presentation, the telephone numbers are: · SE: +46 8 56 64 26 94 · FI: +358 9 81 71 04 92 · UK: +44 20 30 08 98 03 Please, call well in advance to register. After the presentation there will be an opportunity to ask questions via audiocast or telephone conference. The presentation material will also be available at that time and on demand at www.eltelgroup.com. For further information:Ingela UlfvesVP – Investor Relations and Group CommunicationsTel: +358 40 311 3009, ingela.ulfves@eltelnetworks.com This information is information that Eltel AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on 20 February 2017. About EltelEltel is a leading European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Transport & Security, with operations throughout the Nordic and Baltic regions, Poland, Germany, the United Kingdom and Africa. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2015 Eltel net sales amounted to EUR 1,255 million. The current number of employees is approximately 9,600. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

NCC to expand Ryhov County Hospital in Jönköping

“We are planning a major investment to improve and modernize the Ryhov County Hospital in Jönköping that will include a state-of-the-art emergency department and several new healthcare units. There is a substantial need to increase capacity at the hospital and this project will make it possible,” says Tomas Calmviken, Property Manager of Region Jönköping County. The new building will be constructed north of the existing hospital and will house several wards, including an additional emergency ward with 48 beds, two wards for medicine, complete with day care and reception centers, a mammography center and educational premises, which will be used for medical training conducted by the University of Linköping. The total floor space will be 34,000 square meters spread across six stories. The project will take the form of a partnering contract, which is a structured cooperative format where NCC and Region Jönköping County jointly draw up system documents, project budget and detailed design plans for the project. NCC has several ongoing construction projects in the hospital and healthcare sector throughout Sweden. This means employees who specifically work with developing hospitals and healthcare projects possess extensive expertise and experience in this area. It enables NCC to be at the forefront in the field. “NCC’s broad expertise and extensive experience in building healthcare establishments will benefit our customers’ new hospital project. It is also a major advantage to enter the process at an early stage when you are involved in a project of this type. It provides added value for all parties,” says Gunnar Masthagen, Deputy Head of Division, NCC Building Sweden. The order is scheduled to be registered in the third quarter of 2017 in the Building business area. Construction is scheduled to commence in the first quarter of 2018 and the extension will come into service in 2020.

SCHMITZ CARGOBULL INVESTS IN RIGID BODY SECTOR GROWTH WITH NEW APPOINTMENT

Schmitz Cargobull has invested in its future growth in the rigid market, with the appointment of a new National Sales Representative - Truck Bodies, to further develop the company’s presence in the rapidly growing sector. Tom Stott, 23, brings more than six years of experience from Cartwright, with a strong emphasis on customer service. In his new role, Stott will help customers of all sizes save money, with rigid truck bodies offering a low total cost of ownership. Stott says: “With urban delivery now a booming market in the UK and Ireland, the rigid body market has huge potential for expansion, and we’re committed to supporting operators in this competitive sector.” He adds: “Schmitz Cargobull’s trailers lead the market thanks to cost-effective features developed in-house, backed by outstanding customer service. Our rigid bodies also offer those advantages, which will benefit customers requiring world-class, high-tech assets combined with the functionality of a rigid. Supported by our range of value-added services, hauliers can get everything they need to maximise the cost-effectiveness of their operations from a single source.” Ideally designed for urban deliveries, Schmitz Cargobull’s rigid bodies incorporate a variety of advanced technologies, including a double-decker pallet stacking system that doubles carrying capacity for non-stackable goods, and flooring that is lighter, more slip-resistant and easier to clean than conventional flooring, as well as being PIEK-certified for low-noise operations. Schmitz Cargobull also offers a range of services designed to reduce the total cost of ownership of each rigid body, including telematics for optimal route planning and temperature control, and full-service contracts for repair and maintenance Europe-wide. The rigid bodies also maintain a higher residual value than comparable products in the market. Stott will be based at Schmitz Cargobull UK and Ireland’s head office in Warrington, reporting to Managing Director Alan Hunt. ends Editor’s notes: Schmitz Cargobull UK and Ireland is a subsidiary company of the German-owned Schmitz Cargobull Group. With an annual production of some 50,000 vehicles and around 5,100 employees, Schmitz Cargobull AG is Europe's leading manufacturer of semi-trailers, truck bodies and trailers for temperature-controlled freight, general cargo and bulk goods. A turnover of € 1.779 billion was reported in the 2015/2016 business year. As a pioneer in the industry, Schmitz Cargobull AG developed a comprehensive brand strategy early on and has consistently established quality standards spanning every level: from research and development, to production, to specialist services such as trailer telematics, financing, spare parts and used trailers. Visit Schmitz Cargobull UK’s dedicated online press room at http://news.cision.com/schmitz-cargobull  Press Contact UK:        James BoleyGarnett Keeler PR                                                        Tel: 020 8647 4467Email: james.boley@garnettkeeler.com   Company Contact Europe:Gerd Rohrsen, Corporate Public RelationsSilke Hesener, Manager Public RelationsTel: +49 02558 811501Email: silke.hesener@cargobull.com  SCB/183/17

Hearts of Iron IV Sells Half a Million Copies

Paradox Development Studio is thrilled to announce that Hearts of Iron IV, its World War II themed strategy wargame, has sold 500,000 copies worldwide since its release in June 2016. This milestone follows record sales for Stellaris, Europa Universalis IV and Crusader Kings II, once again confirming Paradox as the premier developer of computer strategy games.Fredrik Wester, CEO of Paradox Interactive, underlines how the continued success of Paradox games justifies the company philosophy.“The PC remains the primary platform for games of this nature,” Wester says. “Even genres that have traditionally been seen as niche can find a large audience, if a developer is dedicated to quality, variety and learning from both previous experiences and the community at large.” Hearts of Iron IV recently saw the release of Together for Victory, the first major expansion to the game. Lead Designer Dan Lind is very pleased with the ongoing development of the game, and the team remains committed to continually improving the HoI experience."As a result of this success we are able to take advantage of extra time to add tweaks and polish to the game. Our community has high standards, and we will work hard to to live up to their expectations in the coming weeks and months. We really want HoI to be the best it can be for our fans."Hearts of Iron IV is currently 33% off at the official Paradox Store. (https://www.paradoxplaza.com/hearts-of-iron-iv) The game is also available on Steam. 

Itiviti Group Holding AB (publ) calls for early redemption of notes with ISIN SE0004872851

Itiviti Group Holding AB (publ) (previously Cidron Delfi Intressenter AB (publ)) has today given notice of exercise of its option for early redemption of all outstanding notes with ISIN SE0004872851 (the "Notes") to all noteholders as of 20 February 2017.The date on which the redemption will occur will be 27 March 2017. The Notes will be redeemed at an amount equal to the sum of:a) 100 per cent. of the nominal amount (i.e. EUR 100,000 per Note);b) 25 per cent. of the interest rate; andc) accrued but unpaid interest.The redemption amount amounts to EUR 63,499,167 in aggregate and EUR 105,831.94 per Note. The record date for redemption is 20 March 2017. In conjunction with the redemption, the Notes will be delisted from the corporate bond list at Nasdaq Stockholm.This information was prior to this release inside information and is information that Itiviti Group Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 4.00 p.m. CET on 20 February 2017.For further information, please contact:Itiviti Group Holding AB (publ)Tony Falck, CFO, tel. +46 8 506 477 24About ItivitiItiviti is a world-leading technology provider for the capital markets industry. Trading firms, banks, brokers and institutional clients rely on Itiviti technology, solutions and expertise for streamlining daily operations, while gaining sustainable competitive edge in global markets.With 13 offices and serving more than 400 customers worldwide, Itiviti was formed by uniting Orc Group, a leader in trading and electronic execution, and CameronTec Group, the global standard in financial messaging infrastructure and connectivity. From its foundation in 2016, Itiviti has a staff of 400 and an estimated annual revenue of SEK 700 million.Itiviti is committed to continuous innovation to deliver trading infrastructure built for today’s dynamic markets, offering highly adaptable platforms and solutions, enabling clients to stay ahead of competitive and regulatory challenges.Itiviti is owned by Nordic Capital Fund VII.www.itiviti.com

Eltel Group: Full-year report January–December 2016

January–December 2016 · Net sales amounted to EUR 1,399.8 million (1,254.9), up 13.5% in local currencies, organic net sales increased by 1.8%* · Operative EBITA amounted to EUR 2.1 million (62.2) or 0.1% of net sales (5.0) · Write-downs and provisions in operative EBITA amounted to EUR 49.8 million · Goodwill impairment of EUR 55.0 million recognised relating to the power transmission business · EBIT amounted to EUR -67.4 million (46.6) · Net financial expenses amounted to EUR -12.6 million (-14.4) · The net result amounted to EUR -82.2 million (43.2) · Earnings per share was EUR -1.33 (0.69) · Operative cash flow was negative at EUR 8.0 million (+45.8), cash conversion was -387.4% on a rolling 12-month basis · The Board proposes that no dividend be paid for the year 2016 (0.24) October–December 2016 · Net sales amounted to EUR 387.1 million (397.3), down 1.8% in local currencies, organic net sales decreased by 2.8%* · Operative EBITA amounted to EUR -14.6 million (20.5) or -3.8% of net sales (5.2) · Write-downs and provisions in operative EBITA amounted to EUR 34.1 million · Goodwill impairment of EUR 55.0 million recognised relating to the power transmission business · EBIT amounted to EUR -73.2 million (16.5) · Net financial expenses amounted to EUR -4.5 million (-2.2) · The net result amounted to EUR -80.3 million (17.3) · Earnings per share was EUR -1.29 (0.27)  · Operative cash flow was positive at EUR 22.5 million (90.4)  Unless otherwise stated, figures in brackets refer to the same period in the preceding year.* Organic net sales excludes the U-SERV acquisition in 2016 and the Norwegian Communication business until 1 September 2016 (Eltel Sønnico) and is presented using comparable exchange rates.  Important decisions and events at the Board meeting on 20 February 2017 Decisions by the Board of Directors to focus and stabilise the operations: · Eltel’s management and Board of Directors have decided on strategic focus on Eltel’s core businesses in Power and Communication · Geographically, the markets in the Nordics and Poland will be prioritised, as will further growth opportunities in Germany · Combined net sales of operations in Power and Communication amounted to approximately EUR 1.2 billion, corresponding to 87% of Group total net sales in 2016 · Following this decision, operations excluding Eltel’s core businesses will be divested, with the intention to find new owners with relevant core expertise in the respective business areas. The decision covers the following businesses:– The power transmission business in Africa– The rail business– The power distribution business in the Baltics · Net sales of businesses intended to be divested amounted to approximately EUR 180 million in 2016 · Eltel and its creditors have agreed on revised covenants for 2016 · The Board of Directors decided to initiate a process for a preferential rights issue to enable required restructuring and growth in core markets · Eltel’s largest shareholders, Zeres Capital, Solero Luxco S.á.r.l., The Fourth Swedish National Pension Fund (AP4), Swedbank Robur Funds and The First Swedish National Pension Fund (AP1), representing 49.02% of Eltel’s share capital as of 31 January 2017, support the decision of a preferential rights issue · The Board has decided to appoint a special investigator regarding the liabilities of potential historical inaccuracies in the accounting of the project business Comments by the CEO  Strategy to achieve stable growth in our core area After taking on my position as CEO of Eltel on 19 September 2016, we initiated an operational review of the project business. Next, a Group Project function was established to execute certain operational improvement actions within the project business, including project governance, risk assessment and reporting. A decision was made to implement an in-depth investigation, led by external auditors, of projects with high risk profile and focus mainly in Africa. In parallel, Eltel’s management, in close cooperation with the Board, has continued to review the remaining business. Our conclusions following the review are clear. Eltel’s core competence is in Power and Communication in our domestic markets in the Nordics and in Poland. Furthermore, there are growth opportunities in Germany – a market that is close to the Nordics both in cultural and structural terms. Expansion in other markets has not been successful. Eltel has had difficulties to achieve critical mass and consequently profitability. In light of the above analysis and Eltel’s financial situation, management has developed a strategy and action plan which the Board has decided to implement in 2017. We will focus Eltel’s operations on our stable and profitable businesses within Power and Communication in the Nordics and Poland, and evaluate our continued growth opportunities in Germany. This is where we have long-term ability to generate stable profitability. These markets also offer attractive market potential, stable customers and an interesting development in fibre and smart meters. In 2016, the operations in Power and Communication in the Nordics, Poland and Germany recorded net sales of approximately EUR 1.2 billion, corresponding to 87% of Group net sales. As a consequence of the decision, Eltel’s operations, excluding the core business, will be divested to new owners with core expertise in the business area concerned. The decision is in line with our ambition to reduce the risk level in our operations and release resources for our core business. As a consequence of the decision, the intention is to initiate sales processes regarding the power transmission business in Africa, the rail business and our power distribution business in the Baltics. In 2016, net sales of these operations amounted to approximately EUR 180 million. To enable execution of stated actions, Eltel and its banks have agreed on revised covenants for 2016. However, in order to create long-term shareholder value, a balance sheet allowing for a balanced debt structure combined with investments in growth in our core markets, is required. The Board has consequently decided to initiate a process for a preferential rights issue. Eltel’s largest shareholders, Zeres Capital, Solero Luxco S.á.r.l., The Fourth Swedish National Pension Fund (AP4), Swedbank Robur Funds and The First Swedish National Pension Fund (AP1), representing 49% of Eltel’s share capital as of 31 January 2017, support the decision of a preferential rights issue. This Board decision and the expressed support by the main owners are important cornerstones for the turnaround now put in action. The outcome of our investigation led by external auditors and covering certain projects shows larger deficiencies than earlier anticipated. This resulted in larger than expected write-downs compared to estimates provided in the profit warning in January. Revenue recognition in power transmission has proven to have been more aggressive than previously anticipated, mainly in projects in Africa. The work, initiated as I started as CEO, to investigate the project business and implementation of new governance and control continues. Eltel’s Board has decided to appoint a special investigator regarding the liabilities of potential historical inaccuracies in the accounting of the project business. Considering the development in the fourth quarter, net sales decreased by 1.8% to EUR 387.1 million. For the full-year 2016, net sales amounted to EUR 1.4 billion, growth by 13.5%, mainly driven by acquisitions in the Communication segment. In the fourth quarter, operative EBITA was negative at EUR -14.6 million and positive at EUR 2.1 million for full-year 2016. In 2016, Group operative EBITA was negatively impacted by EUR 49.8 million of provisions and write-downs mainly related to the project business in power transmission in Africa and the rail business in Norway. Of these, EUR 34.1 million were recorded in the fourth quarter. The weak result is concerning, although there are clear explanations. At the same time, I feel great confidence in us now taking right actions. Eltel’s operations are fundamentally solid with highly skilled employees and loyal customers. We have a strong and solution-focused culture and a long track record of delivering value-adding services. Our decision to refocus on our core businesses and markets goes back a long way, and we know our customers and markets well. Together with our Board and our owners, we will now channel all our efforts on implementing this action plan to restore Eltel to become a stable company that will have what it takes to capitalise on the clear growth opportunities in our core business. –Håkan Kirstein, President and CEO For further information:Ingela UlfvesVP – Investor Relations and Group CommunicationsTel: +358 40 311 3009, ingela.ulfves@eltelnetworks.com  This information is information that Eltel AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on 21 February 2017. About EltelEltel is a leading European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Transport & Security, with operations throughout the Nordic and Baltic regions, Poland, Germany, the United Kingdom and Africa. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2016, Eltel net sales amounted to EUR 1.4 billion. The current number of employees is approximately 9,500. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

Nel ASA: Awarded frame contract for multiple hydrogen fueling stations in California by Royal Dutch Shell Plc

(Oslo, 21 February 2017) Nel Hydrogen Solutions, a division of Nel ASA (Nel, OSE:NEL), has entered into a framework contract for the supply, construction and maintenance of H2Station® hydrogen fueling stations in California for Royal Dutch Shell Plc (“Shell”) in a partnership with Toyota Motor Corp. “Being exclusively chosen by Shell and Toyota for this framework contract is a great honor and proves that our technology is state of the art. We look forward to working with our partner to roll out their Californian hydrogen fueling network”, says Mikael Sloth, Vice President Business Development in Nel. On Friday 17th of February 2017, the California Energy Commission (CEC) announced the Notice of Proposed Awards (NOPA) for the Grant Funding Opportunity. Following the NOPA announcement, Nel and Shell finalized the framework contract for the exclusive supply, construction and maintenance for H2Station® hydrogen fueling stations in California. Through this project, Shell will build seven fueling stations for hydrogen cars in California through a partnership with Toyota Motor Corp, these stations will support the target for 100 hydrogen fueling stations by 2020 in the state. The California Energy Commission is considering $16.4 million in grants toward these stations, with Shell and Toyota contributing their part. The contract between Nel and Shell has a potential value in excess of NOK 140 million depending of number of H2Stations and scope of equipment and services that Shell choses to execute under the framework contract. “As communicated yesterday, this is our largest single order for fueling stations ever. Working with great partners like Shell and Toyota is a privilege and we will do our best to ensure that this project becomes a success for other to follow.”, says Jon André Løkke, Chief Executive Officer of Nel. Nel Hydrogen installed the first H2Station® for Shell in 2014 at a conventional gas station in Hamburg, Germany, and will use this experience for the deliveries to Shell in California. ENDS For additional information, please contact: Jon André Løkke, CEO, +47 9074 4949 About Nel| www.nelhydrogen.com       Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

REPORT FOR THE FOURTH QUARTER 2016 AND PRELIMINARY RESULT FOR 2016

Financial and operating highlights 4Q 2016 (4Q 2015 in brackets):  · Operating revenues were NOK 2 630 million (NOK 3 613 million) · EBITDA (operating result before depreciation, impairment and finance) was NOK 1 065 million (NOK 1 419 million) · Impairments were NOK 213 million (NOK 1 376 million · EBIT (operating result) was NOK 92 million (NOK - 922 million · Net finance was NOK -14 million (NOK -302 million). · Net result after tax was NOK 31 million (NOK -1 098 million Post quarter event: · Proposed dividend for 2016: NOK 2.00 per share Offshore drilling · EBITDA NOK 810 mill. (NOK 1 227 mill.) · Challenging markets · 3 units in operation · Waiver of loan covenants Renewable energy · EBITDA NOK 212 mill. (NOK 261 mill.) · Like-for-like generation down 18% · Including Fäboliden and Crystal Rig III, down 11% · Crystal Rig III commenced production · Higher prices throughout all markets · 20% weakening of GBP/NOK Shipping / Offshore wind · EBITDA NOK 35 mill. (NOK -35 mill.) · Utilization for installation vessels 64% (39%) · Impairment of CTVs NOK 103 mill. · Contract pipeline into 2019 covered 42% by firm contracts and 14% options Cruise · EBITDA NOK 18 mill. (NOK -10 mill.) · 20% weakening of GBP / NOK · 18% weakening of GBP/USD · Strong bookings · Passenger days up 6%  · Net ticket income per diems up 10% Financial information The Group‘s operating revenues amounted to NOK 2 630 million (NOK 3 613 million). Offshore drilling had operating revenues of NOK 1 310 million (NOK 2 262 million), Renewable energy NOK 306 million (NOK 372 million), Shipping / Offshore wind NOK 264 million (NOK 219 million) and Cruise NOK 401 million (NOK 433 million). Within Other investments NHST Media Group had operating revenues of NOK 337 million (NOK 332 million). EBITDA (operating result before depreciation, impairment, result from associates, financial items and tax) was NOK 1 065 million (NOK 1 419 million). Offshore drilling achieved EBITDA of NOK 810 million (NOK 1 227 million), Renewable energy NOK 212 million (NOK 261 million), Shipping/Offshore wind NOK 35 million (NOK -35 million), while Cruise achieved EBITDA of NOK 18 million (NOK -10 million). Within Other investments EBITDA were NOK -10 million (NOK -24 million). Depreciation in the quarter was NOK 760 million (NOK 966 million). Impairments were NOK 213 million (NOK 1 376 million) of which offshore drilling units amounted to NOK 90 million (NOK 1 375 million), Crew Transfer Vessels within Shipping/Offshore Wind NOK 103 million (0) and write down of development projects within Renewable energy of NOK 20 million (0). EBIT (operating result after depreciation and impairment before result from associates, financial items and tax) was NOK 92 million (NOK -922 million). Net financial items in the quarter were NOK - 13 million (NOK - 302 million). Net interest expenses were NOK 131 million (NOK 192 million) and net currency gain amounted to NOK 73 million (NOK 62 million) Net unrealized gains related to fair value adjustment of financial instruments were NOK 62 million(NOK - 33 million). Dividends received in the quarter was 35 million (NOK 1 million). Other financial items (inclusive impairment of investments) amounted to NOK - 53 million (NOK - 140 million). Net result in the quarter was NOK 31 million (NOK -1 098 million), of which NOK 11 million are attributable to the shareholders of the parent company (NOK -573 million). The non-controlling interests´ share of net result in the quarter was thus NOK 20 million (NOK -525 million). Revenues in 2016 were NOK 12 415 million (NOK 14 640 million), EBITDA was NOK 5 072 million (NOK 6 243 million) and EBIT was NOK - 294 million (NOK – 2 361 million). EBIT was heavily influenced by impairments of total NOK 2 037 million whereof offshore units were impaired with NOK 1 914 million (NOK 4 903 million). Net financial items were NOK - 410 million (NOK - 535 million). Net result after estimated tax was NOK -1 021 million (NOK – 2 804 million), of which NOK - 499 million (NOK - 1 261 million) are attributable to the shareholders of the parent company. Annual General meeting / Dividend With regard to the Annual General Meeting in 2017, the board will propose a dividend of NOK 2.00 per share. For the company NOK 85.1 million. The annual general meeting is scheduled for Wednesday 24 May 2017.

NeuroVive Pharmaceutical AB Year End Report January - December 2016

Business operations Important events October – December 2016 •   The development of CicloMulsion for acute kidney injury was discontinued and as a consequence, the value of the subsidiary NeuroVive Asia was written-down by 50 percent and all previously capitalized expenditure in connection with CicloMulsion was recognized as an impaired value •   New business model implemented which encompass out-licensing of projects for common indications, as well as proprietary development of orphan indication projects •   Positive preclinical results obtained in an experimental model for non-alcoholic steatohepatitis (NASH), a very serious and common disease for which no medication is currently available •   In a termination agreement, all rights for NV556 were returned to NeuroVive from Arbutus Biopharma. NeuroVive also received material manufactured by Arbutus valued at USD 1.5 million Important events after the end of the period • The company’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells and the results were presented at a scientific conference • The company decided to redirect research resources from Asian subsidiary to parent. The operations in Taiwan have been sold to the current Taiwanese shareholders • A mitochondrial medicine research agreement regarding the NVP015 project was signed with US key opinion leader • A collaboration agreement was signed with Karolinska Institutet, Stockholm, Sweden, and the indication mitochondrial myopathy was added to the project portfolio Financial information Fourth quarter (October – December 2016) •   Net revenues were SEK 14,000 (0) and other operating income was SEK 14,000 (23,000) •   Loss before tax was SEK 14,580,000 (7,366,000) •   Loss per share* was SEK 0.34 (1.75) •   Diluted loss per share** was SEK 0.34 (1.75) Twelve months (January-December 2016) •   Net revenues were SEK 14,000 (2,502,000) and other operating income was SEK 104,000 (522,000) •   Loss before tax was SEK 71,845,000 (90,801,000) •   Loss per share* was SEK 1.67 (3.01) •   Diluted loss per share** was SEK 1.67 (3.01) *    Profit/loss for the period divided by the average number of shares before dilution at the end of the period.**  Profit/loss for the period divided by the average number of shares after dilution at the end of the period.   The complete Year End report is available for download below and through the NeuroVive web site www.neurovive.com. For more information concerning this report, please contact CEO Erik KinnmanTelephone: +46 (0)46-275 62 20 This information is information that NeuroVive Pharmaceuticals (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 21 February 2017. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production. NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 LundTel: 046-275 62 20 (switchboardl)ir@neurovive.comwww.neurovive.com

Sobi™ enters into new distribution agreement with Valeant for Ammonul®

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) today announces that the company has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul® (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East and North Africa. The new agreement replaces the current distribution agreement with Valeant Pharmaceuticals North America LLC for the same territory. Under the new agreement, Sobi will have exclusive rights and license for sales and distribution of Ammonul in Europe, the Middle East and North Africa until 31 December 2019 for named patient use (NPU) programmes. “We are very pleased to extend our long-term partnership with Valeant to continue to provide access to Ammonul in the territory,” says Alan Raffensperger, Chief Operating Officer at Sobi. “This agreement complements Sobi’s portfolio within the area of Urea Cycle Disorders and creates a wider range of treatment alternatives for patients suffering from these rare conditions”.  Ammonul is approved by the US Food and Drug Administration (FDA) for the treatment of acute Urea Cycle Disorders (UCDs). The product is not registered in the European Union, Middle East or North Africa but is only available under NPU programmes. --- About Ammonul®Ammonul is approved in the US and indicated as adjunctive therapy in paediatric and adult patients for the treatment of acute hyperammonaemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonaemic episodes, ammonia-lowering therapies should be considered. For full safety information please see fda.gov. (http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020645lbl.pdf)  About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and   Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.   For more informationplease contact:Media relations Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor RelationsT: + 46 708 73 40 95, + T: +1 347-224-0819, +1 21246 8 697 31 74   -579-0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com

Coor Service Management announces proposed new Board of Directors

Ahead of the Annual General Meeting, Coor Service Management’s Nomination Committee proposes to decrease the Board of Directors with one Director. Søren Christensen and Anders Narvinger (currently Chairman of the Coor Board) have declined re-election, and as new Board member Anders Ehrling (for more information, see below) is proposed. The following Board members are proposed for re-election: Mats Granryd, Mats Jönsson, Monica Lindstedt, Kristina Schauman, Heidi Skaaret and Mikael Stöhr. The Nomination Committee also proposes Mats Granryd as the Chairman of the Board, as previously communicated. The Nomination Committee’s goal has been to provide the Board of Directors with the overall competence and experience required to continue to lead and develop the company’s operations optimally, and to ensure continued profitable growth. The proposal also takes into account versatility, as well as, breadth of experience and background, and complies with the stipulations of the Swedish Code of Corporate Governance regarding non-affiliation. Anders Ehrling (born in 1959) was most recently CEO & President of BRA—Braathens Regional Airlines. Previous positions include: CEO of Scandic Hotels, and held several senior positions with SAS, including President of SAS Sverige AB. Mr. Ehrling is a Director of Parks & Resorts Scandinavia AB, and Chairman of the Board of Nordic Cinema Group. The Annual General Meeting will be held in Kista Entré, Knarrarnäsgatan 7, Kista (Stockholm), Sweden on May, 4, 2017 at 15:00 CET. The Nomination Committee of Coor Service Management consists of Jan Andersson (Swedbank Robur Fonder), Malin Björkmo (Handelsbanken Funds), Ulrika Danielson (Second AP Fund), Jan Särlvik (Nordea Funds), and Anders Narvinger (Chairman Coor). For more information, images etc., please visit www.coor.com or contact: Jan Andersson, Chairman of the Nomination Committee, +46 76 139 55 00, jan.andersson@crossmore-adsors.com Erik Strümpel, General Counsel at Coor, +46 734 101 389, erik.strumpel@coor.com Åsvor Brynnel, Sustainability and Communications Director at Coor, +46 10 559 59 83, asvor.brynnel@coor.com  

ABB uncovers criminal activity in South Korean subsidiary

ABB has uncovered a sophisticated criminal scheme related to a significant embezzlement and misappropriation of funds in its South Korean subsidiary. The treasurer of the South Korean subsidiary is suspected of forging documentation and colluding with third parties to steal from the company. The suspected individual went missing on February 7, 2017 and subsequently ABB discovered significant financial irregularities in South Korea. The company immediately launched a full investigation in South Korea engaging independent forensic and legal specialists and collaborating with law enforcement authorities. ABB is working with the local police on the investigation and Interpol’s engagement. This embezzlement and misappropriation of funds will have an impact on the previously reported unaudited 2016 results. Current estimate is a pre-tax charge of approx. $100 million. ABB has initiated mitigating actions to reduce the impact of this criminal activity on its results significantly including recovery of misappropriated funds, legal claims and insurances. The company has checked and reconfirmed the balances of its global bank accounts and can confirm that this situation is limited to South Korea. ABB has a zero-tolerance approach to unethical behavior and maintains the highest standards regarding integrity and ethical business practices. As a consequence of the ongoing investigation, ABB will publish its 2016 Annual Report latest by March 16, 2017. ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing more than a 125-year history of innovation, ABB today is writing the future of industrial digitalization and driving the Energy and Fourth Industrial Revolutions. ABB operates in more than 100 countries with about 132,000 employees. www.abb.com  Important notice about forward-looking information This press release includes forward-looking information and statements. This information is generally identifiable by statements containing words such as “expects,” “believes,” “estimates,” “intends” or similar expressions. Because there are uncertainties, many of which are beyond our control, the actual results may differ. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will not change.

Year-end Report, January – December 2016 - Coor Service Management Holding AB

Fourth quarter of 2016 · Net sales in the fourth quarter were largely unchanged at SEK 2,045 (2,042) million. Organic growth excluding foreign exchange effects was -3 per cent. · Adjusted EBITA increased by 8 per cent to SEK 119 (110) million and the operating margin expanded to 5.8 (5.4) per cent. · EBIT was SEK 66 (56) million and profit after tax was SEK 43 (45) million. Profit after tax in the year-before period was affected by positive net financial income, driven by foreign exchange effects. · Earnings per share were SEK 0.5 (0.5). · Operating cash flow was SEK 225 (268) million. · The Board of Directors proposes a dividend for 2016 of SEK 3.00 (2.00) per share, of which SEK 1.55 (1.40) is ordinary and SEK 1.45 (0.60) is extraordinary. Full year 2016 · Net sales for the twelve-month period increased by 2 per cent to SEK 7,631 (7,482) million. Organic growth was 3 per cent. · Adjusted EBITA increased by 18 per cent to SEK 440 (374) million and the operating margin expanded to 5.8 (5.0) per cent. · EBIT was SEK 242 (82) million and profit after tax was SEK 124 (201) million. Profit after tax in the previous year was affected by a significant positive tax effect in the second quarter. · Earnings per share were SEK 1.3 (-3.6). · Operating cash flow was SEK 426 (274) million. · Net debt at year-end was SEK 808 (947) million and the leverage was 1.7 (2.2).  "2016 was a strong year in which we increased our margins across the board, creating scope for an extraordinary dividend.”Mikael Stöhr, President and CEO of Coor  GROUP EARNINGS SUMMARY Oct - Dec Jan - Dec(SEK m) 2016 2015 2016 2015Net sales 2,045 2,042 7,631 7,482Organic growth, % -3 6 3 10Adjusted EBITA 119 110 440 374Adjusted EBITA-margin, % 5.8 5.4 5.8 5.0EBIT 66 56 242 82Income for the period 43 45 124 201Operating cash flow 225 268 426 274Earnings per share, SEK 0.5 0.5 1.3 -3.6  Invitation to press and analyst presentationOn 22 February, at 9:30 a.m. CET, the company’s President and CFO will give a presentation on developments in the fourth quarter in a webcast. To participate in the webcast, please register in advance using the following link http://edge.media-server.com/m/p/ks8xy4v6. To listen to the presentation by telephone, dial +46 8 566 426 92 (Sweden), +47 23 50 02 52, (Norway), +45 35 44 55 79 (Denmark), +358 981 710 492 (Finland) or +44 203 008 98 07 (UK).   The briefing material and a recording of the webcast will be published after the briefing on the company’s website, www.coor.com , under Investors/Reports and presentations.  Annual General Meeting 2017The Annual General Meeting will be held on 4 May, at 3 p.m., at the Kista Entré conference centre, Knarrarnäsgatan 7, Kista, Sweden. Information on how to register along with the notice of AGM and other information will be available on the company’s website from March, 30.  Financial calendar 2017Interim Report January – March 2017                           4 May 2017Interim Report January – June 2017                             20 July 2017Interim Report January – September 2017                    27 October 2017Interim Report January – December 2017                     February 2018 The Annual Report 2016 will be published on the company’s website in week 15 of 2017.  More information and contactFor questions concerning the financial report, please contact Olof Stålnacke, CFO and IR Manager (+46 10 559 59 20, olof.stalnacke@coor.com). For other questions concerning the operations or the company, please contact CEO Mikael Stöhr (+46 10 559 59 35, mikael.stohr@coor.com) or Communications- and Sustainability Manager Åsvor Brynnel (+46 10 559 54 04, asvor.brynnel@coor.com). IR Coordinator: Sara Marin (+46 10 559 59 51, sara.marin@coor.com). More information is also available on our website: www.coor.com.  This information is such that Coor Service Management Holding AB (publ) is obliged to publish in accordance with the EU market abuse regulation. This information was submitted through the efforts of the above-mentioned contact persons for publication on 22 February, 2017, at 7:30 a.m. CET.  Coor is a leading provider of facility management services in the Nordics, focusing on integrated and complex service undertakings (IFM). Coor offers specialist expertise in workplace services (soft FM), property services (hard FM) and strategic advisory services for development of customers’ service activities. Coor creates value by executing, leading, developing and streamlining its customers’ service activities, ensuring that they provide optimal support to the core business over time. Coor’s customer base includes many large and small companies and public-sector organisations across the Nordic region, including AB Volvo, Aibel, Det Norske Veritas, E.ON, Ericsson, EY, NCC, Politiet (Danish Police), Saab, Sandvik, SAS, Skanska, Statoil, Telia, Swedish Transport Administration, Vasakronan and Volvo Cars. Coor was founded in 1998 and is listed on Nasdaq Stockholm since 2015. Coor takes responsibility for the operations it conducts, in relation to its customers, employees and shareholders, as well as for its wider impact on society and the environment. Read more at www.coor.com

CXENSE ASA ANNOUNCES FOURTH QUARTER AND PRELIMINARY YEAR END RESULTS FOR 2016

OSLO, NORWAY – FEBRUARY 22, 2017 - CXENSE ASA TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDING DECEMBER 31, 2016. Highlights: ·2016 was marked by strong growth within Cxense’s core business, software for personalization of websites and apps ·Full-year 2016 group revenue up 40% to USD 25.5 million ·Q4 data management & personalization software revenue up 31% year-over-year to USD 4.5 million ·EBITDA reflects investments in the company’s sales and overall growth capacity ·Ramping-up sales team with substantial increase in number of sales people, sharpened focus on North America and larger customers ·Further strengthening Cxense’s market leading personalization offering, signed licensing agreement with social media analytics company RepKnight and investing GBP 3.0 million in the company ·Industry recognition increasing, Cxense included in research group Gartner’s “Magic Quadrant for Digital Marketing Hubs“ together with companies such as Adobe, Salesforce, Oracle and IBM CEO comment “Last year, we delivered strong growth within our core business area, personalization of websites and apps. We are even more excited about the opportunities we see ahead of us. Our market is expanding, our technology and software deliver market-leading results and we experience increasing industry recognition. Adding to that we invest substantially in our sales capacity and in further developing our offering. We believe we are just beginning to see the impact Cxense’s software will have in the coming years” said Ståle Bjørnstad, Cxense CEO. Material: The Q4 2016 report and presentation are attached to this notice and can also be found under the following link: https://www.cxense.com/investors/financial-reports Webcast: Cxense ASA will present its Q4 2016 results at 08:30 am CET. The presentation will take place at the Felix Conference Center, Bryggetorget 3, Oslo, Norway. A live webcast will be available at: http://webtv.hegnar.no/presentation.php?webcastId=44475097   About Cxense: Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide. Cxense customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, AEON, DMM and many more. For more information, go to: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE’. Investor Relations Contact: Jørgen Loeng, Chief Financial Officer Email: ir@cxense.com Mobile: +47 906 60 062

Enea and Lanner demonstrate multi-architecture Proof-of-Concept vCPE solution at Mobile World Congress

STOCKHOLM, Sweden, February 22, 2017 – Enea® (NASDAQ OMX Nordic:ENEA) together with Lanner Electronics Inc. (TAIEX 6245) today announced a Proof-of-Concept (PoC) of a commercial Network Function Virtualization (NFV) solution built on OPNFV running on both x86 and ARM based COTS hardware. Using Commercial Off-The-Shelf (COTS) virtual Customer Premise Equipment (vCPE) brings a promise of lower cost and lower power consumption, and equips customers with better architectural choice for their specific use case. vCPE is clearly among the hottest topics in the NFV discussion today and together with Lanner, Enea will demonstrate a unique ability to mix hardware platform architectures in Enea’s stand 6H21 in Hall 6 at the Mobile World Congress in Barcelona, February 27 to March 2, 2017. The NFV edge Proof-of-Concept The PoC shows how NFV will help to push functionality and data streams to the edge where it can run on cheaper hardware and not congest the network. Enea will run its network virtualization software platform on a central office server that sets up and initiates a video call between two tablets; one connected to an x86 based Lanner device, and one connected to an ARM based device. The demo highlights how data can stream between two efficient vCPE devices without putting a load on nodes in the network. “Our OPNFV based software platform is flexible enough to seamlessly mix different vCPE architectures, and delivers the characteristics necessary for leveraging the benefits of NFV in the edge use case”, said Karl Mörner, SVP Product Management at Enea. “With the Enea NFV, customers save time-to-market and cost, while opening up for new revenue streams and guaranteeing better customer satisfaction.” “As the world leader in network appliances, we engineer and manufacture vCPE devices based on x86 and ARM platforms,” said Jeans Tseng, Vice President of Telecommunication Applications at Lanner. “With validation through Enea’s NFV software, Lanner and Enea can deliver vCPE solutions optimized for next-gen hybrid NFV architecture and help accelerate time-to-market for service providers and telecom equipment manufacturers”. Further reading Enea NFV Lab: http://www.enea.com/solutions/pharos-lab/ Enea NFV Lab services: http://services.enea.com/services/packaged-services/enea-nfv-lab Enea at the Mobile World Congress: http://www.enea.com/about-us/Events/Trade-shows/Mobile-World-Congress-2017/ Lanner network appliances: http://www.lannerinc.com/products/network-appliances/x86-rackmount-network-appliances/nca-4010 Contact: Fredrik Medin, SVP Marketing and CommunicationsPhone: +46 709 71 40 11E-mail: fredrik.medin@enea.com About Lanner Lanner Electronics Inc (TAIEX 6245) is a world leading provider of design, engineering and manufacturing services for advanced and customizable SDN and NFV network computing appliances for system integrators, service providers and application developers. Lanner possesses a wide range of network appliances including desktop vCPE devices designed for SD-WAN and SD-Security, as well as NEBS-compliant, NFVi-ready platforms with multiple processors, network I/O blades, and high availability features. www.lannerinc.com About Enea Enea is a global supplier of network software platforms and world class services, with a vision of helping customers develop amazing functions in a connected society. We are committed to working together with customers and leading hardware vendors as a key contributor in the open source community, developing and hardening optimal software solutions. Every day, more than three billion people around the globe rely on our technologies in a wide range of applications in multiple verticals – from Telecom and Automotive, to Medical and Avionics. We have offices in Europe, North America and Asia, and are listed on NASDAQ OMX Nordic Exchange Stockholm AB. Discover more at www.enea.com and start a conversation at info@enea.com. Enea®, Enea OSE®, Netbricks®, Polyhedra®, Zealcore®, Enea® Element, Enea® Optima, Enea® LINX, Enea® Accelerator,  Enea® dSPEED Platform and COSNOS® are registered trademarks of Enea AB and its subsidiaries. Enea OSE®ck, Enea OSE® Epsilon, Enea® Optima Log Analyzer, Enea® Black Box Recorder, Polyhedra® Lite, Enea® System Manager, Enea® ElementCenter NMS, Enea® On-device Management and Embedded for LeadersTM are unregistered trademarks of Enea AB or its subsidiaries. Any other company, product or service names mentioned above are the registered or unregistered trademarks of their respective owner. All rights reserved. © Enea AB 2017. 

Canadian State Visit to ESS

Today's visit was also the King's first to the ESS construction site in northeast Lund. From the site office's viewing deck, the King, the Governor General and the Swedish and Canadian delegates could get an overview of the construction site, where the world leading materials research facility is beginning to take shape. The facility's unprecedented capabilities within neutron scattering will enable unique research possibilities and contribute to future big discoveries in for example life science, transport, alimentation and energy. Canada's Governor General was pleased to see the site and talked about how Canada and Sweden can further enhance their collaboration in innovation: “I was delighted to visit the construction site of the European Spallation Source and to learn more about this impressive facility,” the Governor General said. “The complexity of this important research project means we have much to gain from working together. I look forward to the results of continued collaboration between Canadian and Swedish innovators and researchers.” The large delegations from Canada and Sweden attending the ESS visit included representatives of the Canadian and Swedish governments, industry and academia. "Canada is an important collaboration partner for Sweden and we hope through this state visit to increase our collaboration within research and innovation," said Helene Hellmark Knutsson, Swedish Minister for Higher Education and Research. "As host country for ESS, Sweden welcomes international partners in this global research infrastructure project." During the visit possible research collaborations between Canada and Sweden were discussed at a round table, where the significance of research facilities such as ESS and the neighbouring synchrotron facility MAX IV for research in areas such as life science, clean tech and information and communications technology was highlighted. Arthur B. McDonald, Professor Emeritus at Queen’s University and 2015 Physics Nobel Laureate, was one of the Canadian delegates who took part in the discussion, as did Lena Ek, Swedish Government's Special Envoy for ESS. Canada's and Sweden's overlapping research priorities, strong support for R&D and legacy of innovation were particularly noted at the round table. “Both Sweden and Canada recognise the importance of sustained investment in the research infrastructures that are needed if we are to make progress on the key cross-cutting challenges of the 21st century, such as energy, materials, and healthcare," said John Womersley, ESS Director General, who led the round table discussion. "ESS is an excellent example of such an investment and we hope that it can help to foster a deeper collaborative relationship between Swedish and Canadian scientists in the coming decade.” In connection to the visit to ESS, a Memorandum of Understanding for cooperation between the two synchrotron facilities MAXIV and Canadian Light Source was also signed.